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Abstract 
Osteoarthritis (OA) is a disease that affects the whole joint, with progressive articular 
cartilage loss. Healthy cartilage must maintain a balance between extracellular matrix 
synthesis and degradation. Metalloproteinases (Matrix metalloproteinases, MMPs and a 
disintegrin and metalloproteinase domain with thrombospondin motifs, ADAMTSs) play an 
important role in cartilage degradation. The collagenases (MMP-1 and MMP-13) and 
aggrecanases (ADAMTS-4 and ADAMTS-5) are implicated in the development of OA 
because of their ability to degrade type 2 collagen and aggrecan. This project aims to 
identify compounds from the diet that could offer protection or slow the progression of OA 
via collagenase and/or aggrecanase inhibition. 
Ninety-six dietary derived compounds selected from a Natural Product Library were 
screened at 10µM for IL1-induced and basal MMP13 inhibition in SW1353 and C28/I2 cells. 
Several compounds inhibited MMP13 at 10µM in both cell lines.  Twenty compounds were 
selected for study in primary human articular chondrocytes. Of these compounds, apigenin 
and isoliquiritigenin showed the greatest inhibition of MMP13 while also inhibiting MMP1, 
ADAMTS4 and ADAMTS5. The effect of apigenin or isoliquiritigenin pretreatment on three 
pathways implicated in OA, the NFκB, TGFβ and Wnt pathways was analysed. Apigenin and 
isoliquiritigenin showed differences in the patterns of inhibition in the NFκB and TGFβ 
pathways. The Human Phospho-Kinase Array Kit was used to perform an unbiased 
dissection of the kinase pathways affected by apigenin and isoliquiritigenin. Apigenin and 
isoliquiritigenin had similar effects on many phosphorylation events, however there were 
kinase phosphorylation events that were specific to either apigenin or isoliquiritigenin 
treatment. Taken together these data suggest that the chondro-protective gene expression 
changes seen with apigenin and isoliquiritigenin treatment involves a complex network of 
signalling pathways that require further characterisation. If these compounds are able to 
get to the site of OA damage they may prevent progression of OA offering an alternative 
treatment. 
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Chapter 1: Introduction 
1.1 Synovial Joint structure 
The most common joint of the human skeleton is the synovial joint. A thin layer of hyaline 
cartilage (Figure 1.1) known as articular cartilage covers the end of bone providing the joint 
with a smooth surface for joint movement. A fibrous capsule encloses the joint, this capsule 
is lined with a synovial membrane. The cells that reside in the synovial membrane secrete 
synovial fluid into the synovial cavity helping to reduce friction and lubricate the joint. 
Ligaments hold the bones of the joint together. 
 
 
Figure 1.1. Diagram showing the structure of the synovial joint. 
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1.1.1 Articular cartilage and structure 
Healthy articular cartilage provides the joint with a friction reducing weight-bearing 
surface. Articular cartilage is highly elastic able to deform and regain its shape. Articular 
cartilage distributes load evenly over the surface of the joint which avoids peak stresses 
occurring on the subchondral bone (James & Uhl, 2001). When compared with other soft 
tissues it has a low level of metabolic activity lacking nerves, lymphatic vessels and blood 
vessels.  
Articular cartilage consists of four distinct regions of matrix (Figure 1.2). The first is the 
superficial zone; this area contains elongated and relatively inactive chondrocytes 
organized parallel to the articular surface. The matrix contains fine fibrils with very few 
polysaccharides. Chondrocytes produce lubricin in this surface layer which creates the 
smooth gliding surface the joint (Chang et al., 2009). The second zone is known as the 
transitional zone. The collagen fibrils of this layer are larger than those of the superficial 
zone and their orientation transitions from parallel to a columnar formation (James & Uhl, 
2001), chondrocyte metabolic activity is also much more pronounced. This transitional and 
deeper zone contain high proteoglycan content and the prominent collagen fibres increase 
in diameter. The third zone is known as the deep zone. This zone also contains 
chondrocytes but they are larger, elongated and are organised in a columnar pattern 
perpendicular to the joint surface with the cells themselves containing lots of intermediate 
filaments. This zone also contains the largest collagen fibrils with the highest content of 
proteoglycans (Pearle et al., 2005). The final zone is the calcified zone that divides soft 
cartilage from subchondral bone. Here the chondrocytes contain almost no endoplasmic 
reticulum and little cytoplasm. Cartilage is anchored to subchondral bone via calcified 
collagen fibres (Clouet et al., 2009). 
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1.1.2 The extracellular matrix structure and function 
The extracellular matrix consists of three main matrices, the pericellular, territorial and 
interterritorial matrices (Figure 1.3). The territorial and interterritorial matrices are 
organised in a way to protect tissue from mechanical load. This matrix is rich in aggrecan, 
chondroitin sulphate proteoglycan and type 2 collagen (Vincent, 2013). The pericellular 
matrix surrounds the chondrocyte and is between 1-5µm thick  (Poole, 1997) and rich in 
hyaluronan, proteoglycans and various aggregates of type 6 collagen (Knudson, 1993). 
The pericellular matrix has become an area of interest recently with research focusing on 
how the pericellular matrix stores growth factors and how the matrix responds to 
mechanotransduction (Vincent et al., 2007). Type 6 collagen is rich in the pericellular 
matrix and is an important molecule that forms a mechanical interface between type 2 
Figure 1.2. The four distinct regions of matrix. Schematic diagram of articular cartilage showing 
its different zones, compositions, and organisation, image adapted from (Levangie & Norkin, 
2005). 
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collagen providing a link between the rigid interterritorial cartilage matrix and the 
chondrocyte  (Söder et al., 2002). Together the chondrocyte and the surrounding 
pericellular matrix are collectively known as a chondron. Chondrons were classically 
described in 1925 by Benninghof as a ‘fluid filled bladder’ (Benninghoff, 1925). Type 6 
collagen plays a major role in mechanical properties of the pericellular matrix. Type 6 
collagen KO mice have an accelerated development of osteoarthritis, which may be due 
to the altered properties of the pericellular matrix which can no longer regulate the 
biomechanical environment of the chondrocyte (Alexopoulos et al., 2009). 
 
 
 
Figure 1.3. The assembly of aggregates and extracellular matrix components.  Articular 
cartilage ECM consists of the pericellular, territorial and interterritorial regions. The territorial 
and interterritorial regions are rich in aggrecan and type 2 collagen. The pericellular and 
territorial regions consist of type 6 collagen which can interface with type 2 collagen. Fibulin 
and tenascin-R can associate with aggrecan. In the interterritorial region aggregates of 
hyaluronan and aggrecan can be found within type 2 collagen networks. The ECM is further 
strengthened by the non-collagenous protein COMP (cartilage oligomeric protein), type 9 
collagen, fibronectin and decorin. Modified from (Dudhia, 2005), (Heinegård & Saxne, 2011). 
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Cartilage is composed of sparsely scattered chondrocytes and an extracellular matrix (ECM) 
comprised of, type 2 collagen along with various other minor collagens, proteoglycans (the 
most common being aggrecan), glycoproteins, glycosaminoglycans (GAGs), water and 
calcium salt. Healthy cartilage has a rapid proteoglycan turnover rate and a slow collagen 
turnover rate. Proteoglycans can be divided into two groups based on the nature of their 
core proteins, the larger hyaluronan-binding proteoglycans such as aggrecan and smaller 
proteoglycans including fibromodulin, biglycan, decorin and epiphycan (Iozzo, 1998). The 
larger proteoglycans are bound to hyaluronan non-covalently (Hardingham & Muir, 1974). 
The smaller proteoglycans core proteins consist of leucine-rich repeat structures, these 
structures can interact with cell membrane components, matrix glycoproteins and collagen 
(Iozzo, 1998).  
Small proteoglycans may have a role in the correct spacing of collagen fibrils via the 
formation of glycosaminoglycan chains (Scott, 1991). Of these smaller glycoproteins 
biglycan and decorin contain either one or two chondroitin/dermatan sulphate chains, 
these chains potentially allow further interactions with other molecules (Bock et al., 2001). 
Decorin and biglycan mRNA has been detected in human bone, skin and periodontal 
ligament cells in culture (Fisher et al., 1989). Within hyaline cartilage from the knee, light 
and electron microscopical immunohistochemistry detected decorin in the interterritorial 
matrix and in vesicles in chondrocytes where it may modulate collagen metabolism (Miosge 
et al., 1994). In the same study the majority of biglycan was found in the pericellular matrix 
adjacent to chondrocytes, with both decorin and biglycan close or on collagen fibrils 
associating with globular structures of the matrix between collagen fibrils.  
 
1.1.3 The structure and function of type 2 collagen 
The collagens are a family of fibrous proteins. In mammals they constitute to 25% of the 
total protein mass (Erat et al., 2009). Collagen is one of the molecules involved in providing 
cartilage with its high tensile strength (Figure 1.4). Collagen forms the basic components of 
the ECM and is necessary for the structural integrity of vertebrate tissues (Liska et al., 
1994). During muscular deformation collagen can store elastic energy (Silver et al., 2009), 
excess energy can then be transferred from the joint back to the attached muscles for 
dissipation (Silver et al., 2001). Collagen fibrils provide a biomechanical scaffold which 
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anchors macromolecules creating an environment for cell attachment, giving shape and 
form to a tissue (Kadler et al. 1996). Depending on the tissue, collagen fibrils can be 
arranged with different suprafibrillar architectures (Jokinen et al., 2004) with diameters in 
the range of 10-500nm (Holmes et al., 1992). 
 
 
 
Molecules of collagen consist of triple – stranded helical structures made from three α 
polypeptide chains, each α chain is made up of a left handed helix with an expanse of 18 
amino acids per turn of the helix (Se-Kwon, 2013). The synthesis of collagens begins in the 
endoplasmic reticulum with the formation of three polypeptide chains forming procollagen 
(Jackson, 1978). The three α chains that form procollagen can be identical, such as with 
type 2 collagen which contains three α1 chains, or different such as type 1 collagen which 
contains two α1 chains and a single α2 chain. The composition of α chains consists of a 
series of triplet Gly-X-Y amino acid sequences. Glycine is the smallest amino acid allowing 
the three helical ɑ chains to pack tightly together to form a right handed superhelix (Cao et 
b 
Figure 1.4. Structure of collagen (a) High resolution crystal structure of a collagen triple helix. 
(b) Ball and stick image of a segment of collagen triple helix. Showing the ladder of interstrand 
hydrogen bonds (Bella et al., 1994). Image adapted from (Shoulders & Raines, 2009). 
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al., 2012). Proline is commonly the X amino acid, its ring structure stabilises the helical 
conformation in each ɑ chain (John et al., 1999). Hydroxyproline is often in the Y position 
of the amino acid sequence. The hydroxyl groups of hydroxyproline form interchain 
hydrogen bonds that help stabilise the triple stranded helix (Hickman et al., 2000). The 
triple stranded helices can cross-link covalently at the N and C terminals via lysine residues 
forming collagen fibrils (Eyre et al., 2005). This cross-linking of helices is catalysed by lysyl 
oxidase. Pro collagen consists of distinct regions (Figure 1.5), the N-propeptide, C-
propeptide, the α-chains and the flanking extrahelical telopeptides (Bulleid et al., 1997). 
Proteolytic processes help convert procollagen into its mature form by specific N terminus 
A Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTSs) cleavage 
during and following secretion from the cell (Fukui et al., 2002). C-propeptides allow the 
procollagen to maintain its solubility prior to its assembly into insoluble polymers (Daviesz 
et al., 1997). N-propeptides are involved in the biogenesis, maturation and function 
(Bornstein, 2002) as well as influence fibril shape and diameter (Cluzel et al., 2000). The 
procollagen which is around 300nm inside the endoplasmic reticulum (Stephens, 2012) is 
then packed into Golgi-to-PM carriers (Canty & Kadler, 2005). Processing of procollagen 
has been thought of as an extra-cellular event as enzymes capable of converting 
procollagen to collagen are found in the medium of cultured cells (Kerwar et al., 1973). 
Fibrils were thought to form spontaneously as mature collagen self assembles, with various 
ECM components involved in the spatial regulation of fibrillogenesis (Kadler et al., 2008). 
However more recent research suggests that nonmuscle myosin 2 transports newly formed 
collagen fibrils at the plasma membrane and is fundamental to the development of collagen 
fibril-rich tissues (Kalson et al., 2013). 
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Figure 1.5. Collagen fibril formation. Procollagen consists of three 300nm long α chains that 
are synthesized in the endoplasmic reticulum. The procollagen α chains aggregate to form a rod 
like triple helix trimer flanked by a trimeric globular N-propeptide and a C-peptide domain. 
Metalloproteinases cleave the procollagen at the N and C terminal globular propeptides 
forming mature collagen. Mature collagen self assembles spontaneously into fibrils which are 
then cross-linked together by lysyl oxidase stabilizing the structure. Image adapted from (Kadler 
et al., 1996), (Canty & Kadler, 2005). 
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Type 2 collagen can interact with other cartilage specific collagens such as collagen types 9 
and 11, aggrecan and other matrix proteins (Table 1) (Goldring, 2000). 
 
Collagen Type Structural features % of total collagen 
2 300nm-long fibrils 
[α1(II)]3 
75%foetal, >90% adult 
3 300nm-long fibrils 
[α1(III)]3 
>10% adult 
6 Periodic globular domains α1(VI),  
α2(VI), α3(VI) 
Chondron basket 
microfilaments <1% 
10 Hexagonal lattice 
[α1(X)]3 
Hypertrophic cartilage only 
11 Fibrillar 
α1(XI),  α2(XI), α3(XI) 
Fibril template 10% foetal, 3% 
adult 
13 Transmembrane (Transmembrane) 
12/14 Fibril associated collagens with 
interrupted triple helices 
[α1(XII)]3/[α1(XIV)]3 
Non-covalently fibril-
associated collagens 
 
 
1.1.4 The structure and function of aggrecan 
The most abundant proteoglycan present in cartilage is aggrecan (Mathews & Lozaityte, 
1958). Aggrecan is a large aggregating proteoglycan. Proteoglycans are distinguished from 
other glycoproteins by the arrangement of their sugar side chains. At least one of the side 
chains of a proteoglycan is a glycosaminoglycan (GAG). Over 90% of the mass of aggrecan 
is comprised of substituted GAG chains (Kiani et al., 2002).  Aggrecan interacts with a 
hyaluronic acid filament bound via globular domain 1 (Figure 1.6). Hyaluronic acid is a 
Table 1. Collagens of cartilage tissue.  Figure adapted from (Lodish, 2000) and (Eyre et al., 
2006). 
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ubiquitous repeating disaccharide unit of D-glucuronate and N-acetyl-D-glucosamine (H. 
Watanabe, 1997). Aggrecan GAG molecules contain chondroitin sulphate and keratin 
sulphate chains linked to a serine rich core protein. Chondroitin sulphate is a repeating 
disaccharide unit of D-glucuronic acid and N-acetyl-D-glucuronic acid. Keratin sulphate is a 
repeating disaccharide unit of D-galactose and N-acetyl-D-glucosamine. The sugar residues 
in GAGs can be sulphated giving them their negative charge. Aggrecan has a direct 
functional role in providing osmotic resistance to the cartilage, allowing cartilage to resist 
compression (Knudson & Knudson, 2001). The negative charge of aggrecan attracts cations 
causing water to be drawn into the molecule. In this hydrated form GAGs enable cartilage 
to absorb large pressure changes (Prydz & Dalen, 2000). This allows cartilage to sustain 
physiological levels of stress in the range of 2-12 mPA (Park et al., 2003).  During 
compression most water leaves the GAG molecule but its strong negative charge prevents 
complete compression. Once pressure has been released GAGs become rehydrated. This 
mechanism allows cartilage to resist compression. This mechanism also causes the 
movement of interstitial fluid vital for the sustenance of chondrocytes in an avascular tissue 
(Y. Wang et al., 2012). A critical and early event in the pathogenesis of OA is the loss of 
aggrecan from cartilage, which is enzymatically mediated by aggrecanase activity 
(Tortorella & Malfait, 2008). 
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1.1.5 Chondrocytes and their function in cartilage 
The single cellular component of adult hyaline cartilage is the terminally differentiated 
chondrocyte. Chondrocytes account for 1-5% of the cartilage total volume (Jerosch, 2011). 
Both collagen and proteoglycan synthesis and degradation are mediated by chondrocytes 
(DeGroot et al., 2001). Chondrocytes arise from mesenchymal progenitors during skeletal 
development where they form the cartilage anlagen (Goldring et al., 2006). Mesenchymal 
cells condense expressing type 1, 2, 3 and 5 collagens with chondroprogenitor cells 
differentiating and expressing cartilage specific collagen types 2, 9, and 11 (Goldring, 2012). 
Chondrocytes then undergo proliferation, terminal differentiation, hypertrophy, eventually 
undergoing autophagy and apoptosis (Goldring et al., 2006).  
Figure 1.6 Schematic representation of aggrecan. HA: hyaluronic acid, CS1, CS2: chondroitin 
sulphate domains 1 and 2 KS: keratin sulphate; G1, G2, G3: globular domains; LP: link protein. 
Image adapted from (Jerosch, 2011). 
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After chondrogenesis occurs long bones develop from the cartilage analgen in a process 
known as endochondral ossification where cartilage matrix becomes calcified and 
chondrocytes switch to a hypertophic phenotype (Ferguson et al., 1998), (Poole, 1982). 
Adult chondrocytes survive in avascular tissue in a severely hypoxic environment (Xu et al., 
2007). When cartilage is healthy chondrocytes have a low turnover of cartilage matrix 
proteins (Maroudas et al., 1998). Chondrocytes in healthy cartilage undergo anabolic 
processes (those that result in the synthesis of cartilage matrix components) and these are 
in equilibrium with catabolic processes (those that result in the normal turnover of matrix 
molecules) (Fukui et al., 2001). When a joint injury occurs chondrocytes attempt to repair 
cartilage by increasing anabolic processes however these repair attempts creates a cycle of 
anabolism and catabolism and eventually catabolic processes overpower the cells anabolic 
processes, this eventually results in cartilage erosion. Chondrocytes are responsible for the 
homeostasis of the ECM and can interact with the ECM via integrins and discoidin domain 
receptors (DDRs) (Aszodi et al., 2003), (van den Berg, 2011). Leucine-rich proteins, 
chondroadherin and PRELP (proline/arginine rich end leucine rich repeat protein) may be 
involved in interactions between chondrocytes and the surrounding matrix. These two 
leucine-rich proteins bind via membrane proteins such as syndecan and α2β1 integrin 
(Goldring, 2000). Chondrocyte senescence is likely to occur extrinsically through chronic 
stress as adult articular chondrocytes rarely if ever divide in normal tissue in vivo (Aigner 
et al., 2001). However in senescent chondrocytes β-gal activity has been reported to 
increase and telomere length decreases in oxidative induced senescence accelerated mice 
(Shimada et al., 2011). Aged chondrocytes are associated with the release of 
glycosaminoglycans and the production of reactive oxygen species, this results in the 
homeostasis of the ECM becoming more difficult to maintain for aged chondrocytes, 
leading to a breakdown and loss of cartilage as well as a decline in the proliferative and 
anabolic response to growth factors such as TGF-β (Loeser, 2009). Chondrocyte autophagic 
cell death has been reported to be higher in osteoarthritis patients when compared to 
healthy aged chondrocytes (Yin, 2013). These senescent and autophagic phenotypes of 
chondrocytes may contribute to age being a risk factor for osteoarthritis.  
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1.2 Osteoarthritis 
Osteoarthritis (OA) is a disease that affects the whole joint with progressive and focal 
hyaline articular cartilage loss with accompanying morphological changes to the  
subchondral bone (Felson et al., 2000). Soft tissue structures in and around the joint are 
also affected, causing pain due to swelling and inflammation (Wise & Factors, 2007). 
Osteoarthritis causes a huge burden on many countries’ healthcare systems. In the UK the 
costs of non-steroidal anti-inflammatory drug treatments (NSAIDS) are predicted to cost 
£44.85 million, with hip and knee replacement costs exceeding £850 million (A. Chen et al., 
2012). The economic strain caused by OA is due to its high prevalence and effects of 
disability. The world’s population is ageing and the prevalence of OA increases with age 
(Lawrence et al., 2008). The burden on healthcare systems will only increase with indirect 
costs from OA causing a loss of economic production over £3.2 billion (A. Chen et al., 2012). 
1.2.1 Epidemiology 
Osteoarthritis is the most common form of arthritis and is responsible for joint replacement 
surgery every 1.5 minutes in Europe (Wieland et al., 2005). In England there are 40 000 
total hip replacements per year thought to be mainly due to the high prevalence of 
symptomatic hip osteoarthritis in the Western world (about 10% of people ⩾60 years) 
(Dreinhöfer et al., 2006). In the UK approximately 8.5 million people suffer from OA with 6 
million people in constant pain (Y. Wang et al., 2011). The disease limits movements in 80% 
of patients with 25% of these patients unable to perform daily activities affecting normal 
every day life (Kean et al., 2004). These disabilities often result in social isolation and 
depression (Rosemann et al., 2007).  
The study of OA epidemiology is problematic due to the heterogeneity in definitions of the 
disease. The complex pathology of OA, the difficulty in detecting the diseases onset and 
grading its severity also make epidemiology challenging. Osteoarthritis is normally 
diagnosed via radiograph, MRI or arthroscopy and the severity of the disease can be graded 
using the Kellgren and Lawrence system (Kellgren & Lawrence, 1957). This grading system 
was developed in the 1950’s by Kellgren and Lawrence when they undertook the first large 
scale epidemiological study of osteoarthritis (Felson et al., 2011). This grading system 
consists of five categories, starting with no radiographical evidence of OA with grade 0 
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through to grade 4 with increasing osteophyte development and joint space narrowing 
(JSN) severity (Kellgren & Lawrence, 1957). More recently a meta-anaylsis has revealed the 
prevalence of OA in the knee 23.9%, hip 10.9% and the hand 43.3% (Pereira et al., 2011).  
1.2.2 Pathology 
Cartilage loss is seen as the structural hallmark of OA and is visualized via joint space 
narrowing (JSN) using radiographs. Other hallmarks include bone changes in the form of 
subchondral sclerosis and osteophytes as well as changes to the ligaments, muscles, 
menisci, the afferent sensory system and the synovium (Roos et al., 2011). Muscle 
weakness is one of the earliest and most frequent findings in patients with OA (Palmieri-
Smith et al., 2010). There are many characteristics of this debilitating disease such as focal 
erosive cartilage lesions.  
Patients with radiographic OA with are reported to have a greater occurence and more 
cartilage lesions when compared to healthy subjects (Dunn et al., 2004), (Reichenbach et 
al., 2010), (Zarins et al., 2010). The cartilage lesions molecular characteristics change 
depending on joint location. Knee lesions generally show matrix degradation whereas ankle 
lesions display matrix synthesis (Moskowitz, 2007). This may potentially explain why knee 
OA is more common than ankle OA. Early up-regulation of matrix synthesis may help to 
control lesion progression whereas an increase in collagenase activity may result in a more 
common, severe pathology (Aurich et al., 2005).  
During the development of OA micro-fractures in the subchondral bone occur.  It is 
hypothesised that the failure to properly absorb impact leads to microdamage in the 
subchondral plate and calcified cartilage (Burr & Radin, 2003). This would result in the 
shock absorbing properties of the subchondral bone being negated (Lajeunesse et al., 
2003). Stress-induced micro-fractures appears to be the first step in the development of 
subchondral cysts (Dürr et al., 2004). The cystic lesion itself is then induced by osteoclast 
reabsorbtion. The cysts can form on the bone during the early phases of OA however the 
prevalence of cysts in patients and whether they always lead to OA development is unclear. 
These sacs extrude from the joint and mainly consist of hyaluronic acid. Their formation 
can lead to pain and loss of mobility. Cysts can improve without medication however the 
symptoms often remain due to the damage cysts cause to the subchondral bone (Swagerty 
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& Hellinger, 2001). Unlike subchondral cyst formation osteophytes at the synovial joint 
margin are not linked to bone resorption. Antiresoprtive drugs such as zoledronate have 
failed to inhibit osteophyte formation and were unable to prevent or correct cartilage 
deterioration (Bagi et al., 2015). Osteophytes can be used to detect OA, whereas joint space 
narrowing, subchondral bone sclerosis and cysts are used to assess the severity (Kijowski 
et al., 2006). Osteophytes may be a repair mechanism helping to stabilise the joint however 
they also cause pain and loss of movement (Blom et al., 2004).  Formation of osteophytes 
are thought to be caused by endochondral ossification (Brandt, 2003). This is the process 
by which avascular cartilage tissue is converted into vascularised bone tissue (Higgs, 2010).  
1.2.3 Aetiology 
There are many risk factors for OA some of which include, age, sex, genetics, obesity and 
joint injury but how these lead to increased risk remains uncertain (Blagojevic et al., 2010).  
1.2.3.1 Aging 
While old age is a major risk factor for OA, growing old does not inevitably result in OA, 
however in the USA 49.7% of adults 65 years or older suffer from reported doctor-
diagnosed arthritis (Barbour, 2013). Aged chondrocytes have an increased susceptibility to 
cell death and respond poorly to growth factors (Anderson & Loeser, 2010). This results in 
chondrocytes being less successful in maintaining homeostasis in the articular cartilage. 
The imbalance between the catabolic and anabolic activities of the chondrocytes is in part 
caused by synovial inflammation. The homeostasis of the cartilage becomes imbalanced 
resulting in OA.  
1.2.3.2 Gender 
The Framingham Knee Osteoarthritis study, a population-based study of OA, reported that 
woman are 1.7 times more likely to develop knee OA than men (Felson et al., 1995).  The 
reasons for this increase in incidence are not clear, however up until the age of 50 
prevalence of OA between men and women are similar  (Kellgren et al., 1963). It is 
hypothesised that hormonal changes brought on by the menopause may play a role in the 
increased incidence of OA in women past the age of 50 (Oliveria et al., 1995). Studies 
focusing on postmenopausal oestrogen intake have not been able to clearly define the 
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association of oestrogen and incident of knee and hip OA (Chaganti & Lane, 2011). Muscle 
weakness may unify the risk factors of sex, obesity, age and joint injury. Muscle strength is 
reduced after injury, is lower relative to body mass in people suffering from obesity, 
females have lower muscle strength than males and this strength simultaneously decreases 
with age (Roos, 2005). 
 
1.2.3.3 Genetic factors 
Genetic factors and heritability currently have a poorly defined role in the onset and 
propagation of OA. As early as 1955 Stetcher et al described Heberden’s nodes as a 
hereditary disease (Stetcher, 1955). Heberden’s nodes are firm swellings over the distal 
interphalangeal joints (Heberden, 1802) and are considered a marker for predisposition to 
OA (Stecher & Hersh, 1944). Various factors can contribute to the difficulty in analysing 
genetic association studies of OA. A lack of consensus on the definition of OA, how to 
compare OA from various joint sites together can make it difficult to group studies and to 
identify genes involved in the disease (Kerkhof et al., 2008). Despite these difficulties 
various single nucleotide polymorphisms (SNPs) have been associated with OA. Frizzled-
related protein 3 is encoded by FRZB an antagonist of the Wnt signalling pathway (Valdes 
et al., 2007). Chondrocyte maturation, function and phenotype are regulated by the Wnt/β-
catenin pathway and its vital for cartilage boundary definition, endochondral ossification 
and growth plate organisation (Tamamura et al., 2005). In a cohort study of 298 males and 
305 females aged between 50-86 with a diagnosis of knee OA, with a control group of 300 
men and 299 women an SNP in FRZB was associated with OA. The FRZB T/G haplotype was 
shown to be involved in the pathogenesis of knee and hip OA in women (Valdes et al., 
2007). Data from the 1000 Genomes Project and a genome-wide association scan for OA 
identified SNP rs11842874 in MCF2L across 19,041 OA patients and 24,504 controls (Day-
Williams et al., 2011). In human cells MCF2L regulates neurotrophin-3, a member of the 
nerve growth factor (NGF) family. Schwann cell migration is regulated by MCFL2 
neurotrophin-3 induction (Z. Liu et al., 2009). Patients with moderate-to-severe OA of the 
knee were treated with Tanezumab, a humanised IgG2 monoclonal antibody directed 
against NGF, this treatment was associated with reduction in pain and an improvement in 
knee function (Lane et al., 2010). A genome-wide association study to identify new 
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susceptibility loci for OA (arcOGEN) found five genome-wide significant loci for association 
with OA (Zeggini et al., 2012). 
 
1.2.3.4 Obesity 
Research from the Framingham Knee Osteoarthritis Study associated overweight men and 
women with a higher risk for developing OA than participants that were not overweight 
(Felson et al., 2007). Obese individuals with a BMI greater than 30kg/m2 were four times as 
likely to suffer from knee OA than intervals with a BMI below 25.0kg.m2 (Magrans-Courtney 
et al., 2011). Wang et al., found that a continuing trend in obesity would present a loss of 
2.2-6.3 million quality-adjusted life years (QALYs) in the UK. This loss in quality of life via an 
increase in obesity is due to non fatal diseases such as OA and hypertension becoming more 
prevalent (Wang et al., 2011). Obesity can contribute to OA in a variety of ways; 
biomechanical stress as well as hormonal and micro-nutritional changes could all 
potentially affect an individual’s likelihood of developing OA. A report by the Arthritis 
Research Campaign titled “Osteoarthritis and obesity” explains that, “Excessive loading of 
the joint is the most important means by which obesity causes osteoarthritis”. This direct 
cause and effect view of OA and mechanical stress may not accurately describe the role 
that obesity plays in the disease. Studies of OA in the hand have shown a clear association 
between obesity and incidence of OA, this association was also much stronger in women 
(Carman et al., 1994). There is an estimated 9-13% increased risk for the onset of the 
disease at the hand with every kilogram increase in body mass (Cicuttini et al., 1996). In 
these studies it appears that obesity is playing a role independent of mechanical stress. 
Systemic factors such as adipose tissue hormones (adipokines) could provide a metabolic 
link between osteoarthritis and obesity (Pottie et al., 2006). Traditionally adipose tissue 
was viewed primarily as a passive energy reserve, its identification as an endocrine organ 
began with the discovery and characterisation of the adipokine leptin (Zhang et al., 1994) 
and adiponectin in 1996. 
 Identified in 1996 (Maeda et al., 1996) adiponectin is an adipokine and its production 
correlates with several inflammatory markers (Francin et al., 2014). Females with erosive 
OA of the hands have an increased serum level of adiponectin (Filková et al., 2009). 
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Adiponectin has been found in the synovial fluid of females with knee OA and adiponectin 
was positively correlated with degraded fragments of aggrecan (Hao et al., 2011). The role 
that adiponectin plays in OA is a complicated one. The mRNA for a receptor of adiponectin 
(AdipoR1) is strongly associated with mRNA expression of type 2 collagen, aggrecan and 
Sox9 in OA articular cartilage (Francin et al., 2014). This suggests that adiponectin may be 
involved in cartilage repair attempts during OA. However the gene encoding adiponectin is 
closely correlated with MMP13 gene expression. An immunoassay analysis of culture 
supernatants indicated that stimulation of primary human chondrocytes with 
physiologically relevant concentrations of the full length adiponectin hormone significantly 
increased MMP-13 activity (Francin et al., 2014).  Further studies are needed to determine 
if adiponectin is protective in OA or if it actively participates in cartilage destruction. 
Hormones such as leptin may have an important role in the pathogenesis of OA and obese 
individuals often suffer from leptin insensitivity. Osteoarthritis is more common in women 
than men and females aged between 32-60 have been shown to have serum leptin levels 
2.3 times higher than males of the same age when corrected for fat mass (Bennett et al., 
1997). High leptin expression levels have been shown to be associated with disease severity 
in OA patients (P. Zhang et al., 2015). Leptin strongly stimulates anabolic activity in 
chondrocytes inducing the synthesis of insulin like growth factor (IGF)-1 and TGF-β 
(Teichtahl et al., 2005). Activities of these proteins are thought to represent a repair 
mechanism for damaged cartilage. 
 
 
1.2.3.5 Signalling pathways in OA 
 TGFβ is known to stimulate proteoglycan and collagen synthesis (Redini et al., 1988). The 
effects of TGFβ on the joint are more complicated than anabolic stimulation of cartilage 
alone. A strong decrease in the content of proteoglycan was found in the cartilage of rabbits 
knees when injected with TGFβ (Elford et al., 1992). Mice injected with TGFβ have increased 
proteoglycan degradation despite concomitant inhibition of IL1 stimulated degradation 
(van Beuningen et al., 1993). Active TGFβ has been shown to be present in the synovial fluid 
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of OA patients, at an average concentration of 4ng/ml (Fava et al., 1989). It was 
hypothesised that at these concentrations TGFβ could stimulate both aggrecan synthesis 
and degradation, resulting in increased aggrecan turnover (Moulharat et al., 2004). The 
resulting proteoglycan fragments produced by TGFβ-stimulated aggrecanases production 
could be the inflammatory trigger for cytokine production by chondrocytes (Pelletier et al., 
2001) leading to an increase in metalloproteinase production and aggrecan and collagen 
degradation seen in OA. The balance of these cytokines is crucial for maintaining healthy 
articular cartilage.  
Wnt signalling can also induce the expression of metalloproteinases in articular  
chondrocytes, promoting cartilage degradation and cartilage catabolism. Rabbit articular 
chondrocyte cultures subjected to experimental activation of β-catenin signalling by Wnt3A 
treatment showed a significant increase in metalloproteinase gene expression (Yuasa et al., 
2008). Transgenic mice have been generated that express an inhibitor of β-catenin and T 
cell factor (ICAT) which was targeted to chondrocytes specifically using the Col2a1 
promotor. ICAT is a naturally occurring inhibitor that specifically disrupts TCF and beta-
catenin interactions.  Inhibition of the Wnt/β-catenin signalling pathway was shown to 
increase chondrocyte cell apoptosis and articular cartilage destruction in Col2a1-ICAT-
transgenic mice (Zhu et al., 2008). These experiments show that both over and under 
activation of the Wnt/β-catenin can result in OA and a joint must have the correct 
homeostasis of the pathway to remain healthy. Without Wnt signalling β-catenin is 
targeted for proteasome-mediated destruction within the Glycogen synthase kinase 3 
(GSK-3) destruction complex brought together by Axin/Axin2 and APC. In the presence of 
Wnt signalling Frizzled receptors inhibit the destruction of β-catenin, resulting in its 
accumulation and translocation to the nucleus (Yuasa et al., 2008). FRZB is a secreted Wnt 
antagonist, this gene has been knocked out in mice, this resulted in cartilage damage via 
increased activity and expression of matrix metalloproteinases which was associated with 
increased Wnt signalling (Lories et al., 2007). 
IL1 is a pro-inflammatory cytokine that has been frequently studied and is found in the OA 
joint. During OA IL1 is primarily produced by chondrocytes (Goldring, 2000) and synovial 
fibroblasts (Sadouk et al., 1995). In OA joints IL1 localises to the superficial zones of OA at 
the site of cartilage degradation (Tetlow et al., 2001). IL1 promotes the synthesis of matrix 
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metalloproteinases in chondrocytes (Zayed et al., 2008) and can cause inflammation by 
inducing the expression of (COX-2) and nitric oxide synthase (iNOS), this can result in the 
synthesis of inflammatory mediators such as nitric oxide (NO) (Vuolteenaho et al., 2005), 
(Hung et al., 2008). IL1 can induce degradation of aggrecan (Ismail et al., 2015), 
proteoglycan (Nguyen et al., 1989) and type 2 collagen (Billinghurst et al., 2000), (Kozaci et 
al., 1997) in human chondrocytes. A local increase in IL1 receptor antagonist (IL1Ra) 
production in OA knee joints by intraarticular injection of transduced synovial cells has 
been shown to reduce the progression of experimentally induced OA lesions in a canine 
model (Pelletier et al., 1997). ILRa has also been shown to significantly improve clinical 
parameters of pain, preserve articular cartilage, and have beneficial effects on the 
histologic parameters of the synovial membrane and articular cartilage in an experimental 
equine OA model (Frisbie et al., 2002). Research into the inhibition of IL1R in humans is still 
rare. An intra-articular injection of 150mg anakinra (a recombinant form of human ILRa) 
has been shown to significantly reduce pain scores in patients suffering with knee OA 
(Chevalier et al., 2005). However this study lacked controls making it difficult to make a 
definitive conclusion on the efficacy of anakinra (Calich et al., 2010). In a randomized, 
double blind, placebo controlled study a 10mg intraarticular injection of anakinra in 
patients with OA of the knee was not associated with improvements in OA symptoms 
compared with placebo (Chevalier et al., 2009). For cartilage to remain healthy there must 
be a balance between matrix synthesis and degradation. How this balance is maintained is 
poorly understood, but anabolic and catabolic cytokines appear to have important roles 
(Buckwalter et al., 2005). When this balance is lost several key metalloproteinases are 
upregulated and cartilage destruction occurs. 
1.3 The Metalloproteinases 
There are six classes of proteinases (aspartic, cysteine, glutamic, metallo-, serine and 
threonine), these are classified according to their catalytic mechanisms (Rawlings et al., 
2004), (Shen & Chou, 2009).  Metalloproteinases contain a metal ion at their active site. 
The metzinicin superfamily of metalloproteinases are defined by the HEXXH motif, a 
histidine as the third zinc ligand and a right hand met-turn. This superfamily includes the 
astacin, adamalysins, serralysin and the matrixin subfamilies (Hooper, 1994). These 
proteases can degrade all ECM components (P. Lu et al., 2011). While many classes of 
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proteases are upregulated in OA the current dogma is that a disintegrin and 
metalloproteinase domain with thrombospondin motis (ADAMTSs) degrade aggrecan 
(Verma & Dalal, 2011) and following this critical step a diverse range of matrix 
metalloproteinases continue to degrade major components of the ECM (G. Smith, 2006). 
1.3.1 ADAMs and ADAMTSs 
The ADAMs (Disintegrin And Metalloproteinase domain) and ADAMTSs (disintegrin, a 
metalloproteinase and thrombospondin motifs) are adamalysins. The ADAMs family  
include both transmembrane and secreted proteins, ADAM-9, ADAM-10 and ADAM-28 can 
be alternatively spliced to be either secreted or membrane-bound (Hotoda et al., 2002), 
(Yavari et al., 1998) (Roberts et al., 1999). Both transmembrane and secreted ADAMs are 
involved in the cleavage of the ectodomain of many receptors, signalling molecules, 
cytokines and growth factors (Edwards et al., 2008). Membrane-bound ADAMs 
proteolytically release the extracellular portions of other transmembrane proteins in a 
process known as shedding (Moss & Lambert, 2002). The ADAMs domain structure consists 
of a prodomain, a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, 
an EGF-like domain, a transmembrane domain and a cytoplasmic tail (Seals & Courtneidge, 
2003). It is thought that it is the cysteine-rich domain that is involved in the regulation of 
ADAMs specific functions (K. Smith et al., 2002).  
While the majority of ADAM proteinases are transmembrane proteins the ADAMTSs have 
no transmembrane domains and are therefore secreted molecules that can bind to the 
ECM (Kaushal & Shah, 2000). ADAMTSs proteins share sequence similarity to the ADAMs 
(A disintegrin and metalloproteinase) (Nicholson et al., 2005). ADAMTS aggrecanases were 
discovered by the end sequences of cleaved aggrecan (termed neo epitopes) found in 
culture medium and synovial fluid in the absence of matrix metalloproteinase activity. 
There are 19 known ADAMTSs numbered 1-20 with no ADAMTS-11 and the function and 
substrates of many of the ADAMTSs are yet to have been characterised (Table 2). ADAMTS-
2, -3 and -14 are pro collagen N-propeptidases these are essential for the maturation of 
triple helical collagen fibrils and are required for fibril assembly (Colige et al., 2002). 
ADAMTS-1, -4, -5, -8, -9 and -15 have been shown to degrade aggrecan matrix proteoglycan 
with varying efficeniency (Kuno et al., 2000), (Tortorella, 1999), (Tortorella et al., 2002), 
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(Collins-Racie et al., 2004), (Somerville et al., 2003), (Yamaji et al., 2001). Of these ADAMTS-
4 and ADAMTS-5 are the most efficient aggrecanases (Abbaszade et al., 1999), (Tortorella 
et al., 1999) with ADAMTS-5 reported as being 1,000 times more active than ADAMTS-4 
under physiological conditions (Gendron et al., 2007). These aggrecanases cleave aggrecan 
at a number of sites in the proteins core, cleavage at the interglobulin domain (IGD) 
between the N-terminal G1 and G2 globular domains predominantly occurring within 
diseased tissue resulting in loss of the entire GAG containing region (Little et al., 2007) 
(Sandy et al., 1992) (Sandy, 2006).  
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The molecular structure of the ADAMTS proteins can be subcategorized into various 
domains and motifs (Figure 1.7). Initially synthesised as inactive pre-proenzymes the 
domains from the N-terminus to the C-terminus consists of a signal peptide, pro-domain, a 
metalloproteinase domain, a disintegrin-like domain, a cysteine-rich domain, a spacer 
Gene Location Factors inducing or (repressing) expression Substrates 
    
ADAMTS1 21q21 Progesterone, Brg1, IL1, S100A8, S100A9, TNFα 
Aggrecan, versican, syndecan 4, 
TFPI-2, semaphorin 3C, nidogen-
1, −2, desmocollin-3, 
dystroglycan, mac-2, gelatin 
(denatured collagen type I), 
amphiregulin, TGF-α, heparin-
binding EGF 
    
ADAMTS2 5q35 Glucocorticoids (in monocytes), IL-6 
Fibrillar procollagens types 1-3 
and V 
ADAMTS3 4q21  
Fibrillar procollagen type 2, 
biglycan 
ADAMTS4 1q23 
IL1 + oncostatin M, TNFα, S100A8, S100A9, 
leptin, IL-6 
Aggrecan, versican, reelin, 
biglycan, brevican, matrilin-3, α2-
macroglobulin, COMP 
  (HDAC inhibitors, pentosan polysulfate)  
ADAMTS5 21q21 IL1, TNFα, S100A8, S100A9, leptin, IL-6 
Aggrecan, versican, reelin, 
biglycan, matrilin-4, brevican, α2-
macroglobulin 
  (HDAC inhibitors)  
ADAMTS6 5q12 TNFα, - 
ADAMTS7 5q24 PTHrP COMP 
  (miR-29a/b)  
ADAMTS8 11q24  Aggrecan 
ADAMTS9 3p14 TNFα, IL1 + oncostatin M, leptin Aggrecan, versican 
  (HDAC inhibitors)  
ADAMTS10 19p13  Fibrillin-1 
ADAMTS12 5p13  COMP 
ADAMTS13 9q34 (IL1) vWF 
ADAMTS14 10q22  
Fibrillar procollagen type I (pNα1 
and pNα2 chains) 
ADAMTS15 11q24  Aggrecan, versican 
ADAMTS16 5p15 Follicle stimulating hormone; forskolin (cAMP); - 
  
Transcription factors: Wilm’s tumor-1; Egr-1, 
Sp1 
 
ADAMTS17 15q26  - 
ADAMTS18 16q23  - 
ADAMTS19 5q23  - 
ADAMTS20 2q12  Versican 
Table 2. ADAMTS genes. Table showing the chromosomal positions, expression-inducing 
factors and substrates of the ADAMTSs  Table adapted from (Kelwick et al., 2015). 
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region and a C-terminal containing variable numbers of thrombospondin repeats with 
additional modules (Porter et al., 2005). The pro domain retains the enzymes latency and 
is thought to also be potentially important for correct protein folding and secretion. While 
the majority of ADAMTSs are synthesised as zymogens that are activated through the 
removal of the pro domain both ADAMTS-7 and -13 retain activity with the pro domain 
attached (Somerville et al., 2004) (Majerus et al., 2003).  
 
 
ADAMTSs appear to play a role in the development of OA. ADAMTS-5 knock out mice had 
a significant reduction in the severity of cartilage destruction after surgically induced 
instability when compared with wild type mice (Glasson et al., 2005a). Interestingly 
deletion of ADAMTS-4 does not confer a similar protection as seen in ADAMTS-4 mice 
(Gendron et al., 2007). ADAMTS-5 has also been shown to be the major aggrecanase in 
mouse cartilage. In a mouse model of inflammatory arthritis ADAMTS-5 was deleted, this 
protected mice against aggrecan loss and cartilage erosion (Stanton et al., 2005). 
Whether ADAMTS-5 is the principal aggrecanase in human cartilage is still unclear (Fosang 
et al., 2008). Two likely deleterious nonsynonymous single-nucleotide polymorphisms 
Figure 1.7. Common structure of ADAMTSs. 
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(SNPs) were identified in ADAMTS-5 using bioinformatic analysis. These genetic variations 
were examined in 2715 patients with knee, hip, or hand OA and in 1185 OA-free controls. 
Genetic variation in ADAMTS-5 appeared to have no participation in OA susceptibility 
(Rodriguez-Lopez et al., 2008). These results indicated that further exploration is needed 
to determine whether aggrecanase ADAMTS-5 in human OA is as critical as in mouse 
models. 
1.3.2 Matrix Metalloproteinases 
Matrix Metalloproteinases (MMPs) also called matrixins are enzymes responsible for the 
cleavage of matrix proteins such as collagen, laminin and fibronectin as well as many other 
substrates (Table 3). The MMP family is composed of 24 matrixin genes including a 
duplicate of MMP-23 resulting in 23 MMPs in humans (Nagase et al., 2006). MMP1 was 
discovered in a tadpole tail during metamorphosis (Gross & Lapiere, 1962) and was the first 
secreted member of a family of enzymes to be discovered (Maskos, 2005). The sequence 
homology with MMP-1, the propeptides cysteine switch motif, and the zinc binding motif 
(HEXXHXXGXXH) in the active site are the signatures used to assign proteinases to this 
family (Visse & Nagase, 2003). The prodomain is an amino-terminal signal sequence that 
directs the molecule to the endoplasmic reticulum (Figure 1.8). The propeptide domain 
contains the zinc-interacting thiol group that maintains the enzyme in its inactive zymogen 
form. This pro-domain consists of about 80 amino acids containing a conserved 
PRCG(V/N)PD amino acid sequence that interacts with the catalytic zinc ion to suppress its 
own proteolytic activity (cysteine switch) (Kim & Joh, 2012). Conformational changes occur 
when the pro-domain is removed and the zinc ion binds to water allowing for hydrolysis of 
peptide bonds when the MMP binds with its substrate (Van Wart & Birkedal-Hansen, 1990). 
Cleavage of the prodomain can be mediated by MMPs themselves in a process called 
autolysis or by another proteinase, allosteric perturbation of the zymogen or modification 
of the free thiol by experimental or physiological means (Tocchi & Parks, 2013) (Springman 
et al., 1990).  
The catalytic domain contains the zinc binding site, 2-3 calcium ions that maintain the 
structure of the active site and a conserved methionine forming part of the ‘met-turn’ 
structure (Bode et al., 1993). The catalytic domain consists of 160-170 amino acids making 
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three α-helices a five-stranded β-sheet and bridging loops (Tallant et al., 2010). The 
haemopexin domain-containing MMPs have a haemopexin like domain at the C-terminus 
that is connected to the catalytic domain by a proline-rich hinge domain, these domains 
mediate interactions with the tissue inhibitors of metalloproteinases, proteolytic 
substrates and cell surface molecules (Egeblad & Werb, 2002). MMP-7, 26 and 23 are 
exceptions to this structure as they contain no hinge or haemopexin domains (Lohi et al., 
2001). 
 
 
 
 
MMPs are grouped into the membrane-type MMPs (MT-MMPs) (MMP-14 to MMP-17 and 
24, 25 or MT1-6-MMP), the stromelysins (MMP-3, 10, 11), a heterogeneous subgroup 
including matrilysin (MMP-7), gelatinases (MMP-2, 9) and the collagenases (MMP-1, 8, 13) 
(Y.E. Chen, 2004) (Table 3). 
 
 
 
 
 
 
 
Figure 1.8. Common structure domain of an MMP. SP – signal peptide and Pro – domain at the 
N terminus. Catalytic site is zinc bound, HG – hinge domain, with a Haemopexin domain at the 
C terminus. Figure adapted from (Brauer, 2006). 
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MMP COMMON NAMES MATRIX SUBSTRATE 
MMP-1 
Collagenase-1, 
fibroblast collagenase 
Type 3>1>2>7>10 collagen gelatin, 
aggrecan, entactin, tenascin, Pro-MMP1, 
Pro-MMP2 
MMP-8 
Neutrophil 
collagenase, 
collagenase-2 
Type 1>2>3,7,10 collagen gelatin, aggrecan, 
Pro-MMP8 
MMP-13 Collagenase-3 
Type 2>3>1, 7,10 collagen, gelatin, entactin, 
tenascin, aggrecan 
MMP-3 
Stromelysin-1, SL-1, 
Transin-1 
Aggrecan, laminin, fibronectin, non triple 
helical regions of type 2, 3, 4, 5, 9, 10 and 
11 collagen, gelatin, Pro-MMP1, 3, 7, 8, 9 
and 13 
MMP-10 
Stromelysin-2, SL-2, 
Transin-2 
Fibronectin, Pro-MMP1, 8 and 10 
MMP-11 
Stromelysin-3, SL-3, 
ST3, STMY3 
Fibronectin, laminin, aggrecan, type 6 
collagen 
MMP-19 Stromelysin-4, SL-4 
Native type 4 collagen, gelatin, laminin, 
fibronectin, tenascin, fibrin/fibrinongen 
MMP-7 
Matrilysin, mat, 
PUMP-1, uterine 
metalloproteinase 
Fibronectin, laminin, non helical segments 
of type 4, 5, 9, 10 and 11 collagen gelatin, 
aggrecan, fibrin/fibronectin 
MMP-26 
Endometase, 
matrilysin-2 
Native type 4 collagen, gelatin, fibronectin, 
fibrin/fibrinogen, Pro-MMP9 
MMP-2 
Gelatinase A, 72-kDA 
gelatinase 
Gelatin, type 1, 4, 5, 7, 10 and 11 collagen, 
elastin, fibronectin, laminin-5, aggrecan, 
vitronectin 
MMP-9 
Gelatinase 
thermometer, 92-KDa 
gelatinase 
Gelatin, type 1, 4, 5, 7, 10, 11  collagen, 
elastin, fibronectin, laminin, aggrecan, 
vitronectin, Pro-MMP2, 9 and 13 
MMP-14 MT1-MMP 
Type 1,2,3 collagen, gelatin, fibronectin, 
vitronectin, aggrecan, Pro-MMP2 and 13 
MMP-15 MT2-MMP Proteoglycan, Pro-MMP2 
MMP-16 MT3-MMP 
Native collagen type 3, fibronectin, Pro-
MMP2 
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MMP-17 MT4-MMP Gelatin, fibrilin/fibronectin, Pro-MMP2 
MMP-24 MT5-MMP Fibronectin, proteoglycans, gelatin 
MMP-25 MT6-MMP 
Type 4 collagen, gelatin, fibronectin, pro-
MMP2, pro-MMP9 
MMP-20 Enamelysin Amelogenin 
MMP-23 
Cysteine array MMP 
femalysin 
Gelatin 
MMP-27  No matrix defined substrates 
MMP-28 Epilysin Casein 
 
 
The collagenases consist of MMP-1, 8, 13. These enzymes are able to cleave interstitial 
collagens 1, 2 and 3 into specific  ¾- and  ¼- collagen fragments (Sorsa et al., 1989). MMP-
2 and MMP-14 have more recently been shown to make this specific cleavage but with less 
catalytic efficiency (Knauper et al., 1996), (Ohuchi et al., 1997), (d’Ortho et al., 1997). 
Collagenases are important for ECM remodelling during tissue development and 
regeneration. The mechanism of collagen breakdown that MMPs facilitate is fundamental 
in normal healthy cells and is involved in tissue reabsorption and remodelling, cell 
proliferation and migration, chemotaxis and apoptosis (Nagase & Woessner, 1999). 
Disruption of this homeostasis can result in diseases such as OA (Israel et al., 1998) and 
tumour metastasis (Ala-aho & Kähäri, 2005).  
The stromelysins consist of MMP-3, 10 and 11. Both MMP-3 and MMP-10 digest 
proteoglycan core proteins, laminin, fibronectin, elastin, gelatin and type 3,4,5,7 and 9 
collagen (D. Li, 2003). Both MMP-3 and MMP-10 participate in proMMP activation. For the 
maturation of proMMP-1 into the fully active MMP-1 it is crucial for MMP-3 to cleave the 
Gin80-Phe81 bond (Suzuki et al., 1990).  The third stromelysin is MMP-11, however this 
MMP can only weakly degrade ECM components apart from type 6 collagen (Murphy et al., 
Table 3. MMP genes. Table to summarise MMPs and their substrates. Table adapted from (S. 
Shapiro, 1998), (Egeblad & Werb, 2002). 
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1993).  The furin recognition sequence is present in MMP-11 suggesting its activated 
intracellularly (Pei & Weiss, 1995). 
The matrilysin group consists of MMP-7 and MMP-26. These MMPs lack a haemopexin 
domain. As well as degrading ECM components matrilysins have been shown to process 
cell surface molecules such as E-cadherin in Madin-Darby canine kidney cells (MDCK). The 
MDCK cells were treated with 100ng/ml of matrilysins for 2 hours, which stimulated E-
cadherin fragments to be released (Noe et al., 2001). Unusually for an MMP, MMP-26 was 
found to be stored intracellularly in MCF7 breast carcinoma cells (Marchenko et al., 2004). 
Gelatinases include MMP-2 and MMP-9. Gelatinases are the main enzymes for the 
digestion of gelatin which is the product of collagen after its degradation by the 
collagenases. These MMPs have three repeats of a fibronectin type 2 motif in the 
metalloproteinase domain. These repeats help the gelatinases bind to gelatin, collagens 
and laminin (Allan et al., 1995).  
There are two groups of Membrane type MMPs (MT-MMPs). There are the type 1 
transmembrane proteins such as MMP-14, 15, 16 and 24 which have a carboxy terminal, 
single span transmembrane domain and a short cytoplasmic tail (Fillmore et al., 2001). 
Finally there are the glycosylphosphatidylinositol (GPI)-anchored MMPs such as, MMP-17 
and MMP-25. These anchors are located downstream of the haemopexin-like domain 
(Sohail et al., 2008). These MT-MMPs all have a RX(R/K)R furin recognition sequence at the 
propeptide C-terminus (Nagase et al., 2006). This allows furin to activate the MT-MMPs 
intracellularly, where they can then be expressed on the cell surface (Thomas, 2002). 
1.3.3 The regulation of Matrix Metalloproteinases 
MMP expression is largely regulated transcriptionally (Figure 1.9). Trans-activators such as 
activator protein-1 (AP-1), PEA3 (polyoma enhancer A binding protein-3), SP1 (specificity 
protein 1), β-catenin/TCF4 and nuclear factor kappa B (NFκB) can regulate MMPs through 
their cis elements (Figure 1.10). NFκB is a trans-activator that can regulate 
metalloproteases and mediates articular chondrocytes responses to proinflammatory 
cytokines such as IL1. The inhibitory κB (IκB) protein associates with NFκB in the cytoplasm 
keeping the protein in its inactive form. IL1 stimulation results in a signaling cascade leading 
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to the release of NFκB from IκB. Activated NFκB then translocates to the nucleus binding 
to its consensus DNA sequence within target genes resulting in their transcription. NFκB 
plays a central role in the development of OA. Cartilage damage has been shown to 
decrease in a surgically induced mouse OA model when treated with siRNA that inhibits 
NFκB/p65 (Chen et al., 2008). IκB overexpression decreases MMP-1, 3, 9, 13 mRNA and 
protein levels (Amos et al., 2006) and IL1 stimulated ADAMTS4 gene expression in human 
OA synovial fibroblasts (Bondeson et al., 2007).  
MMP promoters can be placed into three groups based on the composition of the cis-
elements. The first group contains MMP-1, 3, 7, 9, 10, 12, 13 and 19, these MMPs contain 
TATA boxes at around -30bp with AP-1 sites around -70bp. MMP8, 11 and 21 contain the 
TATA box but no AP-1 sites in the proximal promoter. Finally MMP-2, 14 and 28 contain 
neither TATA boxes or AP-1 sites in the proximal promoter (Gosset et al., 2010). This last 
group’s expression is determined by SP1 transcription factors that bind to a proximal GC 
group (Yan & Boyd, 2007).  
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Figure 1.9. MMP regulation. MMP function is regulated at many levels. This regulation occurs 
at the RNA transcription and protein levels but also by the secretion, intracellular trafficking, 
subcellular or extracellular localization, activation of the zymogen form, expression of their 
endogenous protein inhibitors of metalloproteinases (TIMPs) and α2-macroglobulin and 
protease degradation. Figure adapted from (Page-McCaw et al., 2007). 
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Cytokines and growth factors such as IL1, tumour necrosis factor ɑ (TNFɑ) and basic 
fibroblast factor (bFGF) convergently transactivate MMP promoters via AP-1 and PEA3 
through p38, c-Jun N-terminal kinases (JNK), mitogen-activated protein kinases (MAPK) and 
protein kinase C (PKC) signalling (Goldring et al., 2011), (S. Ahmed et al., 2003), (S. Ahmed 
et al., 2005), (Tower et al., 2003), (Muddasani et al., 2007), (Im et al., 2007). Cell surface 
Figure 1.10. MMP Promoters. Diagram showing cis elements in human MMP and TIMP 
promoters. C/EBP-β, CCAAT enhancer-binding protein. TIE, TGF-β inhibitory element. AP-1, 
activator protein-1. PEA-3, polyoma enhancer A binding protein-3. OSE-2, osteoblastic cis-acting 
element. TATA, TATA box. AP-2, activator protein-2. Sil, silencer. GC, Sp-1 binding site. NF-κB, 
NF-κB binding site. CCAAT, CCAAT box. GATA, GATA binding site. INR, initiator-like sequence. 
Taken from (Deschamps & Spinale, 2006). 
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receptors such as integrins can activate focal adhesion kinase (FAK), which can potentially 
interact with the MAPK pathway leading to trans activation of AP-1 and/or PEA3 resulting 
in MMP expression. (Yan & Boyd, 2007). 
There has been some evidence of epigenetic control of MMPs in the form of methylation 
(Barter et al., 2012). In one study the promoter of MMP-9 was methylated and silenced in 
lymphoma cell line (Chicoine et al., 2002). Another study used wild type colon cancer cells 
to demonstrate that demethylating agents could yield an induction of MMP-3 expression 
(Couillard et al., 2006). Histone deacetylase inhibitors trichostatin A (TSA) and sodium 
butyrate (NaBy) have been shown to repress MMP-1 and MMP-13 at the mRNA and protein 
levels in SW1353 cells (Young et al., 2005). 
MMPs are synthesised as pre-proenzymes. During translation the signal peptide is removed 
generating the zymogen. An important regulatory step of MMP activity is the activation of 
the zymogen (Nagase et al., 2006). There are also MMPs that are processed into the active 
form at the cell membrane. An example of this form of activation is the MT-MMP mediated 
cascade that activates proMMP-2 (Sato et al., 1994). 
1.3.4 Tissue inhibitors of metalloproteinases 
Tissue inhibitors of metalloproteinases (TIMPs) have a molecular weight of 21-30kDA, 
consist of 184-194 amino acids and are inhibitors of MMPs (Yadav et al., 2011). While TIMPs 
inhibit the activity of all MMPs tested so far (Nagase et al., 2006) with the exceptions of 
MT1-MMP and MT3-MMP for TIMP1 (Will et al., 1996), (Shimada et al., 1999) TIMP3 can 
also inhibit ADAMTSs. There are four human inhibitors in the TIMP family, TIMP1-TIMP4, 
these inhibitors are expressed in a range of different tissues. Many of the functional 
interactions between MMPs and TIMPs have been established by crystallographic structure 
analysis, crystal structures for MT1-MMP/TIMP2 and MMP-3/TIMP1 have both been solved 
and described (Fernandez-Catalan et al., 1998), (Gomis-Rüth et al., 1997). TIMPs have 12 
cysteine residues that have been shown to form disulphide bonds that form a 6 loop 
structure (Figure 1.11). The N-terminal and VIRAK amino acid sequence is conserved in all 
TIMPs (Caterina et al., 1998).  
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The catalytic zinc ion of a MMP is bidentate-chelated by the N-terminal amino group and 
the carbonyl group of the TIMP, this expels the water molecule bound to the zinc atom 
inactivating the MMP (Visse & Nagase, 2003).  TIMPs bind tightly to MMPs in a 1:1 ratio, 
meaning that if MMP production is below TIMP protein levels ECM degradation is 
prevented (Cawston & Wilson, 2006). 
While all TIMPs share basic similarities they also exhibit different structural features, 
expression patterns and biochemical properties, this may suggest that various TIMPs may 
have distinct and particular roles in vivo (Baker et al., 2002). TIMPs have also been reported 
to have activities other than MMP inhibition, these biological activities include promoting 
cell, promoting cell proliferation, anti-angiogenic, pro and anti-antiapoptotic and synaptic 
plasticity activities (Brew & Nagase, 2010) as well as activation of some proMMPs 
(Bernardo & Fridman, 2003).  In isolated rabbit mature osteoclasts TIMP1 and TIMP2 
stimulated bone-resorbing activity. Bone-resorbing activity was stimulated at lower 
concentrations of TIMPs (∼ng/ml) than concentrations needed to inhibit bone-resorbtion 
(∼µg/ml). This activity appeared to be MMP independent as MMP inhibitors BE16627B and 
R94138 could not mimic the osteoclast activity caused by TIMPs (Sobue et al., 2001).  
Figure 1.11. Structure of TIMP. Diagram shows the six loop structure of TIMP1. Image adapted 
from (Murphy & Willenbrock, 1995). 
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TIMPs -1, -2 and -4 are all soluble proteins whereas TIMP-3 is associated with the ECM 
through its C-terminal domain which recognises and binds to heparan sulphate in its 
glycosylated (27KDa) and unglycosylated (24KDa) forms (M. Lee et al., 2007) (W. Yu et al., 
2000). Of the four TIMPs TIMP-3 has the broadest inhibition spectrum and is the most 
potent inhibitor of the ADAMTS family (Brew & Nagase, 2010). There are also more subtle 
differences between the affinities of different TIMPs for other MMPs. TIMP-2 and -3 are 
weaker inhibitors than TIMP-1 for MMP-3 and MMP-7 which contrasts with their affinities 
for other MMPs (Hamze et al., 2007). TIMP-4 expression is selectively elevated in the 
human heart but has also been shown to be increased in human osteoarthritic femoral 
head cartilage, but while TIMP-4 may be increased as a defence mechanism against MMPs, 
these levels may not be enough to prevent cartilage damage in OA (Greene et al., 1996) 
(Huang et al., 2002). 
The expression of TIMPs are carefully regulated during normal physiological conditions and  
are upregulated in response to cartilage growth factors after joint damage, however this 
upregulation is not sustained whereas the MMP upregulation is sustained which can result 
in collagen destruction (Cawston et al., 1999). 
Inactivation of TIMPs can occur by neutrophil elastase, trypsin, and chymotrypsin, resulting 
in the degradation of TIMP into small fragments (Itoh & Nagase, 1995). 
1.3.5 Matrix metalloproteinases in osteoarthritis 
MMPs play an important role in articular cartilage degradation (Haslauer et al., 2013), 
(Poole et al., 2003). The collagenases are important in the development of OA because of 
their ability to degrade type 2 collagen, the predominant collagen in cartilage. While MMP-
8 can cleave type 2 collagen it has a higher specificity for type I collagen. MMP-8 is a major 
collagenase in tissues such as human dentin, highly expressed in human neutraphils and 
potentially important in cardiovascular disease, periodontis and breast cancer (Sulkala et 
al., 2007), (Gioia et al., 2002), (Sorsa et al., 2011), (Decock et al., 2008). However MMP-8 
appears to play a minor role in articular cartilage chondrocytes with no significant 
upregulation of MMP8  in OA cartilage in vivo nor by IL1 in vitro (Stremme et al., 2003). 
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MMP’s ADAMTSs and TIMP expression have been profiled in three comprehensive screens 
of end stage OA (Kevorkian et al., 2004) (Davidson et al., 2006) (Swingler et al., 2009).  
Kevorkian et al and Davidson et al screened for metalloproteinase gene expression in OA 
femoral head cartilage versus normal femoral head cartilage. The screen by Davidson et al 
also included gene expression from the synovium of the joint. Swingler et al screened the 
entire degradome in OA versus normal femoral head cartilage. All three screens showed 
anomalistic gene expression for ADAMTSs and MMPs in OA cartilage. Aggrecanases 
ADAMTS4 and 5 were shown to be decreased in cartilage and synovium however aggrecan 
loss via proteolysis is an early event in OA so mRNA expression may only be detected in 
earlier OA samples than the tissues used in these studies. MMP1 was also decreased in the 
screens while MMP13 was one of the most significantly increased in all three screens, 
helping to support the theory that MMP13 is the key collagenase involved in collagen type 
2 breakdown and the progression of OA. 
MMP-1 and MMP-13 are able to cleave native fibrillar collagen and both contribute to the 
pathological cleavage of collagen fibrils in OA (Burrage et al., 2006). Animal models have 
shown the potential protective effects that MMP1 inhibition may have in OA however the 
lack of a well characterised murine homologue has significantly limited the study of MMP1 
and the development of MMP-targeted therapeutics (Foley & Kuliopulos, 2014). Elevated 
MMP-1 activity has been reported in equine synovial OA joints (Brama et al., 2010). Twenty 
rabbits that underwent anterior cruciate ligament transection to induce OA had 
significantly reduced MMP-1 at the mRNA and protein level when treated with 
carboxymethylated chitin (CMC). Cartilage degradation was less severe in CMC treated 
rabbits and it was suggested that this was due to MMP-1 inhibition (Hongbin et al., 2004). 
Selective inhibitors have shown that MMP-13 may be the collagenase predominantly 
responsible for collagen release from human OA cartilage (Billinghurst et al., 1997). 
Selective inhibitors that could inhibit MMP-8 and MMP-13 but not MMP-1 were used on 
articular cartilage samples from 11 patients with OA and 5 adults without OA. A 
collagenase-generated neoepitope was used to reflect cleavage of type 2 collagen. The 
neoepitope was used to show that the inhibitor for MMP-8 and MMP-13 but not MMP-1 
was able to inhibit digestion of type 2 collagen in OA cartilage (Dahlberg et al., 2000). MMP-
13 appears to be the collagenase with the highest specificity for type 2 collagen with the 
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most efficient cleavage of the protein (Minond et al., 2006). The inhibition of MMP-13 has 
been studied in animal models of OA. In one model MMP13 knock out mice were surgically 
induced for knee OA. The MMP13 knock out mice had reduced cartilage erosion in the 
presence of aggrecan depletion 8 weeks after surgery (Little et al., 2009). 
Immunohistochemistry and dUTP nick end labeling (TUNEL) staining was used to detect 
aggrecan degradation. Although inhibition of MMP13 may have prevented cartilage 
degradation via reduced type 2 collagenolysis other mechanisms were also suggested. 
Reduced degradation of other MMP-13 substrates such as fibromodulin or type IX collagen  
could participate in the reduction of cartilage erosion. MMP-13 is also able to activate other 
MMPs such as proMMP-9, activation of these MMPs may contribute to cartilage erosion 
(Knäuper et al., 1997). It is possible that MMP-13 could regulate inflammatory cytokine and 
chemokine activity with roles in cartilage degradation (Manicone & McGuire, 2008). Taken 
together this research suggests that MMP13 inhibition could have a potential therapeutic 
effect in OA. 
1.4 Current Treatments 
Current treatments for OA have focused on anti-inflammatory drugs and pain relief rather 
than addressing the degradation of cartilage. 
As OA is associated with muscle weakness and obesity, current treatments have included 
lifestyle changes to the patient’s traditional diet and exercise regime. This form of 
treatment is useful as physical inactivity can also act as a severe risk factor for developing 
OA (Vijay et al., 2002). When body weight is reduced pain is reduced and functional capacity 
of the joint is improved. Alleviating obesity through these methods has been suggested to 
be among the most beneficial methods of relieving pressure on OA joints (Magrans-
Courtney et al., 2011).  
Clinicians routinely recommend that adults with OA strengthen muscles with exercise as 
strengthening has been linked with a reduction in pain and morbidity in patients (O’Grady, 
2001). However individuals with local joint abnormalities such as maligned or lax knees 
have an increased likelihood of tibiofemoral osteoarthritis progression with greater 
quadriceps strength (Sharma et al., 2003). It is possible that by building up quadriceps 
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strength the greater joint reaction force exerted by the muscle exceeds the stabilizing 
benefit gained, resulting in osteoarthritis progression.  
Acetaminophen (paracetamol) is a weak inhibitor of the synthesis of prostaglandins 
recommended as a first-line oral analgesic for knee OA (Zhang et al., 2008). (Jordan, 2003). 
A six week randomised control test in 25 patients showed that pain at rest for knee OA 
significantly improved with paracetamol over placebo (Jordan, 2003). Paracetamol’s action 
at the molecular level is still unclear (Graham & Scott, 2005), but it appears to raise the 
patients pain threshold through a central rather than a peripheral mechanism (Zhang et al., 
2004). However meta-analysis of clinical data has shown that both non steroidal anti-
inflammatory drugs and COX-2 inhibitors are more effective at pain relief and restoring 
physical function than acetaminophen (Neame et al., 2004). 
Non-steroidal anti-inflammatory drugs (NSAIDs) are small molecule drugs used to treat OA. 
They are effective for treating pain and are commonly used if the patient does not respond 
well to acetaminophen. NSAIDs target the isoforms of cyclooxygenase COX-1 and COX-2. 
COX-1 is expressed in many different cell types and COX-2 is induced more specifically at 
sites of inflammation. There are 2 subsets of NSAIDs, non-selective NSAIDs that inhibit both 
COX-1 and COX-2 and selective NSAIDs (coxibs) that target only COX-2. NSAIDs provide pain 
relief and have anti-inflammatory effects due to their ability to inhibit prostaglandin 
synthesis. COX enzymes are able to convert arachidonic acid into PGH2. PGH2 is then 
further catalysed by synthases into 5 bioactive prostaglandins, (PGE2, PGI2, PGF2a, PGD2, 
and thromboxane A2) (Chen et al., 2008). These prostaglandins then contribute to 
peripheral nerve sensitisation through protein kinase A mediated phosphorylation of 
sodium channels in nociceptor terminals, causing increased excitability and reducing the 
pain threshold (Wieland et al., 2005). When compared to paracetamol NSAIDs have 
generally had better efficacy but increased gastrointestinal side effects. For a 2 year 
randomised control trial Naproxen (a non-specific NSAID) was compared to acetaminophen 
in 178 patients. Although Naproxen led to greater reductions in pain than acetaminophen 
patient drop out was high due to acetaminophens lack of efficacy and adverse 
gastrointestinal side effects caused by Naproxen (Williams et al., 1993). As COX-1 is found 
in many different cell types it is thought that by only inhibiting the more specific COX-2 
targets there would be less gastrointestinal side effects. However COX-2 is also present in 
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high levels in the kidney potentially causing hypertension and fluid retention in patients 
(Petit-Zeman, 2004). COX-2 inhibitors have also been linked with myocardial complications. 
In a comparison between 8076 patients taking either Naproxen or Rofecoxib (a selective 
inhibitor of COX-2) fewer clinically important upper gastrointestinal events were found 
when using Rofecoxib. However Rofecoxib also increased myocardial infarction rates (Krotz 
et al., 2005). 
Intra-articular corticosteroid injections are used to deliver steroids directly to a joint with 
OA while avoiding most of the systemic effects caused by oral steroids. Oral steroids can 
cause peptic ulceration, aggravate diabetes, osteoporosis and muscle weakness. Injections 
of corticosteroids have been shown to significantly improve symptoms in a randomised 
trial of 101 patients. Patients were given either a placebo injection, an injection of 
corticosteroids or an injection of hyaluronic acid. While the corticosteroids had a clinical 
effect when compared to placebo it was short-lived with no protective effect seen at a 3 
month follow up. The injections of hyaluronic acid caused no statistically significant change 
in patient outcome (Qvistgaard et al., 2006). Corticosteroid and hyaluronic acid intra-
articular injections can cause pain with injection, cause post-injection flare, fat atrophy and 
can introduce infection into the joint (Kruse, 2008). A retrospective cohort study of 80 
patients has shown the potential adverse immunosuppressive effect intra articular 
injections can have, seen by their effect on the eventual outcome of total joint replacement 
due to increased incidence of post operative joint infection (Kaspar & de V de Beer, 2005). 
Osteotomy is surgery involving reshaping of bones. Osteotomy of the knee changes the 
position of the joint so that the weight bearing on the joint is on a healthy area of cartilage. 
Valgus high tibial osteotomy has been shown to improve joint function and reduce pain in 
the knee in eleven trials (Brouwer et al., 2005). Long term osteotomy cannot stop the 
degenerative process with the majority of patients eventually requiring total knee 
arthroplasty (van Raaij et al., 2007). Arthroplasty is a surgical procedure that replaces the 
arthritic joint surface with prosthesis. Joint replacement is used primarily in patients with 
late stage arthritis (Shen et al., 2011). With any surgery there are inherent risks such as 
bleeding, blood clots, breathing complications and infection as well as heart attack and 
stroke.  
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Synthetic MMP inhibitors such as S-34291 a wide spectrum inhibitor with preferential 
selection on MMP-13 and MMP-1 have successfully prevented the loss of cartilage ex vivo 
and in a guinea pig model (Cawston & Wilson, 2006). While several MMP inhibitors have 
shown impressive results in animal models Ro32-3555 (Trocade) a collagenase selective 
inhibitor did not prevent progression of joint damage in patients with rheumatoid arthritis 
(Close, 2001). Broad-spectrum synthetic inhibitors have also been linked to side effects 
such as musculoskeletal pain and tendonitis (Drummond et al., 1999). Selective MMP-13 
inhibitors have shown chondro-protective effects in animals (Li et al., 2011) and could 
potentially offer a treatment for OA. 
Although there are many different treatments available for OA there is a need for effective 
disease-modifying drugs. A new approach to treatment is needed. Prevention or slowing of 
OA via dietary intervention or supplementation is an attractive alternative.  
 
1.5 Diet derived bioactives as a potential therapy 
Pharmacological intervention for OA has had a lack of clinical efficacy. This may be due to 
pharmacological treatments typically only having a single mode of action and OA being a 
multifactoral disease. For this reason nutrition can be seen as an attractive alternative 
treatment as foods typically contain multiple bioactives that can interact with multiple 
cellular pathways (Ameye & Chee, 2006). Bioactive compounds are substances found in the 
diet that have an effect on living tissue. They are an attractive alternative strategy for 
treating OA due to their low side effect profile. Nutrition is potentially a modifiable factor 
that could have a significant impact on OA. Pharmaceuticals are normally prescribed after 
the onset of disease. Bioactive compounds and changes to the diet can be used to help 
prevent disease. Williams et al showed that a diet high in fruit and vegetables had a 
protective association with radiographic hip OA.  Allium vegetable consumption was shown 
to have a protective association with hip OA. Diallyl disulphide is a compound found in 
alliums and it was shown that this compound could repress expression of MMPs in SW1353 
chondrosarcoma cells (Williams et al. 2010). This form of treatment could potentially delay 
the onset of OA as well as reduce the severity and progression of the disease. Detailed 
molecular studies ahead of a full clinical trial are required in order optimally to design trials 
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to examine potential efficacy. There is currently limited data on the inter-relationship 
between diet and OA. Currently there is a large amount of variability in studies e.g. in 
animal models.  
While a dietary intake approach would be optimal in order to relate to human exposure 
many studies use intra-articular injection and many use concentrations of compounds that 
would not be achievable through diet or supplementation. Intervention trials in man have 
variable numbers of patients, the length of time of each study can be vastly different and 
many of the studies are only of a short duration. Before dietary advice can be given for the 
prevention of OA, better quality studies need to be completed. Diet derived bioactive 
compounds with potential health benefits can be classed into several different groups. 
These groups consist of flavonoids (and related compounds), carotenoids, plant sterols, 
glucosinolates and others. 
1.5.1 Flavonoids 
Flavonoids are diphenylpropanes possessing 15 carbon atoms containing two benzene 
rings joined by a 3 linear carbon chains (Crozier et al., 2006).  Flavonoids occur in plants and 
are common components of the human diet (Cao et al., 1997). There are several 
subcategories of flavonoids including flavan-3-ols, anthocyanins, flavonols, flavones, 
isoflavones and flavanones (Figure 1.12).  
Flavonoids have been shown to have anti-platelet, anti-lipoperoxidant, anti-tumoral, anti-
ischemic anti-inflammatory effects (Tzeng et al., 1991), (Joyeux et al., 1995), (Parajuli et al., 
2009), (Leonardo & Doré, 2011). Flavonoids have also been shown to have the potential to 
protect against collagen matrix breakdown via inhibition of MMPs (M. Ahmed et al., 2005). 
Human chondrocytes from OA cartilage were incubated with epigallocatechin-3-gallate 
(EGCG) 20-100µM before with or without 5ng/ml of IL1 for 24 hours. EGCG inhibited the 
expression and activities of MMP-1 and MMP-13 in a dose dependent manner. It was 
hypothesized that EGCG had this effect due to inhibition of transcription factors such as 
NFκB at the mRNA level (S. Ahmed et al., 2004). In another study SW1353 cells were 
stimulated with IL1 at 10ng/ml for 24 hours before being treated with apigenin, a plant 
derived flavonoid at 25-5µM for 6 hours. Apigenin strongly inhibited MMP13 induction. 
SW1353 cells were then treated with apigenin at 5-25µM for 2 hours before IL1 treatment 
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for 30 minutes. Cells were then lysed and nuclear extract was prepared for the 
electrophoretic mobility shift assay (EMSA). Apigenin did not reduce NFκB activation, 
however AP-1 was inhibited from binding to its corresponding DNA site and the 
translocation of c-fos was also inhibited. 
1.5.2 Flavan-3-ols 
Of the flavonoids the flavan-3-ol subclass is the most complex. The structures of flavan-3-
ols can range from complex polymeric compounds such as procyanidins to simple 
monomeric catechins (Neilson & Ferruzzi, 2011). Flavon-3-ols such as catechins and 
procyanidins have been found in green and black tea as well as red and white wine (Auger 
et al., 2004). While not dietary derived Pycnogenol is a pine bark extract rich in procyanidins 
(D’Andrea, 2010). Pycnogenol has been reported to inhbit the activation of NFκB and the 
activity of MMPs (Grimm et al., 2006) (Grimm et al., 2004). While Pycnogenol has had 
positive outcomes in small trials (Belcaro et al., 2008), (Cisár et al., 2008) a Cochrane review 
of Pycnogenol stated that it was not possible to reach definite conclusions on either efficacy 
or safety of Pycnogenol (Schoonees et al., 2012).  
1.5.3 Anthocyanins 
Anthocyanins are sugar conjugates of anthocyanidins (Crozier et al., 2006). Anthocyanins 
often give pigmentation to fruit flesh and foliage (Chagne et al., 2012). Anthocyanins are 
thought to pigment plants to protect them from excess light and insect herbivory 
(Karageorgou & Manetas, 2006). Anthocyanins are thought to pigment plants to protect 
them from excess light and insect herbivory (Karageorgou & Manetas, 2006).  Delphinidin 
an anthocyanidin found in pigmented fruits and vegetables has been shown to be an 
inhibitor of IL1 induced production of cartilage-degrading molecule PGE2 via inhibition of 
COX-2 expression. Delphinidin was shown to block the activation of NFκB by suppressing 
the activation of upstream kinases NFκB-inducing kinase and IL1 receptor-associated 
kinase-1 in human OA chondrocytes (Haseeb et al., 2013). 
1.5.4 Flavonols 
Flavonols are commonly consumed in various teas, fruits and vegetables (Hertog et al., 
1993). Myricetin, quercetin and kaempferol are commonly found as glycosylated flavonols. 
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During the fermentation of wine the glycosylated compounds are often released as free 
flavonols (Tsanova-Savova & Ribarova, 2002). The flavonol quercetin has been shown to 
prevent cartilage degradation in tissue explants. The loss of total aggrecan in cartilage 
explants maintained in catabolic medium for 6 days containing either 10-50µM of quercetin 
was examined. Quercetin suppressed total aggrecan loss in a dose dependent manner. 
Cartilage explant RNA was extracted and analysed using quantitative real time PCR (qRT-
PCR). Quercetin suppressed IL1 stimulated expression of ADAMTS4 and basal expression of 
ADAMTS5. Quercetin may protect cartilage from stimulated aggrecan loss by inhibiting the 
expression of ADAMTS4 and ADAMTS5 (Lay et al., 2012). 
1.5.4 Flavones 
Flavones are less common than flavonols. Celery and parsley are both edible sources of 
flavones containing luteolin and apigenin (Manach et al., 2004). Luteolin has been shown 
to inhibit IL1 induced MMP13 via inhibition of IL1-induced extracellular signal-regulated 
Kinase (ERK) activation in a dose-dependent manner in osteoblasts (Yang et al., 2012).  
SW982 hyman synovial cells treated with 1-10µM  luteolin over 24 hours had reduced IL1 
induced MMP-1 production via inhibition of phosphorylated JNK and p38 levels (Choi & 
Lee, 2010). Flavones in a polymethoxylated form include nobiletin and tangeritin, found in 
citrus fruits (Swift, 1960), (Takanaga et al., 2000). Nobiletin is a polymethoxyflavone found 
in citrus fruit peel (S. Guo et al., 2012). Nobiletin has been shown to inhibit gene expression 
of IL1 and IL6 in mouse J774A.1 macrophages (Lin et al., 2003). Tangeritin has been shown 
to have both inhibit MMP2 and MMP9 in human brain tumour cell lines in vitro (Rooprai et 
al., 2001). MMP-2 and MMP-9 are gelatinases, however they also activate proMMP-13 a 
collagenase. Inhibition of MMP2 and MMP9 could reduce the activiation of MMP-13 
preventing degradation of type 2 collagen. 
1.5.5 Isoflavones 
Isoflavones have the B-ring attached at C3 rather than the C2 position (Figure 1.12). 
Isoflavones are found in leguminous plants with high concentrations in soyabean (Sung et 
al., 2004). Genistein from soy protein has been shown to reduce serum total and low 
density lipoprotein  (LDL)-cholesterol in humans (van der Schouw et al., 2000). Currently 
the data for genistein and OA are limited, in vitro and preclinical trials have not been able 
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to clearly define whether genistein has a protective effect on articular cartilage (Henrotin 
et al., 2011). While genistein has been reported to have no effect on cartilage metabolism 
(Claassen et al., 2008), it has been reported to inhibit COX-2 production giving genestin an 
anti-inflammatory  effect in human chondrocytes (Hooshmand et al., 2007). It has been 
hypothesised that there is a relationship between OA and a changes to estrogen 
metabolism in menopausal women. As genistein shares a similar ring system with 
oestrogen it could have the capacity to alter the function of the reproductive system 
(Jeschke et al., 2005). 
1.5.6 Flavanones 
Flavanones have a chiral centre at C2 with no Δ2,3 double bond (Figure 1.12). In most 
flavanones the C-ring is attached to the B-ring at C2. Flavanones such as hesperidin and 
narirutin are commonly found in sweet oranges, tangerines and tangors (Peterson et al., 
2006). 7, 3′-dimethoxy hesperetin (DMHP) a derivative of the parent compound hesperidin 
which has been reported to have have anti-inflammatory properties. Adjuvant arthritis (AA) 
was induced in rats and DMHP was administered intragastrically once a day from 12-21 
days after AA induction. DMHP significantly inhibited hind paw swelling and arthritis index. 
The expression of IL6 in AA rat synovium was suppressed in a dose dependent matter with 
DMHP treatment (Li et al., 2012). 
 
 
Figure 1.12. Structures of Flavonoid subgroups. General features of flavonoid structures. Image 
adapted from (Crozier et al., 2006). 
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1.5.7 Carotenoids 
Carotenoids are a diverse group of tetraterpenes. β-carotene (Figure 1.13) is the most 
widely known tetraterpene in plants and is a direct precursor to vitamin A  (Weeks, 1986). 
Vitamin A and its derivatives, retinoids, are known to have profound effects on cartilage 
and the skeleton and may contribute to osteoarthritis (Davies et al., 2009). The diverse set 
of structures that carotenoids have results in the compounds having a wide range of 
colours. Carotenoids give red and yellow colours to many fruits, vegetables, flowers, roots, 
algae, yeasts mushrooms and egg yolks (Isler et al., 1967). Carotenoids are apolar lipophylic 
molecules that are normally insoluble in water (Ziouzenkova et al., 1996), (Polyakov et al., 
2009). Dietary sources of carotenoids such as lutein, lycopene, β-crytoxantin were found in 
foods such as carrots, citrus fruits, spinach, peas and tomatoes (O’Neill et al., 2001). Dutta, 
Chaudhuri, and Chakraborty described the health promoting functions of carotenoids as 
being involved in prevention of cancer, cardiovascular disease, cataract formation and 
macular degeneration. Epidemiological studies have shown that consuming carotenoids 
such as β-crytoxanthin in the form of a glass of freshly squeezed orange juice a day is 
associated with a reduced risk of developing inflammatory disorders such as rheumatoid 
arthritis (Pattison et al., 2005). Phytotene and phytofluene are colourless carotenoids that 
have been able to inhibit MMP1 expression in IL1 induced fibroblasts at 15µg/ml (Fuller et 
al., 2006). Although this inhibition of collagenase was seen in fibroblasts carotenoids may 
have the potential to downregulate MMPs in chondrocytes. 
 
Figure 1.13. Structure of β-carotene. β-carotene is a widely known tetraterpene in plants. 
Image adapted from (Sies & Stahl, 1995). 
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1.5.8 Plant sterols 
Plant sterols are found in all plants and like carotenoids are terpenoids (Figure 1.14). Plant 
sterol esters have been added to foods such as spreads. These reduced fat spreads 
containing plant sterols have been showed to reduce low density lipids (LDL) and high 
density lipids (HDL) cholesterol as well as triacylglycerol levels in subjects on a 5 week diet 
when compared to control diet groups (Maki et al., 2001). The plant sterol stigmasterol has 
shown potential anti-osteoarthritic properties. Human primary OA chondrocytes 
stimulated IL1 were pre-incubated with 20µg/ml of stigmasterol for 48 hours. MMP3, 
MMP13 and ADAMTS4 was significantly reduced. IKβ protein levels was reduced by 
stigmasterol at 20µg/ml (Gabay et al., 2010). These results suggest that plant sterols such 
as stigmasterol can inhibit MMPs and ADAMTSs involved in OA induced cartilage 
degradation in part through the inhibition of the NFκB pathway. 
 
 
1.5.9 Glucosinolates 
Glucosinolates are β-thioglucoside N-hydroxysulphates containing a variable side chain 
(Crozier et al., 2006), (Figure 1.15). Glucosinolates are found in hundreds of cruciferous 
vegetables (Vaughan et al., 1976) and many are precursors to isothiocyanates such as 
sulforaphane (SFN) (Figure 1.15). Vegetables such as broccoli are high in glucosinolates and 
often present in the human diet. When the vegetable is chopped or chewed the 
Figure 1.14. Structure of Stigmasterol. Stigmasterol is a major constituent of the sterol profiles 
of plant species. Image adapted from (Dufourc, 2008). 
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glucosinolates are exposed to the enzymatic action of myrosinase. Myrosinase coexists in 
crucifers and once in contact with glucosinolate it hydrolysis its thioglucosidic bond 
releasing isothiocyanates, nitrile or thiocyanates causing the bitter taste of the vegetables 
(T. Shapiro et al., 2001), (Crozier et al., 2006). Bacterial myrosinase present in the human 
colon can also hydrolyse glucosinolates (Johnson, 2002). Mild cooking of cruciferous 
vegetables can denature the epithiospecifier protein (ESP) that normally prevents 
isothiocyanate formation, instead ESP promotes formation of nitriles (Traka & Mithen, 
2008). This cooking method results in more of the beneficial isothiocyanates but prolonged 
heating may also denature myrosinase (Matusheski et al., 2004). While prolonged cooking 
does not seem to effect glucosinolates themselves they can leech into water if boiled 
(López-Berenguer et al., 2007). Studies have shown that isothiocyanates could potentially 
protect against cancer, diabetes and renal damage as well as neurodegenerative, ocular, 
respiratory and cardiovascular disorders (Seow, 2002), (Ragheb et al., 2009), (Nyengaard 
et al., 2004), (Trinh et al., 2008), (Gao et al., 2001), (Riedl et al., 2009), (Angeloni et al., 
2009). 
Isothiocyanates such as SFN have been shown to have potential anti-osteoarthritic effects. 
Human primary chondrocytes treated with 1-20µM of SFN and stimulated with IL1 an hour 
later for 24 hours had a reduced production of PGE2 and NO protein levels as well as MMP1 
and MMP13 mRNA. At 5µM SFN inhibited COX-2 and iNOS at the mRNA and protein levels. 
At 10µM SFN significantly reduced IL1 stimulated NFκB promoter luciferase activity (H. Kim 
et al., 2012). This research suggests that SFN is capable of inhibiting a range of catabolic 
mechanisms in articular chondrocytes. 
 
 
Figure 1.15. Structure of Sulforaphane. Suforaphane is a plant derived isothiocyanate obtained 
in the diet through consumption of cruciferous vegetables. Image adapted from (Boddupalli et 
al., 2012) 
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1.6 Conclusion and Aims 
There are many compounds present in the habitual diet which have been shown to have 
activity in both laboratory models of osteoarthritis though this has not been convincingly 
proven in human disease to date. Current treatments for OA such as painkillers and anti-
inflammatories are unable to prevent the progression of the disease. Joint replacement is 
offered to patients at end-stage disease, at large financial burden to the National Health 
Service (NHS). MMP-13, MMP-1, ADAMTS-4 and ADAMTS-5 have been shown to be a key 
collagenases and aggrecanases in cartilage degradation. We hypothesise that bioactives 
from the habitual diet will be chondro-protective. This project aims are to: 
1. Build a custom dietary derived library of compounds from a Bioactive Compound 
library 
 
2. Screen compounds from the custom built dietary derived library for inhibition of 
IL1-induced and basal MMP13 expression and cytotoxicity in SW1353 and C28/I2 
cells. 
 
3. Select 20 compounds from the custom built dietary derived library for inhibition 
of IL1-induced and basal MMP13 and MMP1 expression in primary chondrocytes. 
 
4. Complete dose-response curves for two candidate compounds from primary cell 
experiments looking at effects on MMP13, MMP1, ADAMTS4 and ADAMTS5 and 
screen for cell cytotoxicity. 
 
5. Use cell based luciferase assays to analyse the two candidate compounds 
mechanism of action, exploring pathways implicated in cartilage homeostasis and 
OA the NFκB, TGFβ and Wnt pathways. 
 
6.  Perform an unbiased dissection of the kinase pathways affected by the two 
candidate compounds in primary chondrocytes by using the Human Phospho-
Kinase Array. 
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Chapter 2: Materials and Method 
2.1 Materials 
2.1.1 Cell lines 
2.1.1.1 SW1353 
The SW1353 human chondrosarcoma cell line was obtained from American Type Culture 
[ATCC (Manassas, VA, USA)].  
2.1.1.2 C28/I2 
The immortalized human juvenile costal chondrocytes cell line C28/I2 were provided by 
Prof. Mary Goldring, Hospital for Special Surgery, New York. The C28/I2 cells were 
established by transduction of primary cultures of juvenile costal chondrocytes with 
vectors encoding simian virus 40 large T antigen (Goldring et al., 1994). 
2.1.1.3 Primary Articular Chondrocytes 
Primary human articular chondrocytes were isolated from the cartilage of patients with 
knee OA (KOA) who underwent knee replacement surgery at the Norfolk and Norwich 
University Hospital in collaboration with Prof. Simon Donell (Consultant Orthopaedic 
Surgeon and Honorary Professor, University of East Anglia, UK). Cartilage from KOA was 
removed from the entire surface of both tibial plateaus and femoral condyles including 
medial and lateral compartments. Cartilage samples were removed from the joint using a 
sterile scalpel and washed in sterile phosphate buffered saline (PBS) solution [Life 
Technologies (Glasgow)] containing 100U/ml penicillin, 100µg/ml streptomycin [Sigma-
Aldrich (Dorset, UK)] and cut into 2-5mm pieces. These pieces were then incubated at 37°C 
in a shaker overnight in digestion media 0.1% (w/v) collagenase type 1A (Sigma-Aldrich) 
and 0.4% (w/v) Hepes (Sigma-Aldrich)  in 50ml Dulbecco's modified Eagle medium (DMEM 
+ GlutaMAX), (Life Technologies)  containing 100U/ml penicillin, 100µg/ml streptomycin 
(Sigma-Aldrich). The digestion mixture was filtered through a cell strainer (BD Falcon) and 
centrifuged at 180g for 5 minutes.  The cell pellet was washed in DMEM + GlutaMAX (Life 
technologies) media containing 100U/ml penicillin and 100µg/ml streptomycin (Sigma-
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Aldrich). Cells were cultured in DMEM + GLUTAMAX (Life Technologies) containing 10% 
(v/v) foetal calf serum (FCS) [American Type Culture Collection (ATCC) (Washington, USA)], 
2mM glutamine, and 100 IU/ml penicillin and 100ug/ml streptomycin (Sigma-Aldrich). Cells 
were seeded at 4x104 cells/cm2 and incubated at 37°C, 5% CO2 (v/v) and allowed to adhere 
for ~8 days. The media was changed following adherence, and at 80-90% confluency, cells 
were either frozen and stored in liquid nitrogen, or utilised in in vitro assays up to passage 
1. 
2.1.2 Diet derived bioactives 
2.1.2.1 Compound screens 
Dietary-derived compounds (Sigma-Aldrich) were selected from the literature for 
suspected anti-inflammatory effects. Ninety six compounds were selected from Bioactive 
Compound Library [Stratech (Suffolk, UK)]. For compound list see Appendix. Compounds 
were stored in dimethyl sulfoxide (DMSO) (Sigma-Aldritch) at 10mM at -80C. 
2.1.2.2 Selected compounds 
Aloe emodin, apigenin and isoliquiritigenin were purchased from (Sigma-Aldrich) and made 
into 50mM stocks with DMSO for use in all dose response and time course experiments. 
2.1.3 Cytokines 
Recombinant human interleukin-1 (IL1), Wnt3a and transforming growth factor beta 
(TGFβ) were purchased from R&D Systems (Abingdon, UK), reconstituted in phosphate-
buffered saline solution (PBS) containing 0.1% (w/v) bovine serum albumin and stored at -
80°C (as recommended by supplier).  
2.1.4 Immunoblotting 
All antibodies used were rabbit polyclonal unless otherwise stated. (Total p38 Antibody 
#9212), [p-p38 (Thr180/Tyr182) Antibody #4511S], (total JNK Antibody #9258S), [pJNK 
(Thr183/Tyr185) Antibody #4668S], [total Erk (Erk1/2) Antibody #9102] and [p-Erk (Erk1/2) 
(Thr202/Tyr204) Antibody #9101S] were purchased from Cell Signaling Technology (Beverly 
MA, USA). Secondary antibody used was a goat polyclonal anti-rabbit IgG, alkaline 
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phosphatase for fluorescent detection [Abcam, (Cambridge)]. Horseradish peroxidase-
conjugated anti-mouse (PO260) secondary antibodies were purchased from Dako UK Ltd 
(Cambridgeshire, UK). 
Polyvinylidene fluoride membrane (PVDF) membrane was purchased from Millipore 
(Watford, UK). Sodium dodecyl sulphate (SDS), N,N,N,N’-Tetramethylethylenediamine 
(TEMED), extra thick filter paper, protein standard Precision Plus dual colour, gel rigs, 
electrophoresis tanks and a Trans-Blot SD Semi-dry electrophoretic transfer cell were all 
purchased from Bio-Rad Laboratories (Hemel Hempstead, UK). Ammonium persulphate 
(APS), polyoxyethylenesorbitan monolaurate (Tween-20), bovine serum albumin (BSA) 
were purchased from Sigma Aldrich (Dorset, UK). Non-fat dry milk powder was purchased 
from Fisher (Leicestershire, UK). 
2.2 Methods 
2.2.1 Cell culture 
Cells were cultured in Dulbecco's modified Eagle medium (DMEM) + GlutaMAX (Life 
Technologies) containing 10% v/v FCS (ATCC) , 2mM glutamine, and 100 IU/ml penicillin 
and 100ug/ml streptomycin (Gibco).Cells were incubated at 37°C in a humidified 
atmosphere of 5%v/v CO2. Every 3 to 4 days media was replaced until cells reached 
confluence. Confluent cells were passaged using trypsin-1mM ethylenediaminetetraacetic 
acid (EDTA) (Life Technologies). For long term storage, cells were cryogenically frozen via 
trypsinisation, centrifuged at 130g for 5 minutes and resuspended in cryo-preservation 
medium (90% v/v FCS, 10% v/v DMSO) before slow freezing (at approximately 1°C per 
minute) in a cell freezing chamber at -80°C. For longer term storage cells were transferred 
to liquid nitrogen. 
2.2.1.1 Cell treatments 
For qrRT-PCR experiments cells were plated at 10x103 cells per well in a 96 well plate (Fisher 
Scientific) in DMEM + GLUTAMAX (life technologies) [+10% (v/v) heat inactivated FCS 
(ATCC) and left to adhere overnight followed by a 12-hour serum starvation (DMEM alone). 
Compounds of interest were added an hour before stimulation with 5ng/ml IL1 (R&D 
Systems Europe Ltd, Abingdon, UK). 
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For cloning SW1353 cells were plated onto a 96-well plate (Fisher Scientific) at 6x103 per  
well in DMEM + GLUTAMAX (life technologies) [+10% (v/v) heat inactivated FCS (ATCC) and 
left to adhere overnight at 37°C, 5% (v/v) CO2 followed by a 12-hour serum starvation 
(DMEM alone). Compounds or interest were added an hour before stimulation with IL1, 
wnt3a or TGF-β (R&D Systems). 
For Western blot analysis Primary KOA chondrocytes or SW1353 cells were plated at 2x105 
cells per well in a 6 well plate (Fisher Scientific) in DMEM + GLUTAMAX (Life Technologies) 
[+10% (v/v) heat inactivated FCS (ATCC) and left to adhere overnight at 37°C, 5% (v/v) CO2 
followed by a 12-hour serum starvation in phenol free DMEM (life technologies). 
Compounds of interest were added an hour before stimulation with IL1 (R&D Systems). 
2.2.1.2 Cytotoxicity assay cell necrosis 
Cytotoxicity of compounds were assessed using the CytoTox 96® Non-Radioactive 
Cytotoxicity as described by the manufacturer's instructions [Promega (Hampshire, UK)]. 
The CytoTox 96® Assay quantitatively measures lactate dehydrogenase (LDH), a stable 
cytosolic enzyme that is released upon cell lysis. Released LDH in culture supernatants is 
measured with a 30-minute coupled enzymatic assay, which results in conversion of a 
tetrazolium salt (INT) into a red formazan product. The amount of colour formed is 
proportional to the number of lysed cells. Visible wavelength absorbance data are collected 
using a 96-well plate reader. Data was presented as percentage of cell death (necrosis) 
relative to total cell death control cell lysis ± mean standard deviation. Total cell death 
control (100% cell death) calculated by freeze thawing no treatment chondrocytes twice 
and measuring LDH released. 
2.2.1.3 Cytotoxicity assay cell apoptosis 
Cytotoxicity of compounds were assessed using the Caspase-Glo® 3/7 Assay as described 
by the manufacturer's instructions (Promega). The Caspase-Glo® 3/7 Assay is a luminescent 
assay that measures caspase-3 and -7 activities in cultures of adherent cells. Total cell death 
control (100% cell death) calculated by treating cells with 1µM stuarosporine for 6 hours. 
The assay provides a proluminescent caspase-3/7 substrate, which contains the 
tetrapeptide sequence DEVD. This substrate is cleaved to release aminoluciferin, a 
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substrate of luciferase used in the production of light. The Caspase-Glo® 3/7 Reagent is 
optimized for caspase activity, luciferase activity and cell lysis. Addition of the single 
Caspase-Glo® 3/7 Reagent in an "add-mix-measure" format results in cell lysis, followed by 
caspase cleavage of the substrate and generation of a “glow-type” luminescent signal.  
2.2.2 cDNA synthesis – Cells-to-cDNA II with MMLV RNA 
Cells were washed in ice-cold PBS twice. Cells were harvested into 30 μl of Cells-to-cDNA II 
cell lysis buffer [Ambion, Applied Biosystems, (Warrington, UK)]. The lysate was transferred 
to a 96-well PCR plate (Applied Biosystems) and incubated at 75°C for 15 minutes.  2U 
DNase I (Ambion) and 10x DNase I buffer (Ambion) were added to each well and incubated 
at 37°C for 15 minutes followed by 75°C for 5 minutes. DNase I-treated lysates (8 μl) were 
transferred to a fresh 96-well PCR plate. Lysates were primed for reverse transcription 
using 10 mM dNTP mix (2.5 mM of each) [Bioline (London, UK)] and 200ng random primers 
(Invitrogen) at 70°C for 5 minutes. Reverse transcription was carried out in a volume of 20μl 
using 100U M-MLV reverse transcriptase (Invitrogen) and 20U RNasin ribonuclease 
inhibitor (Promega) according to the manufacturer's instructions (Promega). Samples were 
incubated at 37°C for 50 minutes then 75°C for 15 minutes.  To each well, 30µl analytical 
grade H20 (Sigma-Aldrich) was added and cDNA stored at -20°C. 
2.2.3 Quantitiative Real Time PCR (qRT-PCR) 
2.2.3.1 Standard Probe-based Real-Time qRT-PCR 
Relative quantification of genes was performed using the ABI Prism 7700 sequence 
detection system (Applied Biosystems) with MicroAmp optical 96-well plates (Applied 
Biosystems) using selected primer probe sets (see Table 4) in accordance with the 
manufacturer's protocol. The constitutively expressed 18S rRNA housekeeping gene was 
used as the control for relative mRNA gene expression. The threshold cycle (Ct) is the cycle 
number during an RT-PCR run where the signal is detectable above baseline. Samples were 
excluded from further analysis if their 18S rRNA Ct level exceded 1.5Ct ± the median 18S 
rRNA Ct to ensure quality of data. Our lab has previously established 18S rRNA to be the 
optimal housekeeping gene for use with chondrocyte cell lines and cartilage samples. For 
genes of interest 5ng of cDNA was used per reaction, for 18S rRNA 1ng of cDNA was used 
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per reaction. 2x Taqman Universal PCR Master Mix (Applied Biosystems), 100nM forward 
and reverse primers (Sigma-Aldrich) and 200nM specific probe (Sigma-Aldrich) was added 
to each reaction. PCR reactions used 5μl of reverse-transcribed RNA (for 18S rRNA analysis 
a 10-fold dilution of cDNA was used), 2x TaqMan Universal Master Mix (Applied 
Biosystems), 100nM of each primer and 200nM of probe in a total volume of 20μl. 
Conditions for the PCR reaction were as follows: 50°C for 2 minutes, 95°C for 10 minutes 
and 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute. Relative quantification 
is expressed as 2-ΔCt, where ΔCtT is Ct (target gene) – Ct (18S). Microsoft Excel was used to 
analyse the data. 
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Gene Sequences Reference 
MMP1 Forward Primer: 5’-AAGATGAAAGGTGGACCAACAATT -3’ 
Reverse Primer: 5’ -CCAAGAGAATGGCCGAGTTC -3’ 
Probe: 5’- FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA -3’ 
(Nuttall et al., 2003) 
MMP13 Forward Primer: 5’- TTCCGCCTGTCTCAAGATGATAT -3’ 
Reverse Primer: 5’- AAAGGACAAAGCAGGATCACAGTT -3’ 
Probe: 5’- FAM-TCAGTCCCTCTATGGACCTCCCCCTGAC-TAMRA -3’ 
(Nuttall et al., 2003) 
ADAMTS4 Forward Primer: 5’- CAAGGTCCCATGTGCAACGT -3’ 
Reverse Primer: 5’- CATCTGCCACCACCAGTGTCT -3’ 
Probe: 5’- FAM-CCGAAGAGCCAAGCGCTTTGCTTC-TAMRA -3’ 
(Porter et al., 2005) 
ADAMTS5 Forward primer: 5’-TGTCCTGCCAGCGGATGT-3’ 
Reverse primer: 5’-ACGGAATTACTGTACGGCCTACA-3’ 
Probe: 5’- FAM-TTCTCCAAAGGTGACCGATGGCACTG-TAMRA -3’ 
(Porter et al., 2005) 
18S rRNA Forward primer: 5’-GCCGCTAGAGGTGAAATTCTTG-3’ 
Reverse primer: 5’-CATTCTTGGCAAATGCTTTCG-3’ 
Probe: 5’-ACCGGCGCAAGACGGACCAG-3’ 
(Corps et al., 2006) 
 
2.2.3.2 Universal Probe-based Real-Time qRT-PCR 
The short 8-9 nucleotide-long locked nucleic acid probes give the Universal Probe library 
[Roche Applied Science (West Sussex)] wide transcript coverage. HO-1 and AXIN2 were 
designed using the Universal Probe Library (Roche).  The PCR reaction mix contained 
Taqman 2x mastermix, 100nM of forward and reverse primer and 200nM of fluorescent 
probe (in a final volume of 25μl). PCR cycles the same as Standard Probe-based Real-Time 
qRT-PCR. 
Table 4. Quantitative Real Time PCR primer probe sets. Primer and probe sets listed for the 
genes analysed using qRT-PCR. FAM was the fluorophore used and TAMRA was the quencher. 
All other primers were designed using the Universal Probe Library Assay Design Center by Roche 
Applied Science and used with probes from the Universal Probe Library. 
 
56 
 
2.2.4 Sub-cloning 
The smad2/3/4 signalling reporter (CAGA12-luc) contains 12 binding sites of the Smad2/3/4 
binding consensus upstream of the pGL3 gene, this reporter was a gift from Dr Andrew 
Chantry, University of East Anglia, UK and is described in (Pais et al., 2010).  
The NFκB signalling reporter (κB) vector contains 5 binding sites of NFκB upstream of the 
firefly luciferase-encoding gene pGL3, this reporter was a gift from Prof. Derek Mann, 
(Newcastle University, UK), (originally from Prof. Ronald Hay, University of Dundee, UK).  
The canonical Wnt signalling reporter (TOPFLASH) vector contains 7 binding sites of 
TCF/LEF upstream of the firefly luciferase encoding gene in the pTAL-Luc vector, this 
reporter was a gift from Prof. Andrea Munsterberg (University of East Anglia, UK), the 
reporter was originally from Prof. Randall Moon (University of Washington, USA).  
2.2.4.1 Preparation of competent DH5α cells Plasmid extraction (Qiagen mini preps) 
E.coli DH5α bacterial colonies were spread onto LB/Agarplates supplemented with 
100µg/µl ampicillin (Sigma-Aldrich) and incubated overnight at 37°C. One colony was 
inoculated into 5ml LB broth [1% w/v Tryptone (Fisher Scientific), 2% w/v Yeast Extract 
(Fisher Scientific) and 0.5% w/v Sodium Chloride (Fisher Scientific] and incubated overnight 
at 37°C. Once cells reached optimal density (OD600 = 0.6) they were chilled on ice for 10 
minutes in 50ml Falcon tubes (Fisher Scientific). Cells were centrifuged at 1000 x g for 10 
minutes at 4°C and supernatant was removed. The cell pellet was re-suspended in 5ml 0.1M 
CaCl (Fisher Scientific) and incubated on ice for 10 minutes before being centrifuged at 
1500g, 4°C for 10 minutes where the supernatant was then removed. The pellet was re-
suspended gently into 1ml ice cold 0.1M CaCl (Fisher Scientific) and glycerol (400μl / ml) 
(Fisher Scientific) and stored frozen at -80°C. 
2.2.4.2 Plasmid extraction (Qiagen mini preps) 
The protocol was followed as per manufacturer’s instructions and all buffers described are 
from [Qiagen (Manchester)]. 1.5ml bacterial cells were spun at 10,000 x g for 5 minutes 
and the supernatant removed. The bacterial pellet was re-suspended in 250μl mini-prep 
buffer P1 to this 250μl mini-prep buffer P2 was added and mixed by inversion. 350µl N3 
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buffer was added, mixed by inversion and centrifuged at 10,000 x g for 10 minutes. All 
supernatant was then transferred into QIAspin columns and centrifuged for 1 minute at 
10,000 x g with flow through removed. 750μl of PE buffer was added to the column and 
spun at 10,000 x g for 1 minute and flow through was discarded. Plasmid was then eluted 
from QIAspin column with 30μl of analytical grade water by centrifugation at 10,000 x g for 
1 minute. 
2.2.4.3 SW1353 transfection 
SW1353 cells were plated onto a 96-well plate (Fisher Scientific) at 6x103/cm2 well in 
DMEM + GLUTAMAX (life technologies) [+10% (v/v) heat inactivated FCS (ATCC) and left to 
adhere overnight at 37°C, 5% (v/v) CO2. Transfections were carried out using 100ng plasmid 
DNA, 500ng Lipofectamine 2000 (Fisher Scientific) and 50ng of Renilla plasmid for 24 hours 
at 37°C, 5% (v/v) CO2 in serum-free culture medium (DMEM alone). Cells were then treated 
for 6 hours. The Promega Dual Luciferase Reporter Assay was used to measure luciferase 
activity according to manufacturer’s instructions. Media was removed from wells of 96 well 
tissue culture plate (Fisher Scientific), and cells washed with cold sterile PBS solution (Life 
Technologies).  Cells were treated with 50µl of lysis buffer (Promega), scraped and 
incubated for 30 minutes at room temperature. 10µl was transferred to an opaque 96 well 
plate and 50µl of luciferase assay reagent II was added and firefly luciferase activity 
measured immediately on a spectrophotometer [EnVision 2103 Multilabel plate reader 
(Perkin Elmer)] (Luminescence 700 setting, 560nm) using Wallac EnVision Manager 
software. 50µl of Stop-andGgo solution (Promega) was added and the plate was measured 
for a second time to measure renilla activity (Luminescence 700 setting on the Envision 
plate reader, 560nm). Firefly luciferase relative light units were normalised to Renilla 
relative light units to account for the transfection efficiency. 
2.2.5 Western blotting 
Primary KOA chondrocytes or SW1353 cells were plated at 2x105 cells per well in a 6 well 
plate (Fisher Scientific) in DMEM + GLUTAMAX (life technologies) [+10% (v/v) heat 
inactivated FCS (ATCC) and left to adhere overnight at 37°C, 5% (v/v) CO2 followed by a 12-
hour serum starvation in phenol free DMEM (Life Technologies). Compounds of interest 
were added an hour before stimulation with IL1 (R&D Systems). For MMP analysis media 
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was harvested and frozen at -20°C. For all other experiments whole cells were washed 
twice in sterile ice cold PBS (Life Technologies) cell lysates were harvested and scraped into 
100μl ice cold radioimmunoprecipitation assay buffer (50 mM Tris HCl, pH 7.6, 150 mM 
NaCl, 1% v/v Triton X-100, 1% w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 
10 mM NaF, 2 mM Na3VO4, 1 protease inhibitor cocktail (Fisher Scientific). Samples were 
centrifuged for 10 minutes at 300g. Supernatant was collected and stored at -20°C. 
2.2.5.1 Bicinchoninic acid (BCA) protein quantification assay 
Protein concentrations of lysate samples as well as conditioned media were assessed using 
the bicinchoninic acid (BCA) protein quantification assay as described by the 
manufacturer's instructions (Life technologies) in order to normalise each sample to 
cellular protein levels before SDS-PAGE analysis. A standard curve of known protein bovine 
serum albumin (BSA) was compared to individual samples to determine their total cellular 
protein concentrations. Increasing amounts of BSA (0.3125-10mg/ml) and equivalent 
volume of samples were plated into 96-well plates. Each well had 200μl of BCA reagent (50 
parts of reagent A (containing sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartate in 0.1M sodium hydroxide) to 1 part of reagent B (solution of 4% copper 
sulfate pentahydrate) added to each well. Samples were then incubated for 30 minutes at 
37°C. Absorbance was determined at 550nm using [EnVision 2103 Multilabel plate reader 
(Perkin Elmer)]. The concentrations of each samples were determined from a standard 
curve that was constructed with the OD values obtained from the known standard (BSA). 
2.2.5.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
A running gel was created by combining 10% v/v acrylamide [BIO-RAD (Hertfordshire)], 
365mM Tris-HCl (pH 8.8) (Sigma Aldrich), 0.1% w/v SDS, 0.05% w/v ammonium persulphate 
(APS) and 0.04% w/v tetramethylethylenediamine (TEMED) (BIO-RAD). This was left at 
room temperature to polymerise. A stacking gel was made by combining 4% v/v 
acrylamide, 365mM Tris-HCl (pH 8.8), 0.1% w/v SDS, 0.1% w/v APS and 0.04% v/v TEMED, 
stacking gel was poured onto running gel. A comb was added to create loading wells and 
the gel was left to polymerise. The SDS-PAGE equipment was assembled and running buffer 
(25mM Tris-HCl, 200mM glycine and 0.1% w/v SDS) was poured into the tank. Samples 
were mixed with 5x sample buffer (10% w/v SDS, 10nM β-mercaptoethanol, 20% v/v 
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glycerol, 0.2M Tris-HCl (pH 6.8), 0.05% w/v Bromophenol Blue) at a ratio of 4:1 and 
incubated at 100°C for 5 minutes. Samples were then loaded to SDS-PAGE gel and ran at 
200v for 45 minutes separating protein samples. 
2.2.5.3 Semi-dry blot transfer 
Protein samples were then transferred to Polyvinylidene Fluoride (PVDF) membrane at 10v 
for 30 minutes using the semi-dry blot technique in transfer buffer (buffer (0.29% w/v 
Glycine, 0.58% w/v Tris, 0.037% w/v SDS and 20% w/v Methanol). Samples on PVDF 
membranes were then covered with blocking solution (5% w/v milk powder, Tris-buffered 
saline solution (TBS- 150mM NaCl, 100mM Tris, pH 7.5)) for 1 hour at room temperature. 
Samples were then washed in wash buffer (TBS, 0.1% w/v Tween 20) and incubated 
overnight with primary antibody in antibody dilution buffer (TBS, 0.1% v/v Tween 20 and 
2.5% w/v milk) (see immunoblotting for primary antibody details). Membranes were then 
washed three times using wash buffer and incubated with secondary antibody in antibody 
dilution buffer. Secondary antibodies used were a horseradish peroxidase-conjugated 
secondary antibody (Dako) for Chemiluminescent detection and a goat polyclonal anti-
rabbit IgG (Abcam) for fluorescent detection in the Odyssey Infrared Imaging System [Li-
COR (Cambridge UK]. 
2.2.6 Human Phospho-Kinase Antibody Array 
The analysis of phosphorylation profiles of 43 kinases and their protein substrates was 
completed with the Human Phospho-Kinase Array as described by the manufacturer's 
instructions (R&D Systems). Capture and control antibodies were spotted in duplicate on 
nitrocellulose membranes. Cell lysates were diluted and incubated overnight with the 
Human Phospho-Kinase Array. The array was washed to remove unbound proteins 
followed by incubation with a cocktail of biotinylated detection antibodies. Streptavidin-
HRP and chemiluminescent detection reagents were applied and a signal was produced at 
each capture spot corresponding to the amount of phosphorylated protein bound allowing 
semi-quantitfication of phosphorylated representatives of the MAP Kinases, Src family and 
Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) JAK/STAT 
pathways amongst others. 
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2.2.7 Statistical analysis 
Microsoft Excel (2008) for Mac was used to analyse data. Students t-test and one-way 
ANOVA with Dunnett's post test was performed using GraphPad Prism version 6 for Mac, 
GraphPad Software, La Jolla California USA, www.graphpad.com. p<0.05 was chosen as the 
cut off for statistical significance. Student’s t-test was used to test the difference between 
two groups.  One-way ANOVA was used when testing for differences between ≥3 groups. 
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Chapter 3: Dietary Derived Bioactive Screen 
3.1 Introduction 
As discussed in the chapter 1, metalloproteinases play a pivotal role in the destruction of 
cartilage seen during OA. In particular, MMP13 has been considered critical for OA 
progression. Pharmacologic inhibition of MMP13 has been shown to be an effective 
strategy to decelerate articular cartilage loss in a murine model of injury-induced knee OA 
(Wang et al., 2013). Few pharmaceutical companies now consider OA as a disease area. 
This is in part due to issues with drug toxicity but also because OA generally progresses 
slowly and there are no validated biomarkers for cartilage destruction (the only FDA 
approved end point in a clinical trial is joint space narrowing which is assessed by x-ray) 
(Kraus, 2012). A potential alternative strategy is to focus on compounds from the habitual 
diet that may prevent the onset or slow the progression of OA. Williams et al., showed that 
a diet high in fruit and vegetables had a protective association with radiographic hip OA. 
Osteoarthritic chondrocytes have been shown to produce MMPs that can result in 
degenerative changes of the cartilage matrix in OA (Tetlow et al., 2001). 
As MMP gene expression is primarily regulated at the transcriptional level (Fanjul-
Fernández et al., 2010) a useful initial readout of MMP13 mRNA levels in SW1353 cells can 
be used to select bioactive compounds for further study. Previous data published by our 
laboratory has shown that SFN significantly inhibited cytokine-induced MMP13 expression 
at 5µM in a dose-dependent manner in SW1353 cells (Davidson et al., 2013).  
We hypothesise that bioactives in the habitual diet will be chondro-protective. The aims of 
this chapter are: 
 
 Design a custom dietary derived library of 96 dietary derived bioactive compounds 
(see Appendix for compound list) from a list of natural products. 
 
 Screen compounds for potential toxic effects using a cell necrosis cytoxicity assay. 
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 Use qRT-PCR to screen 96 dietary derived bioactives for inhibition of IL1-induced 
and basal MMP13 expression in SW1353 cells.  
 
 Rescreen these compounds in the C28/I2 cell line to eliminate compounds with cell 
line specific effects.  
 
 Select compounds that show MMP13 inhibitory effects in both cell lines for further 
analysis in primary chondrocytes. 
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3.2 Results 
3.2.1 Designing the custom dietary derived library 
The original Bioactive Compound Library contained a collection of bioactive chemical 
compounds from synthetic and natural sources. Only compounds that were produced by 
living organisms were selected from this list creating the Natural Product Library. Ninety six 
dietary derived compounds were selected from the Natural Product Library and compiled 
into a custom-built library in a 96-well plate format. Criteria for compound selection shown 
in Figure 3.1. 
 
 
Figure 3.1. Custom dietary derived compound library design. In order to be selected for the 
96-well plate custom library the natural products had to be dietary derived. The library was 
designed to contain bioactive compounds with a range of chemical structures including 
flavonoids, anthocyanins, terpenoids, carotenoids and other polyphenols as well as precursors 
of dietary compounds such as polydatin (a natural precursor of resveratrol). 
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3.2.2 Cell cytotoxicity screen 
3.2.2.1 Dietary derived compounds effects on cell necrosis - Lactate dehydrogenase 
assay 
SW1353 chondrosarcoma cells were cultured and plated as described in section 2.2.1.1. 
SW1353 cells were treated with one of 96 dietary-derived compounds described in section 
2.1.2.1 at 10µM for 6 hours. The CytoTox 96® Non-Radioactive Cytotoxicity assay was used 
as described by the manufacturer's instructions (see Chapter 2 section 2.7.2 for more 
details). LDH was detected in harvested supernates as a measure of compound toxicity.  
Compounds from the custom built dietary derived library had no significant effect on cell 
necrosis compared to no treatment control (Figure 3.2). 
 
Figure 3.2. Fold change in percentage cell necrosis relative to untreated control samples in 
SW1353 cells. SW1353 cell line pre-treated with 10μM of one of 96 diet derived compounds 
(see Appendix for compound list). Compounds effect on fold change in % cell necrosis relative 
to untreated control was analysed using one way ANOVA with a Dunnetts post hoc test. All 
samples treated with compounds for 6 hours. Data plotted as mean ± SEM, n=3. Dotted line 
represents cell necrosis in untreated control sample cells with ± standard deviation. 
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3.2.3 Bioactive compound screen in SW1353 cells 
3.2.3.1 SW1353 IL1 induced MMP13 expression screen 
SW1353 chondrosarcoma cells were cultured and plated as described in section 2.2.1.1. 
SW1353 cells were treated with one of 96 dietary-derived compounds described in section 
2.1.2.1 at 10µM for 6 hours. Compounds of interest were added an hour before stimulation 
with 5ng/ml IL1.  Emodin, ursolic acid, oleanolic acid, luteolin, polydatin, apigenin, 
neohesperidin dihydrochalcone, l-carnitine and isoliquiritigenin significantly inhibited IL1 
induced MMP13 expression in SW1353 cells (p<0.05-0.0001) (Figure 3.3). DL-Carnitine 
hydrochloride significantly increased IL1 induction of MMP13 expression in SW1353 cells 
(Figure 3.3).  
 
 
Figure 3.3. Fold change in MMP13 gene expression normalised to 18s relative to IL1 treated 
control samples in SW1353 cells. SW1353 cell line pre-treated with 10μM of one of 96 diet 
derived compounds (see Appendix for compound list). Compounds effect on IL1 induced 
MMP13 levels was analysed using one way ANOVA with a Dunnetts post hoc test. All samples 
treated with IL1 (5ng/ml) for 6 hours. and plotted as mean ± SEM, n=3. Dotted line represents 
IL1 treatment alone. * p<0.05, *** p<0.001, **** P<0.0001 
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3.2.3.2 SW1353 Basal MMP13 expression screen 
SW1353 chondrosarcoma cells were cultured and plated as described in section 2.2.1.1. 
SW1353 cells were treated with one of 96 dietary-derived compounds described in section 
2.1.2.1 at 10µM for 6 hours without IL1 stimulation. Myricetin, theobromine and sesamin 
significantly inhibited basal MMP13 expression in SW1353 cells (p<0.01) (Figure 3.4). 
 
 
 
 
Figure 3.4. Fold change in MMP13 gene expression normalised to 18s relative to untreated 
control samples in SW1353 cells. SW1353 cell line pre treated with 10μM of one of 96 diet 
derived compounds (see Appendix for compound list). Compounds effect on basal MMP13 
levels was analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean 
± SEM, n=3. Dotted line represents no treatment (NT) control samples. ** p < 0.01. 
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3.2.4 Bioactive compound screen in C28/I2 cells 
3.2.4.1 C28/I2 IL1 induced MMP13 expression screen 
C28/I2 chondrocyte cells were cultured and plated as described in section 2.2.1.1. C28/I2 
cells were treated with one of 96 dietary-derived compounds described in section 2.1.2.1 
at 10µM for 6 hours. Compounds of interest were added an hour before stimulation with 
5ng/ml IL1.  Apigenin, troxerutin, luteolin, aloe-emodin, methyl-hesperidin, ursolic acid, 
emodin, fisetin, genistin and polydatin significantly inhibited IL1 induced MMP13 
expression in C28/I2 cells (p<0.05-0.0001) (Figure 3.5).  
 
 
Figure 3.5. Fold change in MMP13 gene expression normalised to 18s relative to IL1 treated 
control samples in C28/I2 cells. C28/I2 cell line pre treated with 10μM of one of 96 diet derived 
compounds (see Appendix for compound list). Compounds effect on IL1 induced MMP13 levels 
was analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean ±  SEM, 
n=3. Dotted line represents IL1 treatment alone. * p<0.05, ** p < 0.01, *** p<0.001, **** 
P<0.0001. 
 
68 
 
3.2.4.2 C28/I2 Basal MMP13 expression screen 
C28/I2 chondrocyte cells were culture and plated as described in section 2.2.1.1. C28/I2 
cells were treated with one of 96 dietary-derived compounds described in section 2.1.2.1 
at 10µM for 6 hours without IL1 stimulation. Apigenin, myricetin, genistin, hesperetin, 
biochanin A significantly inhibited basal MMP13 expression in C28/I2 cells (p<0.01-0.0001) 
(Figure 3.6). 
 
 
 
Figure 3.6. Fold change in MMP13 gene expression relative to untreated control samples in 
C28/I2 cells. C28/I2 cell line pre treated with 10μM of one of 96 diet derived compounds (see 
Appendix for compound list). Compounds effect on basal MMP13 levels was analysed using one 
way ANOVA with a Dunnetts post hoc test. Data plotted as mean ± SEM, n=3. Dotted line 
represents no treatment (NT) control samples. * p<0.05, ** p < 0.01, *** p<0.001, **** 
p<0.0001. 
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3.2.4 Selecting compounds of interest  
Compounds showing either a statistically significant effect on MMP13 expression or a trend 
for inhibition of MMP13 expression were selected from each screen and entered into a four 
set Venn diagram (Figure 3.7). Compounds inhibiting MMP13 in a single screen included:  
 Oleonolic acid, naringin dihydrochalcone, rhein, salacin, sitosterol and bilobalide 
inhibited IL1 induced MMP13 in the SW1353 screen alone. 
 Troxerutin, gastrodin, usniacin, shikmic acid, fisetin, glycyrrhizic acid, coenzyme 
Q10, and indole butyric acid inhibited IL1 induced MMP13 in the C28/I2 screen 
alone. 
 Sesamin, palmatinechloride, osthole, ergosterol, salidroside, icariin and artesunate 
inhibited basal MMP13 in the SW1353 screen alone. 
 Sclareol, ammonium glycyrrhizinate, gynostemma extract, hesperidin, formonetin, 
biochanin A, fumalic acid, dihydroartemisinin, capsaicin and hesperetin inhibited 
basal MMP13 in the C28/I2 screen alone.  
Compounds inhibiting MMP13 in screens included: 
 Aloe emodin, ursolic acid and isoliquiritigenin inhibited IL1 induced MMP13 in the 
SW1353 and C28/I2 screens. 
 Kinetin, methyl-hesperidin and theobromine inhibited IL1 induced MMP13 in the 
C28/I2 screen and inhibited basal MMP13 in the SW1353 screen. 
 Indole-3-carbinol and orotic acid inhibited basal MMP13 in the SW1353 and C28/I2 
screens. 
 Myricetin inhibited IL1 induced and basal MMP13 in the C28/I2 screen and inhibited 
basal MMP13 in the SW1353 screen. 
 Luteolin inhibited IL1 induced and basal MMP13 in the SW1353 and C28/I2 screens. 
 Quercetin, neohesperidin dihydrochalcone, rheochrysidin and naringin inhibited IL1 
induced and basal MMP13 in the SW1353 screen. 
 L-carnitine and nobiletin inhibited IL1 induced and basal MMP13 in the SW1353 
screen and inhibited basal MMP13 in the C28/I2 screen. 
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 Apigenin, genistin, polydatin and emodin inhibited IL1 induced MMP13 in the 
SW1353 screen and inhibited IL1 induced and basal MMP13 in the C28/I2 screen. 
= IL1 SW1353
= IL1 C28/I2
= Basal SW1353
= Basal C28/I2
Oleonolic acid
Rhein
Bilobalide
Naringin Dihydrochalcone
Sitosterol
Salicin
Troxerutin
Gastrodin
Usniacin
Fisetin
Glycyrrhizic acid
Coenzyme Q10
Indolebutyric acid
Sesamin
Artesunate
Palmatine chloride
Ergosterol
Icariin
Osthole
Salidroside
Hesperetin
Biochanin A
Gynostemma extract
Ammonium Glycyrrhizinate
Formononetin
Fumalic acid
Hesperedin
Capsaicin
Dihydroartemisinin
Sclareol
Kinetin
Theobromine
Aloe emodin
Ursolic acid
Isoliquiritigenin
Myricetin
Luteolin
Polydatin
Quercetin
Naringin
L-carnitine
Nobiletin
Apigenin
Emodin
Genistin
Orotic acid
Indole-3-carbinol
Shikmic acid
Methyl-Hesperidin
Rheochrysidin
Neohesperidin
Dihydrochalcone
  
 
 
 
 
 
 
Figure 3.7. Four set Venn diagram. Ellipses displaying compounds that reduced IL1 and/or basal 
levels of MMP13 in SW1353 and C28/I2 cell lines. 
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3.3 Discussion 
This project aims to identify novel compounds found in the habitual diet that could offer 
protection or slow the progression of OA. A custom-built library of 96 compounds was 
designed from a selection of compounds from a Bioactive Compound Library (Figure 3.1). 
Ninety six compounds were selected and compiled into a custom-built library in a 96-well 
plate format. This format was selected to ensure accurate comparisons between 
compounds, all compounds were at 10µM and dissolved in DMSO. The advantages of using 
a custom-built library in this format was the standardisation of compounds in terms of 
purity, concentration and form. Purchasing compounds individually often requires a 
minimum quantity and can quickly become expensive narrowing the range of bioactive 
compounds that can be explored. The library was designed to contain bioactive compounds 
with a range of chemical structures including flavonoids, anthocyanins, terpenoids, 
carotenoids and other polyphenols as well as precursors of dietary compounds such as 
polydatin (a natural precursor of resveratrol).  
Compounds were screened at an initial concentration of 10µM for IL1 induced and basal 
MMP13 inhibition in SW1353 cells. A 0.1-10µM dose range of anthocyanin metabolites has 
been proposed to be physiologically relevant with phenolic metabolites reported ranging 
from 0.1-2µM with cumulative concentrations of metabolites reaching 10µM in plasma 
after oral consumption of a bolus containing 500mg/day of anthocyanins (Ferrars et al., 
2014), (Ferrars et al., 2014), (Amin et al., 2015). Cells outside of the gut may not see parent 
compounds as these are often metabolised during digestion, possibly resulting in 
metabolites of the parent compounds reaching chondrocytes. However chondrocytes have 
been shown to metabolise parent compounds such as SFN and accumulate metabolites of 
the parent compound in vitro (Davidson et al., 2013). 
For this study 10µM was selected as an initial concentration to represent a ‘high’ but 
physiologically relevant concentration that may be obtained via diet or supplementation of 
bioactive compounds. Compounds were screened at an initial concentration of 10µM for 
IL1 induced and basal MMP13 inhibition in SW1353 cells. Inhibition of the expression of 
MMP13 was selected as an initial readout for a bioactive compounds potential as a 
chondro-protective agent, as discussed in chapter 1 MMP-13 is the collagenase with the 
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highest specific activity for type 2 collagen i.e. has the most efficient cleavage of the protein 
(Minond et al., 2006) and it’s thought to be the predominant collagenase involved in OA 
(Knäuper et al., 1996), (Billinghurst et al., 1997), (Flannelly et al., 2002) compared to other 
collagenases such as MMP1. A qRT-PCR approach to analysing MMP13 was selected as a 
strategy to give a medium-high throughput screen using relatively low cell numbers 
compared to other techniques such as northern blots. MMP13 mRNA levels have also been 
shown to be comparable to MMP-13 protein levels (Ahmad et al., 2009), this allows us to 
predict compound effects on the MMP-13 protein levels using the medium-high 
throughput screen, whilst using a western blot method to measure the effect of each 
compound on actual MMP-13 protein levels would be prohibitively expensive and time 
consuming. 
The SW1353 chondrosarcoma cell line was used as an in vitro model for primary human 
adult articular chondrocytes (PHC). In both SW1353 and PHC cell systems MMP1, MMP3 
and MMP13 are strongly induced by IL1 making SW1353 cells a useful model for primary 
chondrocytes at the transcriptional level with respect to catabolic effects after IL1 
treatment (Gebauer et al., 2005a). The high throughput nature of the dietary derived 
bioactive screen would be limited by the lack of sufficient PHCs from operative procedures 
(Goldring et al., 1994), (Finger et al., 2003), rapid dedifferention of PHC cells after 
proliferation and the screens would need to be repeated with many patient samples due 
to gene expression variability (Bonaventure et al., 1994). The SW1353 cells also display a 
consistent response to phenotype modulating stimuli and have adequate proliferative 
activities (Gebauer et al., 2005a).  
SW1353 cells were treated each compound at 10µM for 6 hours. A 6 hour treatment was 
selected as a preliminary timepoint, as 5ng/ml of IL1 has been shown to significantly 
upregulate MMP13 at 6 hours and chondrocytes treated with SFN  for 6 hours have shown 
significant inhibition of IL1 induced MMP13 in our lab (Davidson et al., 2013). 
The one-way analysis of variance (ANOVA) with Dunnett’s post test was used to measure 
the statistical significance of a compounds effect on IL1 stimulated MMP13. While multiple 
t-tests could have been used to measure significance the chances of a Type 1 error 
occurring increases with each t-test performed. With 96 compounds being screened 96 t-
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tests would need to be completed and the chance of a Type 1 error occurring would be 
unacceptably high. Using an ANOVA controls for these errors so that the chance of a Type 
1 error never exceeds 5%. 
Cell cytoxicity was analysed by measuring cell necrosis after compound treatment. Cell 
necrosis was measured using the CytoTox 96® Non-Radioactive Cytotoxicity as described 
by the manufacturer's instructions (see Chapter 2 section 2.2.1.2 for more details). For 
compounds to be considered as being protective to cartilage they must have no significant 
effect on cell necrosis. All dietary derived compounds had no significant effect on cell 
necrosis in SW1353 cells (Figure 3.2).  
Emodin, ursolic acid, oleanolic acid, luteolin, polydatin, apigenin, neohesperidin 
dihydrochalcone, l-carnitine and isoliquiritigenin significantly inhibited IL1 induced MMP13 
expression and DL-carnitine hydrochloride significantly increased IL1 induction of MMP13 
in SW1353 cells (Figure 3.3). DL-carnitine is found in mutton and beef (Yonei et al., 2008), 
while this compound would not be a useful bioactive for prevention of OA its potential role 
in MMP13 induction is interesting, however researching compounds that induce MMPs is 
beyond the scope of this project. Myricetin, theobromine and sesamin significantly 
inhibited basal MMP13 expression (Figure 3.4).  
The C28/I2 cell line are immortalised transformed human costal chondrocytes (provided by 
Dr. Mary Goldring, Hospital for Special Surgery, New York). The C28/I2 cells were 
established by transfection of primary cultures of juvenile costal chondrocytes with vectors 
encoding simian virus 40 large T antigen (Goldring et al., 1994). This cell line was used as a 
comparison to the SW1353 cell line to eliminate compounds with cell line specific effects 
before moving candidate compounds into PHC cells. C28/I2 cells were treated with each of 
the compounds from the 96 dietary derived bioactive compound library for 6 hours. 
Apigenin, troxerutin, luteolin, aloe-emodin, methyl-hesperidin, ursolic acid, emodin, 
fisetin, genistin and polydatin significantly inhibited IL1 induced MMP13 expression in 
C28/I2 cells (Figure 3.5). Apigenin, myricetin, genistin, hesperetin, biochanin A significantly 
inhibited basal MMP13 expression in C28/I2 cells (Figure 3.6).  
As some of these compounds had either IL1/basal or SW1353/C28/I2 specific effects the 
top twenty compounds showing either a statistically significant effect on MMP13 
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expression or a trend for inhibition of MMP13 expression were selected from each screen 
and entered into a four set Venn diagram (Figure 3.7). Compounds were selected from the 
Venn diagram and compiled into a top twenty compound list for further study in KOA 
chondrocyte cells if the compound effected more than one of the MMP13 expression 
screens. This was done to eliminate compounds that only had an effect in a single 
experiment and to include compounds that showed a trend of inhibition of MMP13 
expression in multiple experiments that may not have reached statistical significance in 
individual screens. List of selected compounds can be seen in Table 5.   
Isoliquiritigenin is a strong nod gene and glyceollin resistance-inducing flavonoid (Kape et 
al., 1992) from liquorice. Nod genes encode for proteins that modify nodulation factors 
which act as signalling molecules between symbiotic bacteria and plants in response to 
flavonoids (Peck et al., 2006). Theobromine is a xanthine alkaloid found in cocoa beans that 
has been described to have a bronchodilator and a vasodilator effect in asthma patients 
comparable to theophylline an anti-asthma medication with no reported side effects 
(Simons et al., 1985). Kinetin is a cytokinin (class of plant hormone that promotes cell 
division) found in coconut (Ge et al., 2005) which is used in plant tissue culture for inducing 
formation of callus (Gavinlertvatana & Li, 1980).  
Myricetin is a naturally occurring flavonol, a flavonoid found in many grapes, berries, fruits, 
vegetables, herbs, as well as other plants. Myricetin has been shown to significantly inhibit 
MMP1 at 1 and 10μM in SW982 chondrosarcoma cells (Lee & Choi, 2010). Emodin is a 
purgative resin trihydroxyanthraquinone from rhubarb and is a commonly used traditional 
herbal treatment in China (Cai et al., 2008). Polydatin (resveratrol-3-O-β-mono-D-
glucoside) is a natural precursor to resveratrol which is much more abundant than 
resveratrol in grape juices (Romero-Pérez et al., 1999), (Falchetti et al., 2001), polydatin is 
likely to be the most abundant form of resveratrol in nature (Regev-Shoshani et al., 2003). 
Ursolic acid is a triterpenoid that exists widely in food (J. Liu, 1995), medicinal herbs and is 
often used in cosmetics which has been shown to inhibit activation of NFB in a leukaemia 
cell line by preventing phosphorylation of Ib (Shishodia et al., 2003).  
Methyl-Hesperidin is a flavonoid found abundantly in citrus fruits, its aglycone form is 
called hesperetin which has been shown to improve endothelial function and reduce 
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inflammatory markers in patients with metabolic syndrome (Rizza et al., 2011). Aloe 
emodin is a hydroxy anthraquinone known to have laxative, anti-fungal, antibacterial, 
antiviral and hepatoprotective activities. Aloe emodin has also been shown to reduce the 
DNA binding activities of NFκB (Suboj et al., 2012). Genistin is a isoflavone from soy that 
attenuates growth factor and cytokine-stimulated proliferation of both normal and cancer 
cells potentially via TGFbeta1-signaling (Kim et al., 1998). Apigenin has already been shown 
to suppress MMP13 expression in IL1 treated SW1353 cells by suppressing the c-fos/AP-1 
and JAK2/STAT1/2 pathways (Lim et al., 2011). Luteolin is a flavone found in celery that has 
been shown to inhibit IL1 induced MMP13 mRNA levels measured by qRT-PCR, via 
inhibition of IL1-induced ERK activation in a dose-dependent manner in osteoblasts (Yang 
et al., 2012).  
Orotic acid is a heterocyclic compound and an acid found in carrots and dairy products 
(Salerno & Crifò, 2002) and is the first pyrimidine formed in the de novo pathway of nucleic 
acid synthesis, becoming elevated whenever the ammonia load exceeds the capacity of the 
urea cycle (Visek & Shoemaker, 1986). Indole-3-carbinol is produced by the breakdown of 
the glucosinolate glucobrassicin, which can be found at relatively high levels in cruciferous 
vegetables (Fahey et al., 2001), it can act as a negative regulator of estrogen potentially 
preventing the development of estrogen-enhanced cancers including breast, endometrial 
and cervical cancers (Auborn et al., 2003).  
Nobiletin is a polymethoxyflavone found in citrus fruit peel (Guo et al., 2012). Nobiletin has 
been shown to inhibit gene expression of IL1 TNF-α and IL-6 in mouse J774A.1 macrophages 
(Lin et al., 2003). Naringin is a flavanone glycoside and a major flavonoid in grapefruit giving 
the grapefruit juice its bitter taste, its supplementation has been suggested to be used as 
a treatment for obesity, diabetes, hypertension and metabolic syndrome (Alam et al., 
2014). L-carnitine is constituent of striated muscle and liver, in the diet it can be found in 
animal products. L-carnitine is used therapeutically to stimulate gastric and pancreatic 
secretions and in the treatment of hyperlipoproteinemias (Stefanutti et al., 1998). 
Neohesperidin dihydrochalcone is an artificial sweetener derived from citrus (Kroeze, 
2000). The flavonol quercetin has been shown to prevent cartilage degradation in tissue 
explants, quercetin has also been shown to suppress IL1 stimulated expression of 
ADAMTS4 and basal expression of ADAMTS5 (Lay et al., 2012). Rheochrysidin is one of the 
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major components of Da-Cheng-Qi decoction used in the treatment of inflammation (Q. Yu 
et al., 2009). 
Compound Dietary Source 
Isoliquiritigenin Liquorice 
Theobromine Cocoa bean 
Kinetin Coconut 
Myricetin Grapes 
Emodin Rhubarb 
Polydatin Grapes 
Ursolic acid Apple 
Methyl Hesperidin Citrus fruits 
Aloe emodin Aloe vera 
Genistin Soy 
Apigenin Parsley, celery, coffee 
Luteolin Celery 
Orotic acid Carrot 
Indole-3-carbinol Broccoli 
Nobiletin Orange 
Naringin Grapefruit 
L-carnitine Beef 
Neohesperidin Dihydrochalcone Citrus fruit 
Quercetin Black elder berry 
Rheochrysidin Curly dock 
 
Table 5. Twenty selected compounds.  Table highlighting the selected compounds for study in 
primary chondrocytes and examples of sources they can be found in. 
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3.3.1 Conclusion 
In conclusion a custom-built dietary derived library was designed, all compounds from this 
library were analysed for toxicity via lactate dehydrogenase assay. All compounds analysed 
had no significant effect on cell necrosis when compared to untreated control.  Several 
compounds were able to inhibit MMP13 at 10µM in SW1353 and C28/I2 cell lines. From 
this original list of 96 dietary derived compounds twenty compounds were selected and 
their effect on primary chondrocytes will be described in the next chapter. 
3.3.2 Strengths of Chapter 3 
 Shortlisted several compounds that have been shown to inhibit MMP13 gene 
expression in two cell lines in a medium-high throughput manner using a qrt-PCR 
based approach. 
 Shown that all compounds have no necrotic effect in SW1353 cells at 10µM. 
3.3.3 Weaknesses of Chapter 3 
 Lack of data for compound effect on MMP-1 or MMP-13 protein levels. 
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Chapter 4: Short-listing dietary-derived bioactives in human 
primary knee osteoarthritis chondrocytes 
4.1 Introduction 
In the previous chapter, 96 dietary-derived bioactive compounds were shortlisted to 20 
compounds for further study. While SW1353 cells are a useful model for protease 
expression in chondrocytes, a gene array comparing 312 genes has shown that the overlap 
between gene expression is small between SW1353 cells and PHC cells (Gebauer et al., 
2005). Gaubauer et al, concluded that the SW1353 cell line cannot be used as a general 
prediction for the behaviour of PHCs. The molecular phenotype of the C28/I2, T/C-28a4 
and T/C-28a2 human chondrocyte cell lines have also been investigated (Finger et al., 
2003). These cell lines showed less expression of genes involved in matrix synthesis and 
turnover in comparison to PHCs. While the C28/I2 cell line displayed the highest levels of 
matrix-anabolic and matrix-catabolic genes, the cell line was described as not being a direct 
substitute for PHCs and that experiments should be validated in PHCs or cartilage-tissue 
cultures (Finger et al., 2003). Twenty compounds selected in chapter 3 (Table 5) were 
tested in KOA chondrocytes. KOA cells were isolated from the cartilage of patients with 
knee OA as described in section 2.1.1.3. The qRT-PCR MMP13 screens from (Chapter 3 
Figure 3.3-3.6) were repeated in the 20 selected compounds in KOA cells. While MMP-13 
plays a pivotal role in collagen cleavage in OA (Knauper et al., 1996) MMP-1 is also able to 
cleave native fibrillar collagen and contributes to the pathological cleavage of collagen 
fibrils in OA (Burrage et al., 2006). Using the qRT-PCR screen format from (Chapter 3 Figure 
3.3-3.6) the effect of the selected 20 compounds (Table 5) on MMP1 expression in KOA 
cells was measured. As before, 10µM was selected as an initial concentration for the qRT-
PCR metalloproteinase screens to represent a ‘high’ but physiologically relevant 
concentration that may be obtained via diet or supplementation. 
As discussed in chapter 1 ADAMTSs also play a role in the development of OA. ADAMTS5 
knock out mice had a significant reduction in the severity of cartilage destruction after 
surgically induced instability when compared with wild type mice (Glasson et al., 2005). 
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ADAMTS5 is constitutively expressed whereas ADAMTS4 is induced following IL1 treatment 
(Tortorella et al., 2001), for this reason only the unstimulated expression of ADAMTS5 was 
measured. ADAMTS4 has been shown to be selectively overexpressed in human 
osteoarthritic cartilage, with a direct correlation with the degree of cartilage destruction 
suggesting that ADAMTS4 may play an important role in the degradation of aggrecan in 
human osteoarthritic cartilage (Naito et al., 2007). Compounds from the dose response 
were screened for effects on ADAMTS4 and ADAMTS5 in KOA cells. Heme oxygenase-1 (HO-
1) is the limiting enzyme in heme catabolism (Rousset et al., 2013), cleaving heme to form 
biliverdin, this prevents production of ROS giving HO-1 anti-inflammatory properties. HO-1 
induction in PHCs cultured in hypoxic conditions prevented IL1 stimulated loss of type 2 
collagen (Guillén et al., 2012). HO-1 was hypothesised to be a physiologically important 
chondro-protective factor. 
Transgenic OA mouse models have indicated that upregulation of β-catenin is responsible 
for the transition of normal chondrocytes into an arthritic phenotype (Wu et al., 2010). β-
catenin levels are up-regulated by Wnt ligands, in the absence of Wnt ligands β-catenin is 
degraded in a glycogen synthase kinase 3 β (GSK3-β) destruction complex brought together 
by Axin/Axin2 and the adenomatous polyposis coli tumour suppressor protein (APC). AXIN2 
is a Wnt/β-catenin responsive gene which has been shown to be upregulated consistently 
with net activation of canonical Wnt signalling (Lustig et al., 2002). Wnt signalling can 
induce the expression of MMPs in articular chondrocytes which promotes cartilage 
degradation and cartilage catabolism (Yuasa et al., 2008). As the upregulation of the Wnt 
pathway may be deleterious for the joint cartilage the compounds from the dose response 
assays were screened for an effect on the expression of AXIN2.  
We hypothesise that bioactives showing significant inhibition of MMP13 and/or MMP1 
expression at 10μM may have an inhibitory effects on other chondro-destructive 
metalloproteinase genes such as ADAMTS4 and ADAMTS5. Potential chondro-protective 
compounds may also up-regulate chondro-protective genes such as HO-1 in a dose 
dependent manner. The aims of this chapter are: 
80 
 
 To use qRT-PCR to screen 20 selected compounds (see Chapter 3 Table 5 for 
selected compounds) for inhibition of IL1-induced and basal MMP13 and MMP1 
expression in KOA chondrocytes. 
 Complete dose response curves for two candidate compounds from KOA cell 
experiments looking at effects on chondro-destructive genes, MMP13, MMP1, 
ADAMTS4 and ADAMTS5.  
 Complete dose response curves for two candidate compounds from KOA cell 
experiments looking at effects on the chondro-protective gene HO-1. 
 Complete dose response curves for two candidate compounds from KOA cell 
experiments looking for effects on AXIN2 as a measurement of Wnt pathway 
activity. 
 Screen the two candidate compounds for potential apoptotic or necrotic effects in 
KOA cells. 
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4.2 Results 
4.2.1 The effect of the twenty shortlisted compounds on genes of interest in KOA 
chondrocyte cells 
4.2.1.1 Effect on IL1 induced MMP13 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Compounds of interest were added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP13 using 
methods described in section 2.2.3.1. Luteolin, aloe-emodin, emodin, isoliquiritigenin and 
apigenin significantly inhibited IL1 induced MMP13 expression in KOA cells (p<0.05-0.0001) 
(Figure 4.1).  
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Figure 4.1 Dietary derived compounds effect on IL1 stimulated MMP13 gene expression 
relative to 18s in KOA cells. Tukey Box and whisker plot showing fold change in MMP13 gene 
expression relative to IL1 treated control samples in KOA chondrocytes treated with 10μM of 
one of the top 20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on IL1 
induced MMP13 levels was analysed using one way ANOVA with a Dunnetts post hoc test. All 
samples treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 
treatment alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to 
the highest or lowest point, whichever is shorter), n=4. Solid line represents IL1 treatment alone 
with dotted lines representing IL1 treated controls standard deviation. *p<0.05, ** p < 0.01, *** 
p<0.001, **** P<0.0001. 
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4.2.1.2 Effect on basal MMP13 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Real-time qRT-PCR was used to measure MMP13 using 
methods described in section 2.2.3.1. Compounds had no significant effect on basal 
MMP13 expression (Figure 4.2).  
 
 
Figure 4.2. Dietary derived compounds effect on unstimulated MMP13 gene expression 
relative to 18s in KOA cells. Tukey Box and whisker plot showing fold change in MMP13 gene 
expression relative to no treatment in KOA chondrocytes treated with 10μM of one of the top 
20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on basal MMP13 levels 
was analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold 
change relative to no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the 
interquartile distance or to the highest or lowest point, whichever is shorter), n=4. Solid line 
represents no treatment (NT) with dotted lines representing standard deviation.  
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4.2.1.3 Effect on IL1 induced MMP1 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Compounds of interest were added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP1 using methods 
described in section 2.2.3.1. Emodin, genistin, luteolin, aloe-emodin, ursolic acid, 
isoliquiritigenin and apigenin significantly inhibited IL1 induced MMP1 expression in KOA 
cells (p<0.05-0.0001) (Figure 4.3).  
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Figure 4.3 Dietary derived compounds effect on IL1 stimulated MMP1 gene expression 
relative to 18s in KOA cells.  Tukey Box and whisker plot showing fold change in MMP1 gene 
expression relative to IL1 treated control samples in KOA chondrocytes treated with 10μM of 
one of the top 20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on IL1 
induced MMP1 levels was analysed using one way ANOVA with a Dunnetts post hoc test. All 
samples treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 
treatment alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to 
the highest or lowest point, whichever is shorter), n=4. Solid line represents IL1 treatment alone 
with dotted lines representing IL1 treated controls standard deviation. *p<0.05,  *** p<0.001, 
**** p<0.0001. 
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4.2.1.4 Effect on basal MMP1 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Real-time qRT-PCR was used to measure MMP1 using 
methods described in section 2.2.3.1. Compounds had no significant effect on basal MMP1 
expression (Figure 4.4). 
 
 
Figure 4.4. Dietary derived compounds effect on unstimulated MMP1 gene expression 
relative to 18s in KOA cells.  Tukey Box and whisker plot showing fold change in MMP1 gene 
expression relative to no treatment in KOA chondrocytes treated with 10μM of one of the top 
20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on basal MMP1 levels 
was analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold 
change relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile 
distance or to the highest or lowest point, whichever is shorter), n=4. Solid line represents no 
treatment (NT) with dotted lines representing  standard deviation.  
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4.2.1.5 Effect on IL1 induced ADAMTS4 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Compounds of interest were added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure ADAMTS4 using 
methods described in section 2.2.3.1. Isoliquiritigenin, apigenin and aloe-emodin 
significantly inhibited IL1 induced ADAMTS4 expression in KOA cells (p<0.05) (Figure 4.5). 
 
Figure 4.5. Dietary derived compounds effect on IL1 stimulated ADAMTS4 gene expression 
relative to 18s in KOA cells. Tukey Box and whisker plot showing fold change in ADAMTS4 gene 
expression relative to IL1 treated control samples in KOA chondrocytes treated with 10μM of 
one of the top 20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on IL1 
induced ADAMTS4 levels was analysed using one way ANOVA with a Dunnetts post hoc test. All 
samples treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 
treatment alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to 
the highest or lowest point, whichever is shorter), n=4. Solid line represents IL1 treatment alone 
with dotted lines representing IL1 treated controls standard deviation. *p<0.05. 
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4.2.1.6 Effect on basal ADAMTS4 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. Real-time qRT-PCR was used to measure ADAMTS4 using 
methods described in section 2.2.3.1. Genistin, apigenin and isoliquiritigenin significantly 
inhibited basal ADAMTS4 expression in KOA cells (p<0.01-0.001) (Figure 4.6). 
 
Figure 4.6. Dietary derived compounds effect on unstimulated ADAMTS4 gene expression 
relative to 18s in KOA cells. Tukey Box and whisker plot showing fold change in ADAMTS4 gene 
expression relative to no treatment in KOA chondrocytes treated with 10μM of one of the top 
20 diet derived compounds (see Chapter 3 Table 5). Compounds effect on ADAMTS4 levels was 
analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold change 
relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance 
or to the highest or lowest point, whichever is shorter), n=4. Solid line represents no treatment 
(NT) with dotted lines representing standard deviation. ** p<0.01, *** p<0.001. 
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4.2.1.7 Effect on basal ADAMTS5 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with one of the selected twenty dietary-derived compounds (described in Chapter 
3 Table 5) at 10µM for 6 hours. In these experiments IL1 did not induce ADAMTS5 
expression so basal ADAMTS5 was measured. Real-time qRT-PCR was used to measure 
ADAMTS5 using methods described in section 2.2.3.1. Luteolin and genistin significantly 
inhibited basal ADAMTS5 expression in KOA cells (p<0.01 - p<0.001) (Figure 4.7). 
 
 
Figure 4.7. Dietary derived compounds effect on unstimulated ADAMTS5 in KOA cells. Tukey 
Box and whisker plot showing fold change in ADAMTS5 gene expression relative to no treatment 
in KOA chondrocytes treated with 10μM of one of the top 20 diet derived compounds (see 
Chapter 3 Table 5). Compounds effect on ADAMTS5 levels was analysed using one way ANOVA 
with a Dunnetts post hoc test. Data plotted as mean fold change relative no treatment ± Tukey 
whiskers (Tukey whiskers are 1.5 times the interquartile distance or to the highest or lowest 
point, whichever is shorter), n=4. Solid line represents no treatment (NT) with dotted lines 
representing standard deviation. ** p<0.01, *** p<0.001 
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4.2.2 Selecting compounds for further study 
Compounds that significantly inhibited genes of interest in the KOA cell screens (Figure 4.1-
4.7) may be chondro-protective and were entered into Table 6 which was used to select 
compounds for KOA cell dose response experiments. Compounds were ranked into order 
based on the number of screens they had a significant effect on. As apigenin and 
isoliquiritigenin significantly inhibited genes of interest in the most screens they were 
selected for further study. 
 
 
 
 
 
Compound IL1 
induced 
MMP13 
Basal 
MMP13 
IL1 
induced 
MMP1 
Basal 
MMP1 
IL1 
induced 
ADAMTS4 
Basal 
ADAMTS4 
Basal 
ADAMTS
5 
Apigenin ****  ****  * **  
Isoliquiritigenin ***  ****  * ***  
Aloe-emodin **  ***  *   
Luteolin *  ***    ** 
Genistin   ***   ** *** 
Emodin **  *     
Ursolic acid   ***     
Table 6. Selecting compounds for further study. Table highlighting dietary derived bioactive 
compounds that significantly inhibited IL1 induced and basal expression of genes of interest in 
KOA cells when using one way ANOVA with a Dunnetts post hoc test (p<0.05 - p<0.0001). 
Selected compounds for further analysis in bold. * p<0.05, ** p < 0.01, *** p<0.001, **** 
P<0.0001. 
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4.2.3 IL1 stimulated MMP13 Time course 
4.2.3.1 Apigenin Time course 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin as before at 10µM and 5ng/ml IL1 for 1, 3, 6, 12, 18 and 24 hours 
(Figure 4.8). Real-time qRT-PCR was used to measure MMP13 using methods described in 
section 2.2.3.1. Apigenin significantly inhibited IL1 induced MMP13 at 6 and 12 hours (p<0.05-
0.001). 
 
 
Figure 4.8. Apigenin treated MMP13 inhibition Time course.  Bar chart showing fold change in 
MMP13 gene expression relative to IL1 treated control samples in KOA chondrocytes treated 
with apigenin at 10µM at 1,3,6,12,18 and 24 hours. All samples treated with IL1 (5ng/ml). Data 
plotted as mean fold change relative to IL1 treatment alone + standard error n=4. The 
expression of MMP13 between each timepoint and IL1 control was analysed by unpaired two-
tailed t test. Dotted line represents IL1 treatment alone. Insert graph shows IL1 dose dependent 
induction of MMP13 at 1,3,6,12,18 and 24 hours relative to no treatment (NT) + standard error 
n=4. Solid line represents no treatment alone. * p<0.05, *** p<0.001. 
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4.2.3.2 Isoliquiritigenin Time course 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin as before at 10µM and 5ng/ml IL1 for 1, 3, 6, 12, 18 and 24 
hours (Figure 4.9). Real-time qRT-PCR was used to measure MMP13 using methods 
described in section 2.2.3.1. Isoliquiritigenin significantly reduced IL1 induced MMP13 at 6, 
12 and 24 hours (p<0.01).  
 
Figure 4.9. Isoliquiritigenin treated MMP13 inhibition Time course.  Bar chart showing fold 
change in MMP13 gene expression relative to IL1 treated control samples in KOA chondrocytes 
treated with isoliquiritigenin at 10µM at 1,3,6,12,18 and 24 hours. All samples treated with IL1 
(5ng/ml). Data plotted as mean fold change relative to IL1 treatment alone + standard error 
n=4. The expression of MMP13 between each timepoint and IL1 control was analysed by 
unpaired two-tailed t test. Dotted line represents IL1 treatment alone. Insert graph shows IL1 
dose dependent induction of MMP13 at 1,3,6,12,18 and 24 hours relative to no treatment (NT) 
+ standard error n=4. Solid line represents no treatment alone. ** p< 0.01. 
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4.2.4 Dose response curves - Apigenin 
4.2.4.1 Apigenin dose response curve - effect on IL1 induced MMP13 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 0.312-40µM for 6 hours. Apigenin was added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP13 using 
methods described in section 2.2.3.1. At 1.25µM apigenin appeared to induce MMP13, this 
did not reach statistical significance and there was no significant difference between donor 
samples. Apigenin significantly inhibited IL1 induced MMP13 from 2.5-40µM (p<0.01-
0.0001) in a dose dependent manner (Figure 4.10). 
 
Figure 4.10. Apigenin IL1 induced MMP13 dose response. Tukey Box and whisker plot showing 
fold change in MMP13 gene expression relative to IL1 treated control samples in KOA 
chondrocytes treated with apigenin at 0.312-40µM for 6 hours. The effect of apigenin on IL1 
induced MMP13 was analysed using one way ANOVA with a Dunnetts post hoc test. All samples 
treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 treatment 
alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to the highest 
or lowest point, whichever is shorter), n=4. Solid line represents IL1 treatment alone with dotted 
lines representing IL1 treated controls standard deviation. ** p<0.01, **** p<0.0001. 
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4.2.4.2 Apigenin dose response curve - effect on IL1 induced MMP1 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 0.312-40µM for 6 hours. Apigenin was added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP1 using methods 
described in section 2.2.3.1. At 0.312µM apigenin appeared to induce MMP1, this did not 
reach statistical significance and there was no significance difference between donor 
samples. Apigenin significantly inhibited IL1 induced MMP1 from 2.5-40µM (p<0.01-
0.0001) in a dose dependent manner (Figure 4.11). 
 
Figure 4.11. Apigenin IL1 induced MMP1 dose response. Tukey Box and whisker plot showing 
fold change in MMP1 gene expression relative to IL1 treated control samples in KOA 
chondrocytes treated with apigenin at 0.312-40µM for 6 hours. The effect of apigenin on IL1 
induced MMP1 was analysed using one way ANOVA with a Dunnetts post hoc test. All samples 
treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 treatment 
alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to the highest 
or lowest point, whichever is shorter), n=4. Solid line represents IL1 treatment alone with 
dotted lines representing IL1 treated controls standard deviation. ** p< 0.01, *** p<0.001, **** 
p<0.0001. 
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4.2.4.3 Apigenin dose response curve - effect on IL1 induced ADAMTS4 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 0.312-40µM for 6 hours. Apigenin was added an hour before 
stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure ADAMTS4 using 
methods described in section 2.2.3.1. Apigenin significantly inhibited IL1 induced ADAMTS4 
from 5-20µM (p<0.01-0.001) in a dose dependent manner (Figure 4.12). At 40µM ADAMTS4 
expression was undetectable.  
 
 
Figure 4.12. Apigenin IL1 induced ADAMTS4 dose response. Tukey Box and whisker plot 
showing fold change in ADAMTS4 gene expression relative to IL1 treated control samples in 
KOA chondrocytes treated with apigenin at 0.312-40µM for 6 hours. The effect of apigenin on 
IL1 induced ADAMTS4 was analysed using one way ANOVA with a Dunnetts post hoc test. At 
40µM ADAMTS4 expression was undetectable. All samples treated with IL1 (5ng/ml) for 6 
hours. Data plotted as mean fold change relative to IL1 treatment alone ± Tukey whiskers 
(Tukey whiskers are 1.5 times the interquartile distance or to the highest or lowest point, 
whichever is shorter), n=4. Solid line represents IL1 treatment alone with dotted lines 
representing IL1 treated controls standard deviation. ** p<0.01, *** p<0.001. 
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4.2.4.4 Apigenin dose response curve - effect on Basal ADAMTS5 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 0.312-40µM for 6 hours. Real-time qRT-PCR was used to measure 
ADAMTS5 using methods described in section 2.2.3.1. Apigenin significantly reduced basal 
ADAMTS5 expression at 20 and 40µM (p<0.01) (Figure 4.13). 
 
 
 
Figure 4.13. Apigenin basal ADAMTS5 dose response.  Tukey Box and whisker plot showing fold 
change in ADAMTS5 gene expression relative to no treatment in KOA chondrocytes treated with 
apigenin at 0.312-40µM for 6 hours. The effect of apigenin on basal ADAMTS5 expression was 
analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold change 
relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance 
or to the highest or lowest point, whichever is shorter), n=4. Solid line represents no treatment 
(NT) with dotted lines representing standard deviation. ** p<0.01. 
97 
 
4.2.4.5 Apigenin dose response curve - effect on Basal HO-1 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 0.312-40µM for 6 hours. Real-time qRT-PCR was used to measure 
HO-1 using methods described in section 2.2.3.2. Apigenin significantly induced basal HO-
1 at 2.5-10µM (p<0.05-0.001) (Figure 4.14). 
 
 
 
Figure 4.14. Apigenin basal HO-1 dose response. Tukey Box and whisker plot showing fold 
change in HO-1 gene expression relative to no treatment in KOA chondrocytes treated with 
apigenin at 0.312-40µM for 6 hours. The effect of apigenin on basal HO-1 expression was 
analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold 
change relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile 
distance or to the highest or lowest point, whichever is shorter), n=4. Solid line represents no 
treatment (NT) with dotted lines representing standard deviation. * p<0.05, ** p<0.01, *** 
p<0.001. 
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4.2.4.6 Apigenin dose response curve - effect on Basal AXIN2 in KOA chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 2.5-40µM for 6 hours. Real-time qRT-PCR was used to measure 
AXIN2 using methods described in section 2.2.3.2. Apigenin significantly inhibited basal 
AXIN2 expression at 10-40µM in a dose dependent manner (p<0.01-p<0.001) (Figure 4.15). 
 
 
 
Figure 4.15. Apigenin basal AXIN2 dose response.  Tukey Box and whisker plot showing fold 
change in AXIN2 gene expression relative to no treatment in KOA chondrocytes treated with 
apigenin at 2.5-40µM for 6 hours. The effect of apigenin on basal AXIN2 expression was analysed 
using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold change relative 
no treatment (NT) ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or 
to the highest or lowest point, whichever is shorter), n=4. Solid line represents no treatment 
(NT) with dotted lines representing standard deviation. ** p<0.01, *** p<0.001. 
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4.2.5 Dose depended response curves - Isoliquiritigenin 
4.2.5.1 Isoliquiritigenin dose response curve - effect on IL1 induced MMP13 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. Isoliquiritigenin was added an hour 
before stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP13 using 
methods described in section 2.2.3.1. Isoliquiritigenin significantly inhibited IL1 induced 
MMP13 from 1.25-40µM (p<0.01-0.001) in a dose dependent manner (Figure 4.16). 
 
Figure 4.16. Isoliquiritigenin IL1 induced MMP13 dose response. Tukey Box and whisker plot 
showing fold change in MMP13 gene expression relative to IL1 treated control samples in KOA 
chondrocytes treated with isoliquiritigenin at 0.312-40µM for 6 hours. The effect of 
isoliquiritigenin on IL1 induced MMP13 was analysed using one way ANOVA with a Dunnetts 
post hoc test. All samples treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold 
change relative to IL1 treatment alone ± Tukey whiskers (Tukey whiskers are 1.5 times the 
interquartile distance or to the highest or lowest point, whichever is shorter), n=4. Solid line 
represents IL1 treatment alone with dotted lines representing IL1 treated controls standard 
deviation. **p<0.01, ***p<0.001. 
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4.2.5.2 Isoliquiritigenin dose response curve - effect on IL1 induced MMP1 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. Isoliquiritigenin was added an hour 
before stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure MMP1 using 
methods described in section 2.2.3.1. Isoliquiritigenin significantly inhibited IL1 induced 
MMP1 from 5-40µM (p<0.001) in a dose dependent manner (Figure 4.17). 
  
 
Figure 4.17. Isoliquiritigenin IL1 induced MMP1 dose response. Tukey Box and whisker plot 
showing fold change in MMP1 gene expression relative to IL1 treated control samples in KOA 
chondrocytes treated with isoliquiritigenin at 0.312-40µM for 6 hours. The effect of 
isoliquiritigenin on IL1 induced MMP1 was analysed using one way ANOVA with a Dunnetts post 
hoc test. All samples treated with IL1 (5ng/ml) for 6 hours. Data plotted as mean fold change 
relative to IL1 treatment alone ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile 
distance or to the highest or lowest point, whichever is shorter), n=4. Solid line represents IL1 
treatment alone with dotted lines representing IL1 treated controls standard deviation. *** 
p<0.001. 
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4.2.5.3 Isoliquiritigenin dose response curve - effect on IL1 induced ADAMTS4 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. Isoliquiritigenin was added an hour 
before stimulation with 5ng/ml IL1. Real-time qRT-PCR was used to measure ADAMTS4 
using methods described in section 2.2.3.1. Isoliquiritigenin significantly inhibited IL1 
induced ADAMTS4 from 10-20µM (p<0.01-0.001) in a dose dependent manner (Figure 
4.18). At 40µM ADAMTS4 expression was undetectable.  
 
Figure 4.18. Isoliquiritigenin IL1 induced ADAMTS4 dose response. Tukey Box and whisker plot 
showing fold change in ADAMTS4 gene expression relative to IL1 treated control samples in KOA 
chondrocytes treated with isoliquiritigenin at 0.312-40µM for 6 hours. The effect of 
isoliquiritigenin on IL1 induced ADAMTS4 was analysed using one way ANOVA with a Dunnetts 
post hoc test. At 40µM ADAMTS4 expression was undetectable. All samples treated with IL1 
(5ng/ml) for 6 hours. Data plotted as mean fold change relative to IL1 treatment alone ± Tukey 
whiskers (Tukey whiskers are 1.5 times the interquartile distance or to the highest or lowest 
point, whichever is shorter), n=4. Solid line represents IL1 treatment alone with dotted lines 
representing IL1 treated controls standard deviation. ** p<0.01, *** p<0.001. 
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4.2.5.4 Isoliquiritigenin dose response curve - effect on Basal ADAMTS5 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. Real-time qRT-PCR was used to 
measure ADAMTS5 using methods described in section 2.2.3.1. Isoliquiritigenin 
significantly induced basal ADAMTS5 expression at 40µM (p<0.05) (Figure 4.19). 
 
 
 
 
Figure 4.19. Isoliquiritigenin basal ADAMTS5 dose response. Tukey Tukey Box and whisker plot 
showing fold change in ADAMTS5 gene expression relative to no treatment in KOA chondrocytes 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. The effect of isoliquiritigenin on basal 
ADAMTS5 expression was analysed using one way ANOVA with a Dunnetts post hoc test. Data 
plotted as mean fold change relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 
times the interquartile distance or to the highest or lowest point, whichever is shorter), n=4. 
Solid line represents no treatment (NT) with dotted lines representing standard deviation. * 
p<0.05. 
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4.2.5.5 Isoliquiritigenin dose response curve - effect on Basal HO-1 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 0.312-40µM for 6 hours. Real-time qRT-PCR was used to 
measure HO-1 using methods described in section 2.2.3.2. Isoliquiritigenin significantly 
induced basal HO-1 at 2.5-20µM (p<0.01-0.001) (Figure 4.20). 
 
 
Figure 4.20. Isoliquiritigenin basal HO-1 dose response.  Tukey Box and whisker plot showing 
fold change in HO-1 gene expression relative to no treatment in KOA chondrocytes treated with 
isoliquiritigenin at 0.312-40µM for 6 hours. The effect of isoliquiritigenin on induced basal HO-
1 was analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean fold 
change relative no treatment ± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile 
distance or to the highest or lowest point, whichever is shorter), n=4. Solid line represents no 
treatment (NT) with dotted lines representing standard deviation. ** p<0.01, *** p<0.001. 
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4.2.5.6 Isoliquiritigenin dose response curve - effect on Basal AXIN2 in KOA 
chondrocytes 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 2.5-40µM for 6 hours. Real-time qRT-PCR was used to 
measure AXIN2 using methods described in section 2.2.3.2. Isoliquiritigenin had no 
significant effect on AXIN2 expression (Figure 4.21). 
 
 
 
 
Figure 4.21. Tukey Box and whisker plot showing fold change in AXIN2 gene expression 
relative to no treatment in KOA chondrocytes. KOA cells were treated with isoliquirtigenin at 
2.5-40µM for 6 hours. The effect of isoliquiritigenin on AXIN2 was analysed using one way 
ANOVA with a Dunnetts post hoc test. Data plotted as mean fold change relative no treatment 
± Tukey whiskers (Tukey whiskers are 1.5 times the interquartile distance or to the highest or 
lowest point, whichever is shorter), n=4. Solid line represents no treatment (NT) with dotted 
lines representing standard deviation. 
105 
 
4.2.6 Cell cytoxicity screens 
4.2.6.1 Apigenin effect on cell necrosis - Lactate dehydrogenase assay 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with apigenin at 2.5-40µM for 6 hours and apigenin at 2.5-40µM with IL1 (5ng/ml). 
The CytoTox 96® Non-Radioactive Cytotoxicity assay was used as described by the 
manufacturer's instructions see section 2.2.1.2 for more details. LDH was detected in 
harvested supernates as a measure of compound toxicity.  Apigenin had no significant 
effect on cell necrosis compared to no treatment control (Figure 4.22).  
 
 
 
Figure 4.22. Apigenin has no effect on cell necrosis. Bar chart showing percentage of cell death 
(necrosis) in KOA chondrocytes treated with apigenin at 2.5-40µM for 6 hours and apigenin at 
2.5-40µM with IL1 (5ng/ml). The effect of apigenin on cell necrosis was compared to no 
treatment (NT) control and was analysed using one way ANOVA with a Dunnetts post hoc test. 
Data plotted as mean percentage of cell death ± standard deviation n=3.  
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4.2.6.2 Isoliquiritigenin effect on cell necrosis - Lactate dehydrogenase assay 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 2.5-40µM for 6 hours and isoliquiritigenin at 2.5-40µM with 
IL1 (5ng/ml). The CytoTox 96® Non-Radioactive Cytotoxicity assay was used as described 
by the manufacturer's instructions see section 2.2.1.2 for more details. LDH was detected 
in harvested supernates as a measure of compound toxicity.  Isoliquiritigenin had no 
significant effect on cell necrosis compared to no treatment control (Figure 4.23). 
 
 
 
Figure 4.23. Isoliquiritigenin has no effect on cell necrosis. Bar chart showing percentage of 
cell death (necrosis) in KOA chondrocytes treated with isoliquiritigenin at 2.5-40µM for 6 hours 
and isoliquiritigenin at 2.5-40µM with IL1 (5ng/ml). The effect of isoliquiritienin on cell necrosis 
compared to no treatment (NT) control was analysed using one way ANOVA with a Dunnetts 
post hoc test. Data plotted as mean percentage of cell death ± standard deviation n=3.  
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4.2.6.3 Apigenin effect on cell apoptosis - Caspase-Glo® 3/7 Assay 
KOA chondrocytes were cultured and plated as described in section 2.2.3.1. KOA cells were 
treated with apigenin at 2.5-40µM for 6 hours. Cytotoxicity of compounds were assessed 
using the Caspase-Glo® 3/7 Assay as described by the manufacturer's instructions see 
section 2.2.1.3 for more details. The Caspase-Glo® 3/7 Assay is a luminescent assay that 
measures caspase-3 and -7 activities in cultures of adherent cells. Total cell death control 
(100% cell death) calculated by treating cells with 1µM stuarosporine for 6 hours. The assay 
provides a proluminescent caspase-3/7 substrate, which contains the tetrapeptide 
sequence DEVD. This substrate is cleaved to release aminoluciferin, a substrate of 
luciferase used in the production of light. Apigenin had no significant effect on cell 
apoptosis compared to no treatment control (Figure 4.24). 
 
 
Figure 4.24. Apigenin has no effect on cell apoptosis. Bar chart showing percentage of cell 
death (apoptosis) in KOA chondrocytes treated with apigenin at 2.5-40µM for 6 hours. The 
effect of apigenin on cell necrosis compared to no treatment (NT) control was analysed using 
one way ANOVA with a Dunnetts post hoc test. Data plotted as mean percentage of cell death 
± standard deviation n=3.  
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4.2.6.4 Isoliquiritigenin effect on cell apoptosis - Caspase-Glo® 3/7 Assay 
KOA chondrocytes were cultured and plated as described in section 2.2.1.1. KOA cells were 
treated with isoliquiritigenin at 2.5-40µM for 6 hours. Cytotoxicity of compounds were 
assessed using the Caspase-Glo® 3/7 Assay as described by the manufacturer's instructions 
see section 2.2.1.3 for more details. Total cell death control (100% cell death) calculated by 
treating cells with 1µM stuarosporine for 6 hours. Isoliquiritigenin had no significant effect 
on cell apoptosis compared to no treatment control (Figure 4.25). 
 
 
 
 
Figure 4.25. Isoliquiritigenin has no effect on cell apoptosis. Bar chart showing percentage of 
cell death (apoptosis) in KOA chondrocytes treated with isoliquiritigenin at 2.5-40µM for 6 
hours. The effect of isoliquiritigenin on cell necrosis was compared to no treatment (NT) control 
and analysed using one way ANOVA with a Dunnetts post hoc test. Data plotted as mean 
percentage of cell death ± standard deviation n=3.  
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4.3 Discussion 
In the previous chapter 20 compounds were selected for further study (see Chapter 3 Table 
5). Here, these compounds were screened for inhibition of cartilage degrading genes 
MMP13, MMP1, ADAMTS4 and ADAMTS5 in primary KOA chondrocytes.  
At 10µM apigenin, isoliquiritigenin, aloe-emodin, luteolin, genistin and ursolic acid 
significantly inhibited IL1 induced MMP13 expression (p<0.05-p<0.0001) (Figure 4.1). These 
results support data shown in Chapter 3 (Figure 3.3) where at 10µM apigenin, 
isoliquiritigenin, emodin, luteolin and ursolic acid significantly inhibited MMP13 expression 
in SW1353 cells (p<0.05-p<0.0001). Similarly apigenin, isoliquiritigenin, aloe-emodin, 
lutelin, genistin and ursolic acid significantly inhibited MMP13 expression in C28/I2 cells at 
10µM (p<0.05-p<0.0001) (Chapter 3 Figure 3.5). These data show that for IL1 induced 
MMP13 expression SW153 and C28/I2 cells are useful models for primary chondrocytes. 
Compounds that significantly inhibited MMP13 in KOA cells (Figure 4.1) were entered into 
Table 6 which was used to select compounds for dose response experiments. 
Compounds screened in KOA chondrocytes had no significant effect on basal MMP13 at 
10µM. Quercetin, methyl-hesperidin, luteolin and naringen showed a trend towards 
inhibition of basal MMP13 which didn’t reach significance (Figure 4.2). Hesperetin is the 
alglycone form of methyl-hesperedin which did show a trend towards inhibition of basal 
MMP13 in KOA chondrocytes (Figure 4.2). While myricetin and theobromine significantly 
reduced basal MMP13 in SW1353 cells (Chapter 3 Figure 3.4) and apigenin, myricetin and 
gensitin significantly reduced basal MMP13 in C28/I2 cells (Chapter 3 Figure 3.6) these 
compounds had no significant effect on basal MMP13 in KOA chondrocytes (Figure 4.2). 
The difference in basal MMP13 expression results seen between the cell models and KOA 
chondrocytes may be due to basal MMP13 inter-patient variability in the KOA chondrocyte 
experiments. As compounds screened in KOA chondrocytes had no significant effect on 
basal MMP13 at 10µM basal MMP13 was not used as a gene on interest in the dose 
response assays. 
Compounds that significantly inhibited IL1 induced MMP1 in KOA cells (Figure 4.3) may be 
chondro-protective and were entered into Table 6 which was used to select compounds for 
dose response experiments. Compounds screened in KOA chondrocytes had no significant 
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effect on basal MMP1 at 10µM. Luteolin showed a trend towards inhibition of basal MMP1 
which didn’t reach significance (Figure 4.4) similar to the trend of inhibition seen with basal 
MMP13 when KOA cells were treated with luteolin (Figure 4.2). As compounds screened in 
KOA chondrocytes had no significant effect on basal MMP1 at 10µM basal MMP1 was not 
used as a gene on interest in the dose response assays. 
As aloe-emodin, apigenin and isoliquiritigenin significantly reduced IL1 induced ADAMTS4 
expression (Figure 4.5) they may be chondro-protective and were entered into Table 6. 
Genistin, isoliquiritigenin and apigenin significantly reduced basal ADAMTS4 expression 
and emodin, aloe-emodin and luteolin showed a trend towards IL1 induced ADAMTS4 
inhibition which did not reach significance in KOA cells (Figure 4.6). Compounds that 
significantly inhibited basal ADAMTS4 may be chondro-protective and were entered into 
Table 6. 
In these experiments IL1 did not induce ADAMTS5 expression so basal ADAMTS5 was 
measured. Luteolin and genistin significantly inhibited basal ADAMTS5 at 10µM (p<0.01-
p<0.001) (Figure 4.7). Compounds that significantly inhibited basal ADAMTS5 may be 
chondro-protective and were entered into Table 5. 
Table 6 shows seven compounds from the 20 selected compounds (Chapter 3 Table 5) that 
significantly inhibited one or more of the cartilage chondro-destructive genes screened at 
10µM. Each of these compounds could be chondro-protective and future studies looking 
at their mechanisms of action and potential synergies between them may be beneficial 
when trying to identify bioactives that protect cartilage from destruction in OA. In the scope 
of this project only two compounds could be selected from Table 6 for further analysis due 
to lack of sufficient KOAs from operative procedures and time constraints. As apigenin and 
isoliquiritigenin significantly inhibited genes of interest in the most screens they were 
selected for further study. Inhibition of MMP13 was required in a candidate compound as 
MMP13 has been considered critical for OA progression. Pharmacologic inhibition of 
MMP13 has been shown to be an effective strategy to decelerate articular cartilage loss in 
a murine model of injury-induced knee OA (Wang et al., 2013). 
Ursolic acid is a triterpenoid that exists widely in food (Liu, 1995), medicinal herbs and is 
often used in cosmetics (Figure 4.26). Ursolic acid is present in a wide variety of fruits such 
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as apples and cranberries (Arnold & Hsia, 1957). Ursolic acid significantly reduced IL1 
induced MMP1 (p<0.001) (Figure 4.3) but had no significant effect on MMP13, ADAMTS4 
or ADAMTS5 in KOA cells at 10µM (Figure 4.1-4.2, 4.4-4.7). In the previous chapter (Figure 
3.3) ursolic acid significantly inhibited IL1 induced MMP13 (p<0.0001) at 10µM, while 
ursolic acid did not significantly inhibit IL1 induced MMP13 in KOA cells (Figure 4.1) there 
was a trend towards inhibition that may have become significant with more cartilage 
samples. Ursolic acid has been shown to inhibit activation of the transcription factor NFB 
in a leukaemia cell line by preventing phosphorylation of IKb (Shishodia et al., 2003). Ursolic 
acid could potentially work through a similar mechanism in primary chondrocytes as MMP1 
and MMP13 are NFB responsive genes. Ursolic acid was not selected for further study as 
at 10µM ursolic acid only inhibited IL1 induced MMP1 in KOA cells (Figure 4.3). 
 
 
 
Figure 4.26. The chemical structure of ursolic acid. Ursolic acid is a triterpenoid it is also called 
prunol, malol, β-ursolic acid, NSC4060, CCRIS 7123, TOS-BB-0966, 3-β-hydroxyurs-12-en-28-oic 
acid with a molecular formula of C30H48O3 and a molar mass of 456.7 g/mol. 
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Genistin is an isoflavone from soy that attenuates growth factor and cytokine stimulated 
proliferation of both normal and cancer cells potentially via TGFβ1 signaling (Kim et al., 
1998). Genistin significantly reduced IL1 induced MMP1 (p<0.05) (Figure 4.3) basal 
ADAMTS4 and ADAMTS5 (Figure 4.6-4.7) but had no significant effect on MMP13 (Figure 
4.1). In the previous chapter (Figure 3.6) genistin significantly inhibited IL1 induced MMP13 
(p<0.0001) at 10µM in C28/I2 cells, while genistin did not significantly inhibit IL1 induced 
MMP13 in KOA cells (Figure 4.1) there was a trend towards inhibition that may have 
become significant with more cartilage samples. Digestive enzymes in the digestive system 
convert genistin into genestein. Genistein has been shown to inhibit MMP-1 synthesis in 
aged normal human dermal fibroblasts and was hypothesised to be a useful agent for 
preventing intrinsic aging (Yang et al., 2007). In KOA cells genistin shows a similar inhibition 
of MMP1 (Figure 4.3), basal ADAMTS4 and ADAMTS5 are also inhibited (Figure 4.6-4.7). 
These results suggest that genistin may be chondro-protective. Genistin was not selected 
for further study as it did not significantly inhibit IL1 induced MMP13 (Figure 4.1). 
 
Luteolin is a flavone found in celery that has been shown to inhibit IL1 induced MMP13 via 
inhibition of IL1 induced ERK activation in a dose-dependent manner in osteoblasts (Yang 
et al., 2012). Luteolin significantly reduced IL1 induced MMP13 (p<0.05) (Figure 4.1), IL1 
induced MMP1 (p<0.001) (Figure 4.3) and basal ADAMTS5 (Figure 4.7) but had no 
Figure 4.27. The chemical structure of genistin. Genistin is an isoflavone from soy it is also 
called genistoside, genistine, genistein 7-glucoside, genistein glucoside, genistein-7-glucoside, 
genisteol 7-monoglucoside and glucosyl-7-genistein with a molecular formula of C21H20O10 and 
a molar mass of 432.37 g/mol. 
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significant effect on ADAMTS4 (Figure 4.5, 4.6). In the previous chapter (Figure 3.3) luteolin 
significantly inhibited IL1 induced MMP13 (p<0.0001) at 10µM in SW1353 cells and C28/I2 
cells (Figure 3.6). These results suggest that luteolin may be chondro-protective and may 
possibly inhibit MMP13 and MMP1 via inhibition of IL1 induced ERK activation. Luteolin 
was not selected for further study as it did not have a significant effect on as many genes 
of interest as apigenin or isoliquiritigenin.  
 
 
Emodin is a purgative resin trihydroxyanthraquinone from rhubarb (Figure 4.29) and is a 
commonly used traditional herbal treatment in China (Xiao et al., 2014). Emodin 
significantly reduced IL1 induced MMP13 (p<0.01) (Figure 4.1), MMP1 (p<0.001) (Figure 
4.3) and basal ADAMTS4 (p<0.05) (Figure 4.6) but had no significant effect on ADAMTS5 
(Figure 4.7). In the previous chapter (Figure 3.3, 3.6) emodin significantly inhibited IL1 
induced MMP13 at 10µM in SW1353 (p<0.001) and C28/I2 cells (p<0.05), supporting the 
results seen in KOA cells (Figure 4.1). The expression of cartilage-degrading 
metalloproteinases is regulated in part by changes in acetylation via histone 
acetyltransferases and HDACs (Higashiyama et al., 2010). At 10µM emodin has been shown 
to inhibit the expression of MMP1 and MMP13 in IL1 stimulated synoviocytes under 
hypoxia, it was hypothesised that this was due to emodin ability to inhibit HDAC activity 
(Ha et al., 2011). These results suggest that emodin may be chondro-protective and may 
Figure 4.28. The chemical structure of luteolin. Luteolin is a flavone found in celery it is also 
called luteolol, digitoflavone, flacitran and luteoline with a molecular formula of C15H10O6 and a 
molar mass of 286.24 g·mol−1. 
114 
 
possibly inhibit MMP13, MMP1 and ADAMTS4 via a reduction in HDAC activity. Emodin has 
been reported to have laxative properties, at 20µM emodin significantly increased 
aquaporin 3 (AQP3) protein and mRNA expression in human intestinal epithelial cells. AQP3 
plays an important role in regulating water transfer in the colon, it was hypothesised that 
emodins laxative effects are associated with the increased expression of AQP3 (Zheng et 
al., 2014). At the concentrations used in the KOA cell experiments emodin may exhibit 
unwanted laxative effects in patients, for this reason emodin was not selected for further 
study. 
 
 
Aloe-emodin is a hydroxy anthraquinone (Figure 4.30) known to have anti fungal, 
antibacterial, antiviral and hepatoprotective activities. Aloe-emodin significantly reduced 
IL1 induced MMP13 (p<0.01) (Figure 4.1), MMP1 (P<0.001) (Figure 4.3) and ADAMTS4 
(p<0.05) (Figure 4.5) but had no significant effect on ADAMTS5 (Figure 4.7). In the previous 
chapter (Figure 3.6) aloe-emodin significantly inhibited IL1 induced MMP13 at 10µM in 
C28/I2 cells (p<0.05), supporting the results seen in KOA cells (Figure 4.1). Aloe-emodin has 
also been shown to reduce the DNA binding activities of NFB (Suboj et al., 2012). Aloe-
emodin could potentially work through a similar mechanism in primary chondrocytes as 
MMP1 and MMP13 are NFB responsive genes. Aloe-emodin may also inhibit HDAC activity 
similar to emodin due to the structural similarities between the two compounds (Figure 
Figure 4.29. The chemical structure of emodin. Emodin is an anthraquinone found in rhubarb 
it is also called 6-methyl-1,3,8-trihydroxyanthraquinone with a molecular formula of C15H10O5 
and a molar mass of 270.24 g·mol−1. 
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4.29, 4.30). These results suggest that emodin may be chondro-protective and may possibly 
inhibit MMP13, MMP1 and ADAMTS4 via a reduction of the DNA binding activities of NFB 
and/or the inhibition of HDAC activity. Aloe-emodin has also been reported to have laxative 
effects (Müller et al., 1996) similar to those seen with emodin treatment (Zheng et al., 
2014), for this reason aloe-emodin was not selected for further study. 
 
 
Isoliquiritigenin is a chalcone (Figure 4.31) found in liquorice root and other plants and has 
been shown to have potent antitumor, antioxidant, and phytoestrogenic activity in vitro 
(Guo et al., 2008). Isoliquiritigenin significantly reduced IL1 induced MMP13 (p<0.001) 
(Figure 4.1), MMP1 (p<0.0001) (Figure 4.3) ADAMTS4 (Figure 4.4) and basal ADAMTS4 
(p<0.01) (Figure 4.6). In the previous chapter (Figure 3.3) isoliquiritigenin significantly 
inhibited IL1 induced MMP13 at 10µM in SW1353 cells (p<0.05), supporting the results 
seen in KOA cells (Figure 4.1). Isoliquiritigenin has also been shown to dose dependently 
(1-10µM) inhibit LPS stimulated (200ng/ml for 16 hours) IL1 and TNFα production in RAW 
264.7 cells. Isoliquiritigenin was also shown to induce heme oxygenase-1 at the mRNA and 
protein level (S. Lee et al., 2009). These anti-inflammatory properties of Isoliquiritigenin 
could be beneficial for patients suffering with OA. These results suggest that 
isoliquiritigenin may be chondro-protective. Isoliquiritigenin was one of the two 
Figure 4.30. The chemical structure of aloe-emodin. Aloe-emodin is an anthraquinone found 
in aloe vera. Aloe-emodin is also called 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-
anthracenedione with a molecular formula of C15H10O5 and a molar mass of 270.24 g·mol−1. 
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compounds selected for further study (Table 6), as it inhibited the most chondro-
degenerative genes out of the compounds screened. 
 
 
Apigenin is a plant-derived flavone (Figure 4.32). Apigenin has been shown to suppress 
MMP13 expression in IL1 treated SW1353 cells by suppressing the c-fos/AP-1 and 
JAK2/STAT1/2 pathways (Lim et al., 2011). SW1353 cells were treated with IL1 and apigenin 
(5, 25µM) for 24 hours. Western blot detected lower MMP-13 levels in cell media when 
SW1353 cells were treated with apigenin, an enzyme-linked immunosorbent assay showed 
that when SW1353 cells were treated with IL1 and apigenin at 10µM for 24 hours there 
was a significant reduction in MMP-13 levels in the media (when compared to IL1 control 
group). In the previous chapter (Figure 3.3) apigenin significantly inhibited IL1 induced 
MMP13 at 10µM in SW1353 cells (p<0.05) and C28/I2 cells (Figure 3.6) (p<0.0001). These 
results support the data seen in KOA cells (Figure 4.1). Apigenin significantly reduced IL1 
induced MMP13 (p<0.001) (Figure 4.1), MMP1 (p<0.0001) (Figure 4.3) ADAMTS4 (Figure 
4.5) (p<0.05) and basal ADAMTS4 (p<0.0001) (Figure 4.6). These results suggest that 
apigenin may be chondro-protective and may possibly inhibit MMP13, MMP1 and 
ADAMTS4 via suppressing the c-fos/AP-1 and JAK2/STAT1/2 pathways. Apigenin was one 
Figure 4.31. The chemical structure of isoliquiritigenin. Isoliquiritigenin is a flavonoid found in 
liquorice. Isoliquiritigenin is also called 6'-deoxychalcone, 2',4,4'-Trihydroxychalcone, 4,2',4'-
Trihydroxychalcone, 4'2'4'-trihydroxychalcone 2',4',4-Trihydroxychalcone with a molecular 
formula of C15H12O4 and a molar mass of 256.25 g/mol. 
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of the two compounds selected for further study (Table 6) as it inhibited the most chondro-
degenerative genes out of the compounds screened. 
 
 
 
The time course of the expression of MMP13 was used to analyse the effects of the two 
selected compounds apigenin (Figure 4.8) and isoliquiritigenin (Figure 4.9) over time. KOA 
cells were treated with apigenin or isoliquiritigenin at 10µM and 5ng/ml IL1 for 1, 3, 6, 12, 
18 and 24 hours. IL1 stimulated MMP13 reached maximal inhibition at 6 hours when 
treated with 10µM of apigenin. IL1 stimulated MMP13 reached maximal inhibition at 12 
hours when treated with 10µM of isoliquiritigenin. These results were used to select a 6 
hour time point for the apigenin and isoliquiritigenin dose response experiments (Figures 
4.10-4.21). Both compounds inhibited MMP13 at 6 hours (Figure 4.8, 4.9) and while 
isoliquiritigenin was more potent at 12 hours, 6 hours was selected to make comparisons 
of MMP13 inhibition between the two compounds more accurate. 0.312-40µM was used 
as the dose range for the dose response assays, as doses between 0.1-10µM have been 
suggested as physiologically relevant concentration for dietary derived bioactive 
compounds (Ferrars et al., 2014), (Amin et al., 2015). Concentrations higher than 10µM 
Figure 4.32. The chemical structure of apigenin. Apigenin is a flavone found in various plants. 
Apigenin is also called Apigenine, Chamomile, Apigenol, Spigenin, Versulin; 4',5,7-
Trihydroxyflavone and C.I. Natural Yellow 1 with a molecular formula of C15H10O5 and a molar 
mass of 270.24 g·mol−1. 
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were considered ‘high’ concentrations likely to only be achieved by supplementation of 
these compounds as opposed to obtaining them from the diet. As apigenin and 
isoliquiritigenin had no effect on basal MMP13 or basal MMP1 at 10µM in KOA cells (Table 
6), they were not analysed in the dose response assays. Basal ADAMTS4 was not analysed 
in the dose response experiments because unstimulated ADAMTS4 expression levels were 
very low in KOA cells. As discussed in the introduction, HO-1 was analysed in the dose 
response assay as a measure of a compounds anti-inflammatory potential and AXIN2 was 
analysed to measure a compounds effect on Wnt signalling.  
Cell cytoxicity was analysed by measuring cell necrosis and cell apoptosis after compound 
treatment. Cell necrosis was measured using the CytoTox 96® Non-Radioactive Cytotoxicity 
as described by the manufacturer's instructions (see Chapter 2 section 2.2.1.2 for more 
details). Cell apoptosis was assessed using the Caspase-Glo® 3/7 Assay as described by the 
manufacturer's instructions (see Chapter 2 section 2.2.1.3 for more details). For 
compounds to be considered as being protective to cartilage they must not significantly 
increase cell necrosis or apoptosis. 
While apigenin showed a trend towards inducing IL1 induced MMP13 at 1.25µM (Figure 
4.10) and MMP1 at 0.312µM (Figure 4.11) these did not reach statistical significance. 
Future experiments should explore the effects of apigenin on MMP13 and MMP1 at these 
lower doses to ensure that apigenin treatment does not result in there upregulation. 
Apigenin significantly inhibited IL1 induced MMP13 from 2.5-40µM (p<0.01-0.0001) in a 
dose dependent manner (Figure 4.10). IL1 induced MMP1 was significantly inhibited by 
apigenin at 2.5-40µM (p<0.01-0.0001) in a dose dependent manner (Figure 4.11). Apigenin 
significantly inhibited IL1 induced ADAMTS4 from 5-20µM (p<0.01-0.001) in a dose 
dependent manner (Figure 4.12.) Apigenin significantly reduced basal ADAMTS5 
expression at 20 and 40µM (p<0.01) (Figure 4.13). Apigenin significantly induced basal HO-
1 at 2.5-10µM (p<0.05-0.001) (Figure 4.14). The bell shaped curve of induction of HO-1 
suggests that apigenin may have the most effective anti-inflammatory effects around 5-
10µM, interestingly this could mean that over supplementation of apigenin may not be as 
protective to cartilage as finding a correct dose for maximal anti-inflammatory and 
chondro-protective effects. Concentrations of apigenin in human subjects have been 
hypothesised to be around 1.7μM after consumption of 10g of dried parsley per day 
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(Shibata et al., 2014), and while it would not be impossible to reach plasma concentrations 
of apigenin used in this project through normal dietary intake, supplementation could 
potentially be used to obtain higher doses. 
Basal AXIN2 expression was inhibited at 10-40µM (p<0.01-p<0.001) (Figure 4.15) by 
apigenin. While inhibition of chondro-destructive genes becomes more pronounced at 
higher concentrations (Figures 4.10-4.12) apigenins potentially anti-inflammatory 
upregulation of HO-1 is lost at these higher concentrations (Figure 4.14). Apigenin dose 
dependently inhibits AXIN2 expression (Figure 4.15) and as discussed in the introduction 
AXIN2 is a Wnt/β-catenin responsive gene which has been shown to be upregulated 
consistently with net activation of canonical Wnt signalling (Lustig et al., 2002).  Wnt 
signalling can induce the expression of MMPs in articular chondrocytes which promotes 
cartilage degradation and cartilage catabolism (Yuasa et al., 2008). Apigenin may be 
downregulating MMPs via Wnt signalling disruption.  Apigenin was non-cytotoxic at all 
concentrations analysed in the dose response assays (Figures 4.22, 4.24). Apigenin had no 
statistically significant effect on cell necrosis (Figure 4.22) showing instead a trend towards 
preventing necrosis. Apigenin had no statistically significant effect on cell apoptosis (Figure 
4.22). At lower concentrations 0.312-1.25µM apigenin appeared to show a trend towards 
inducing MMP13 and MMP1 (Figure 4.10-4.11), these trends could be further explored by 
increasing the range of concentrations between lower concentrations of apigenin and 
including higher patient numbers in future experiments. These results suggest that at 
concentrations between 2.5-10µM apigenin may be of most benefit to chondrocytes, 
having both anti-catabolic and anti-inflammatory effects in chondrocytes.  
Isoliquiritigenin significantly inhibited IL1 induced MMP13 from 1.25-40µM (p<0.01-0.001) 
in a dose dependent manner (Figure 4.16). IL1 induced MMP1 was significantly inhibited 
by isoliquiritigenin at 5-40µM (p<0.001) in a dose dependent manner (Figure 4.17). 
Isoliquiritigenin significantly inhibited IL1 induced ADAMTS4 from 10-20µM (p<0.01-0.001) 
in a dose dependent manner (Figure 4.18). Isoliquiritigenin significantly induced basal 
ADAMTS5 expression at 40µM (p<0.05) (Figure 4.19). Isoliquiritigenin significantly induced 
basal HO-1 at 2.5-20µM (p<0.01-0.001) (Figure 4.20) and basal AXIN2 expression at 40µM 
(p<0.05) (Figure 4.21). These results show that isoliquiritigenin may have chondro-
protective properties at potentially physiologically relevant concentrations of 1.25µM. 
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While inhibition of chondro-destructive genes becomes more pronounced at higher 
concentrations (20-40µM) basal ADAMTS5 (Figure 4.19) was induced at the very high 
concentration of 40µM which may cause aggrecan destruction in the joint, isoliquiritigenins 
anti-inflammatory upregulation of HO-1 was lost (Figure 4.20) and isoliquiritigenin showed 
a trend towards AXIN2 upregulation, potentially increasing Wnt activity (Figure 4.21) at 
these higher concentrations. Oral doses of isoliquiritigenin (100mg/kg) in mice have 
achieved these high concentrations in blood plasma, the highest concentration of 
isoliquiritigenin found in plasma was 55.8µM (Wang et al., 2014), (Qiao et al., 2014). At 
these high doses isoliquiritigenin posed little toxicity to the organs, including heart, liver, 
spleen, lung and kidney, when mice were fed 100mg/kg/day for 3 months  (Wang et al., 
2014). While these concentrations of isoliquiritigenin are unlikely consumed in the normal 
human diet they could potentially be reached by supplementation so it could be important 
not to over supplement isoliquiritigenin so as not to reach concentrations that could 
potentially increase basal ADAMTS5 (Figure 4.19). Isoliquiritigenin was non-cytotoxic at all 
concentrations analysed in the dose response assays (Figures 4.23, 4.25). Isoliquiritigenin 
had no statistically significant effect on cell necrosis (Figure 4.23) or cell apoptosis (Figure 
4.25). These results suggest that at concentrations between 1.25-20µM isoliquiritigenin 
may be of most benefit to chondrocytes, having both anti-catabolic and anti-inflammatory 
effects in chondrocytes. 
4.3.1 Conclusion 
In conclusion several of the compounds selected in the previous chapter from the SW1353 
and C28/I2 screens were able to inhibit MMP13, MMP1 ADAMTS4 and ADAMTS5 at 10µM 
in KOA chondrocytes. Of these compounds apigenin and isoliquiritigenin showed the 
greatest statistically significant inhibition of MMP13 while also inhibiting MMP1, ADAMTS4 
and ADAMTS5. These two selected candidate compounds inhibited MMP13, MMP1 and 
ADAMTS4 and upregulated the anti-inflammatory gene HO-1 in KOA cells. Apigenin may be 
having these effects via regulation of the Wnt pathway as it dose-dependently inhibited 
AXIN2, a Wnt/β-catenin responsive gene. Apigenin and isoliquiritigenin appear to have 
chondro-protective properties and show no cytotoxic effects in chondrocytes. In the next 
chapter we will begin to explore apigenin’s and isoliquiritigenin’s mechanisms of action. 
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4.3.2 Strengths of Chapter 4 
 This chapter has shown that several compounds are able to inhibit genes that are 
involved in OA in KOA cell islets from four different patient donors. 
 While only apigenin and isoliquiritigenin have been selected for further study this 
chapter has shown that aloe-emodin, luteolin, genistin, emodin and ursolic acid 
could still have chondroprotective activity as they inhibited chondro-destructive 
genes at 10µM. 
  Apigenin and isoliquiritigenin have been shown to have no necrotic or apoptotic 
effects in KOA cells when used in concentrations up to 40µM. 
4.3.3 Weaknesses of Chapter 4 
 Dose responses could be extended to look at effects of concentrations below 
0.312µM or above 40µM. 
 The inhibition of MMP13 by Isoliquiritigenin was stronger at 12 hours than at 6 
hours (Figure 4.9), while isoliquiritigenin was more potent at 12 hours, 6 hours was 
selected to make comparisons of MMP13 inhibition between isoliquiritigenin and 
apigenin more accurate. Experiments could be repeated to see if a 12 hour 
timepoint increases isoliquiritigenin inhibition of genes of interests. 
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Chapter 5: Mechanism of action of apigenin and 
isoliquiritigenin 
5.1 Introduction 
In the previous chapter, I identified two dietary-derived bioactive compounds that 
significantly reduced expression of chondro-destructive genes MMP13, MMP1, ADAMTS4 
and ADAMTS5 while inducing the anti-inflammatory gene HO-1. These compounds 
included, apigenin a plant-derived flavone and isoliquiritigenin a chalcone found in 
liquorice root. In this chapter, I will explore the mechanism of action of these compounds 
by analysing their effect on cell signalling pathways and transcription factors. Lipid-based 
transfection protocols show transfection efficiencies ranging from 1.5 to 27% of the total 
number of PHCs (Morrey et al., 2008), (Gresch et al., 2004), (Madry & Trippel, 2000). In our 
lab we have been unable to transfect PHC cells. For this reason the easily transfected 
SW1353 cell line was selected as a transfection model for primary chondrocytes. We used 
cell based luciferase assays to measure NFκB, TGFβ and Wnt pathways in SW1353 cells. As 
discussed in the introduction the NFκB, TGFβ and Wnt pathways are known to be 
implicated in cartilage homeostasis and OA  (Chen et al., 2008), (Moulharat et al., 2004), 
(Lories et al., 2007). The effects of apigenin and isoliquiritigenin seen in the previous 
chapter may be dependent on these pathways.  
To select a time point to study compounds mechanism of action total and phosphorylated 
extracellular signal-regulated kinases (ERK), p38 and c-Jun N-terminal kinases (JNK) protein 
levels were analysed. The phosphorylation of the MAPK family of serine/threonine kinases, 
ERK, p38 and JNK were selected for analysis as they are known to be involved in the 
regulation of metalloproteinase gene expression and were included in the 43 kinases of the 
Human Phospho Kinase screen. Inflammatory cytokines, osmostic stress and apoptotic 
signals activate the JNKs and p38 kinases (Davis, 2000). ERKs are activated by cytokines, 
growth factors and phorbol esters (Garrington & Johnson, 1999) (Kolch, 2000). Stimulation 
activates the MAPK kinase kinases (MAPKKKs) which phosphorylate and activate MAPK 
(Vincenti & Brinckerhoff, 2002). Activated MAPKs translocate to the nucleus where they 
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phosphorylate and activate various transcription factors. ERKs  and JNKs phosphorylate and 
activate activating protein-1 (AP-1) family member c-JUN which dimerises with c-Fos during 
MMP gene transcription (Karin, 1995), (Leppä et al., 1998). The p38 kinases phosphorylates 
activating transcription factor-2 , driving the c-jun promoter and the ternary complex factor 
Elk-1 which activates the c-fos promoter, indirectly contributing to MMP transcription by 
promoting expression of AP-1 genes (Davis, 2000). 
As discussed in chapter 1, OA is a multifactorial disease and bioactive compounds were 
considered an attractive alternative treatment for OA as they can simultaneously interact 
with multiple cellular pathways (Ameye & Chee, 2006).  The Proteome Profiler Array 
Human Phospho-Kinase Array Kit is able to simultaneously detect the relative levels of 
phosphorylation of 43 kinase phosphorylation sites and 2 related total proteins (see 
Chapter 2 section 2.2.6 for more details) making it an attractive strategy for measuring 
compounds effects across multiple cell pathways. While IL1 does not induce the 
phosphorylation of all the kinases in the Human Phospho Kinase screen it was selected to 
stimulate the assay as the effect of apigenin and isoliquiritigenin on IL1 stimulated gene 
expressions from chapter 4 was under investigation.  
I hypothesise that the chondro-protective gene changes seen in KOA cells treated with 
apigenin or isoliquiritigenin in the last chapter may be the result of changes to the NFκB, 
TGFβ and/or Wnt pathways. Also, apigenin’s and isoliquiritigenin’s patterns of kinase 
activity may be different from each other, providing an insight into the variations seen 
between the compounds in the chondro-protective gene screens seen in the last chapter. 
The aims of this chapter are: 
 To use cell based luciferase assays to analyse the effect of apigenin and 
isoliquiritigenin pretreatment on the NFκB, TGFβ and Wnt pathways in IL1 
stimulated and unstimulated SW1353 cells. 
 Measure phosphorylated and total ERK, p38 and JNK levels in IL1 stimulated KOA 
cells after treatment with apigenin or isoliquiritigenin and to find a timepoint at 
which compounds inhibit kinase phosphorylation for use in the Human Phospho-
Kinase Array. 
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 Ascertain the effects apigenin and isoliquiritigenin have on 43 kinases and 2 related 
total proteins in IL1 stimulated and unstimulated KOA cells at the time point 
selected in the previous aim using Human Phospho-Kinase Array. 
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5.2 Results 
5.2.1 NFκB, TGFβ and Wnt pathways in SW1353 cells 
SW1353 cells were cultured and plated as described in section 2.2.4.3. SW1353 cells were 
transfected with either 100ng NFκB signalling reporter (κB) vector (Figure 5.1a) and 10ng 
of Renilla expression vector, or 100ng of the Smad2/3/4 signalling reporter (CAGA12-luc) 
(Figure 5.1b) and 10ng of Renilla expression vector, or 100ng of the canonical Wnt signalling 
reporter (TOPFLASH) vector (Figure 5.1c) and 10ng of Renilla expression vector. (For more 
details on the reporters see Chapter 2 section 2.2.4). 
 
 
 
Figure 5.1. The NFκB, Smad2/3/4 and Wnt signalling reporters. (a) The NFκB signalling reporter 
(κB) vector contains 5 binding sites of NFκB upstream of the firefly luciferase-encoding gene 
pGL3. (b) The Smad2/3/4 signalling reporter (CAGA12-luc) contains 12 binding sites of the 
Smad2/3/4 binding consensus upstream of the pGL3 gene. (c) The canonical Wnt signalling 
reporter (TOPFLASH) vector contains 7 binding sites of TCF/LEF upstream of the firefly luciferase 
encoding gene in the pTAL-Luc vector. (For more details on the reporters see Chapter 2 section 
2.2.4). 
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5.2.1.1 Cytokine stimulated luciferase assay Time course 
κB vector transfected SW1353 cells were stimulated with IL1 5ng/ml at 1,3,6,12 and 24 
hours (Figure 5.2a). IL1 significantly increased NFκB relative luciferase activity at 3, 6, 12 
and 24 hours (p<0.05-0.01). Smad2/3/4 signalling reporter (CAGA12-luc) transfected cells 
were stimulated with TGFβ1 5ng/ml at 1,3,6,12 and 24 hours (Figure 5.2b). TGFβ1 
significantly increased Smad relative luciferase activity at 3,6,12 and 24 hours (p<0.01-
0.001). Wnt signalling reporter (TOPFLASH) vector transfected cells were stimulated with 
Wnt3a 50ng/ml at 1,3,6,12 and 24 hours (Figure 5.2c). Wnt3a significantly increased Wnt 
relative luciferase activity at 6,12 and 24 hours (p<0.05-0.01).  
 
 
 
 
 
 
 
 
 
Figure 5.2. The regulation of the NFκB, TGFβ and Wnt pathways by IL1. (a) SW1353 cells were 
transfected with the NFκB signalling reporter (κB) vector, IL1 (5ng/ml) was added for the time 
points shown and luciferase activity measured and normalised to Renilla activity as a loading 
control.  (b) SW1353 cells were transfected with the Smad2/3/4 signalling reporter (CAGA12-
luc), TGFβ (5ng/ml) was added for the time points shown and luciferase activity measured and 
normalised to Renilla activity as a loading control. (c) SW1353 cells were transfected with Wnt 
signalling reporter (TOPFLASH) vector, Wnt3a 50ng/ml was added for the time points shown 
and luciferase activity measured and normalised to Renilla activity as a loading control.  Means 
± standard errors are presented, n=3. The difference of luciferase activity was analysed by 
Student’s unpaired two-tailed t test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
NFκB Smad 
Wnt 
127 
 
5.2.1.2 Effect of apigenin on the NFκB pathway in SW1353 cells 
SW1353 cells (Figure 5.3a,b) were transfected with 100ng of κB vector (Figure 5.1a) and 
10ng of Renilla expression vector as described above. SW1353 cells were treated with 
apigenin at 1.25-40µM for 6 hours. In Figure 5.3a apigenin was added an hour before 
stimulation with 5ng/ml IL1. Figure 5.3b samples were left unstimulated. As compounds 
were suspended in DMSO, DMSO controls were used to show that DMSO had no significant 
effect on luciferase activity. Luciferase assay data shows that apigenin significantly reduced 
IL1 induced NFκB activity at 20 and 40µM (p<0.001) in a dose dependent manner (Figure 
5.3a) and significantly reduced unstimulated NFκB activity at 40µM (p<0.05) in a dose 
dependent manner (Figure 5.3b).  
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Figure 5.3. The effect of apigenin on the NFκB pathway. (a) Bar chart showing NFκB 
luciferase/renilla activity relative to fold change of IL1 luciferase/renilla activity in SW1353 cells 
treated with apigenin at 1.25-40µM for 6 hours ± standard deviation n=3. (b) Bar chart showing 
NFκB luciferase/renilla activity relative to fold change of untreated control luciferase/renilla 
activity in SW1353 cells treated with apigenin at 1.25 - 40µM for 6 hours ± standard deviation 
n=3. The effect of apigenin on luciferase/renilla activity was analysed using one way ANOVA 
with a Dunnetts post hoc test.  * p<0.05, *** p<0.001. 
 
IL1 stimulated 
Unstimulated 
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5.2.1.3 Effect of apigenin on the Smad2/3/4 pathway in SW1353 cells 
SW1353 cells (Figure 5.4a,b) were transfected with 100ng of the Smad2/3/4 signalling 
reporter (CAGA12-luc) (Figure 5.1b) and 10ng of Renilla expression vector as described 
above.  SW1353 cells were treated with apigenin at 1.25-40µM for 6 hours. In Figure 5.4a 
apigenin was added an hour before stimulation with TGFβ1 5ng/ml. Figure 5.4b samples 
were left unstimulated. As compounds were suspended in DMSO, DMSO controls were 
used to show that DMSO had no significant effect on luciferase activity. Luciferase assay 
data shows that apigenin significantly reduced TGFβ1 stimulated Smad2/3/4 activity at 10, 
20 and 40µM (p<0.001) in a dose dependent manner (Figure 5.4a) and significantly reduced 
unstimulated Smad2/3/4 activity at 5, 10, 20 and 40µM (p<0.01-0.001) in a dose dependent 
manner (Figure 5.4b). 
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Figure 5.4. The effect of apigenin on the Smad2/3/4 pathway. (a) Bar chart showing 
Smad2/3/4 luciferase/renilla activity relative to fold change of TGFβ1 stimulated 
luciferase/renilla activity in SW1353 cells treated with apigenin at 1.25-40µM for 6 hours ± 
standard deviation n=3. (b) Bar chart showing Smad2/3/4 luciferase/renilla activity relative to 
fold change of untreated control luciferase/renilla activity in SW1353 cells treated with apigenin 
at 1.25 - 40µM for 6 hours ± standard deviation n=3. The effect of apigenin on luciferase/renilla 
activity was analysed using one way ANOVA with a Dunnetts post hoc test.  ** p<0.01, *** 
p<0.001. 
 
TGFβ1 stimulated 
Unstimulated  
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5.2.1.4 Effect of apigenin on the Wnt pathway in SW1353 cells 
SW1353 cells (Figure 5.5a,b) were transfected with 100ng of the canonical Wnt signalling 
reporter (TOPFLASH) vector (Figure 5.1c) and 10ng of Renilla expression vector as described 
above.  SW1353 cells were treated with apigenin at 1.25 - 40µM for 6 hours. In Figure 5.5a 
apigenin was added an hour before stimulation with Wnt3a 50ng/ml. Figure 5.5b samples 
were left unstimulated. As compounds were suspended in DMSO, DMSO controls were 
used to show that DMSO had no significant effect on luciferase activity. Luciferase assay 
data shows that apigenin significantly reduced Wnt3a stimulated Wnt activity at 5, 10, 20 
and 40µM (p<0.05-0.01) in a dose dependent manner (Figure 5.5a) and had no significant 
effect on unstimulated Wnt activity (Figure 5.5b). 
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Figure 5.5. The effect of apigenin on the Wnt pathway. (a) Bar chart showing Wnt 
luciferase/renilla activity relative to fold change of Wnt3a stimulated luciferase/renilla activity 
in SW1353 cells treated with apigenin at 1.25-40µM for 6 hours ± standard deviation n=3. (b) 
Bar chart showing Wnt luciferase/renilla activity relative to fold change of untreated control 
luciferase/renilla activity in SW1353 cells treated with apigenin at 1.25-40µM for 6 hours ± 
standard deviation n=3. The effect of apigenin on luciferase/renilla activity was analysed using 
one way ANOVA with a Dunnetts post hoc test. * p<0.05, ** p<0.01. 
 
Wnt3a stimulated 
Unstimulated 
133 
 
5.2.1.5 Effect of isoliquiritigenin on the NFκB pathway in SW1353 cells 
SW1353 cells (Figure 5.6a,b) were transfected with 100ng of κB vector (Figure 5.1a) and 
10ng of Renilla expression vector as described above. SW1353 cells were treated with 
isoliquiritigenin at 1.25 - 40µM for 6 hours. In Figure 5.6a isoliquiritigenin was added an 
hour before stimulation with 5ng/ml IL1. Figure 5.6b samples were left unstimulated. As 
compounds were suspended in DMSO, DMSO controls were used to show that DMSO had 
no significant effect on luciferase activity. Luciferase assay data shows that shows that 
isoliquiritigenin significantly reduced NFκB activity at 10, 20 and 40µM (p<0.05-0.001) in a 
dose dependent manner (Figure 5.6a) and had no significant effect on unstimulated NFκB 
activity in a dose dependent manner (Figure 5.6b).  
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Figure 5.6. The effect of isoliquiritigenin on the NFκB pathway. (a) Bar chart showing NFκB 
luciferase/renilla activity relative to fold change of IL1 luciferase/renilla activity in SW1353 cells 
treated with isoliquiritigenin at 1.25-40µM for 6 hours ± standard deviation n=3. (b) Bar chart 
showing NFκB luciferase/renilla activity relative to fold change of untreated control 
luciferase/renilla activity in SW1353 cells treated with isoliquiritigenin at 1.25-40µM for 6 hours 
± standard deviation n=3. The effect of apigenin on luciferase/renilla activity was analysed using 
one way ANOVA with a Dunnetts post hoc test.  * p<0.05, ** p<0.01, *** p<0.001. 
 
IL1 stimulated 
Unstimulated 
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5.2.1.6 Effect of isoliquiritigenin on the Smad2/3/4 pathway in SW1353 cells 
SW1353 cells (Figure 5.7a,b) were transfected with 100ng of the Smad2/3/4 signalling 
reporter (CAGA12-luc) (Figure 5.1b) and 10ng of Renilla expression vector as described 
above.  SW1353 cells were treated with isoliquiritigenin at 1.25-40µM for 6 hours. In Figure 
5.7a isoliquiritigenin was added an hour before stimulation with TGFβ1 5ng/ml. Figure 5.7b 
samples were left unstimulated. As compounds were suspended in DMSO, DMSO controls 
were used to show that DMSO had no significant effect on luciferase activity. Luciferase 
assay data shows that isoliquiritigenin significantly reduced TGFβ1 stimulated Smad2/3/4 
activity at 10, 20 and 40µM (p<0.05-0.001) in a dose dependent manner (Figure 5.7a) and 
significantly reduced unstimulated Smad2/3/4 activity at 40µM (p<0.05) (Figure 5.7b). 
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Figure 5.7. The effect of isoliquiritigenin on the Smad2/3/4 pathway. (a) Bar chart showing 
Smad2/3/4 luciferase/renilla activity relative to fold change of TGFβ1 stimulated 
luciferase/renilla activity in SW1353 cells treated with isoliquiritigenin at 1.25-40µM for 6 hours 
± standard deviation n=3. (b) Bar chart showing Smad2/3/4 luciferase/renilla activity relative to 
fold change of untreated control luciferase/renilla activity in SW1353 cells treated with 
isoliquiritigenin at 1.25-40µM for 6 hours ± standard deviation n=3. The effect of apigenin on 
luciferase/renilla activity was analysed using one way ANOVA with a Dunnetts post hoc test.  * 
p<0.05, *** p<0.001. 
 
TGFβ1 stimulated 
Unstimulated 
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5.2.1.7 Effect of isoliquiritigenin on the Wnt pathway in SW1353 cells 
SW1353 cells (Figure 5.8a,b) were transfected with 100ng of the canonical Wnt signalling 
reporter (TOPFLASH) vector (Figure 5.1c) and 10ng of Renilla expression vector as described 
above. SW1353 cells were treated with isoliquiritigenin at 1.25-40µM for 6 hours. In Figure 
5.7a apigenin was added an hour before stimulation with Wnt3a 50ng/ml. Figure 5.7b 
samples were left unstimulated. As compounds were suspended in DMSO, DMSO controls 
were used to show that DMSO had no significant effect on luciferase activity. Luciferase 
assay data shows that isoliquiritigenin significantly reduced Wnt activity at 10, 20 and 40µM 
(p<0.05-0.001) in a dose dependent manner (Figure 5.8a) and had no significant effect on 
unstimulated Wnt activity (Figure 5.8b). 
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Figure 5.8. The effect of isoliquiritigenin on the Wnt pathway. (a) Bar chart showing Wnt 
luciferase/renilla activity relative to fold change of Wnt3a stimulated luciferase/renilla activity 
in SW1353 cells treated with isoliquiritigenin at 1.25-40µM for 6 hours ± standard deviation 
n=3. (b) Bar chart showing Wnt luciferase/renilla activity relative to fold change of untreated 
control luciferase/renilla activity in SW1353 cells treated with isoliquiritigenin at 1.25-40µM for 
6 hours ± standard deviation n=3. The effect of isoliquiritigenin on luciferase/renilla activity was 
analysed using one way ANOVA with a Dunnetts post hoc test. * p<0.05, ** p<0.01, ***p<0.001. 
 
Wnt3a stimulated 
Unstimulated 
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5.2.2 The effect of apigenin on MAPK kinase expression and activation 
KOA chondrocytes were cultured and plated as described in section 2.2.5. KOA cells were 
treated with apigenin at 10µM for 5, 10, 30 and 60 minutes and stimulated with 5ng/ml 
IL1. 10µM was selected as a concentration to screen for effects on MAPK kinase expression 
and activation as at this concentration apigenin and isoliquiritigenin inhibited many 
chondro-degenerative genes (Figure 4.10-4.15), apigenin inhibited the Smad2/3/4 and Wnt 
pathways (Figure 5.4-5.5), 10µM represents a ‘high’ but physiologically relevant 
concentration that may be obtained via diet or supplementation of bioactive compounds. 
A 5-60 minute time course was selected as time points of interest as previous research has 
shown dietary compounds such as SFN effect MAPK activation in KOA cells across these 
time points (Davidson et al., 2013). 
Total protein was extracted and resolved by SDS-PAGE described in section 2.2.5.2-2.2.5.3. 
Total ERK (tERK) and p-ERK, total p38 (tp38) and p-p38, total JNK (tJNK) and p-JNK were 
assessed by immunoblotting with specific antibodies described in section 2.1.4 (Figure 5.9).  
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b) c) 
d) 
Figure 5.9. The effect of apigenin on MAPKs. Immunoblot analysis of apigenin effect on ERK, 
p38 and JNK in KOA cells. (a) Representative immunoblot of ERK (t-ERK),  p-ERK, total p38 (tp38) 
and p-p38, total JNK (tJNK) and p-JNK showing effects of 10µM apigenin treatment over 0-60 
minute timecourse in KOA cells. n =2.  (b) Analysis of ERK activity (pERK/tERK ratio), bar chart 
showing p-ERK/tERK ratio showing effects of 10µM apigenin treatment over timecourse in KOA 
cells. (c) Analysis of p38 activity (p-p38/tp38 ratio), bar chart showing p-p38/tp38 ratio showing 
effects of 10µM apigenin treatment over timecourse in KOA cells. (d) Analysis of JNK activity (p-
JNK/tJNK ratio), bar chart showing p-JNK/tJNK ratio showing effects of 10µM apigenin treatment 
over timecourse in KOA cells. n =2 ± mean. 
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5.2.3 The effect of isoliquiritigenin on MAPK kinase expression and activation 
KOA chondrocytes were cultured and plated as described in section 2.2.5. KOA cells were 
treated with apigenin at 10µM for 5, 10, 30 and 60 minutes and stimulated with 5ng/ml 
IL1. 10µM was selected as a concentration to screen for effects on MAPK kinase expression 
and activation as at this concentration isoliquiritigenin inhibited many chondro-
degenerative genes (Figure 4.16-4.21), isoliquiritigenin inhibited the NFκB, TGFβ and Wnt 
pathways (Figure 5.6-5.8) and 10µM represents a ‘high’ but physiologically relevant 
concentration that may be obtained via diet or supplementation of bioactive compounds. 
A 5-60 minute time course was selected as time points of interest as previous research has 
shown dietary compounds such as SFN effect MAPK activation in KOA cells across these 
time points (Davidson et al., 2013). 
Total protein was extracted and resolved by SDS-PAGE described in section 2.2.5.2-2.2.5.3. 
Total ERK (tERK) and p-ERK, total p38 (tp38) and p-p38, total JNK (tJNK) and p-JNK were 
assessed by immunoblotting with specific antibodies described in section 2.1.4 (Figure 
5.10).  
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b) c) 
d) 
Figure 5.10. The effect of isoliquiritigenin on MAPKs. Immunoblot analysis of apigenin effect 
on ERK, p38 and JNK in KOA cells. (a) Representative immunoblot of ERK (t-ERK),  p-ERK, total 
p38 (tp38) and p-p38, total JNK (tJNK) and p-JNK showing effects of 10µM isoliquiritigenin 
treatment over 0-60 minute timecourse in KOA cells. n =2.  (b) Analysis of ERK activity 
(pERK/tERK ratio), bar chart showing p-ERK/tERK ratio showing effects of 10µM isoliquiritigenin 
treatment over timecourse in KOA cells. (c) Analysis of p38 activity (p-p38/tp38 ratio), bar chart 
showing p-p38/tp38 ratio showing effects of 10µM isoliquiritigenin treatment over timecourse 
in KOA cells. (d) Analysis of JNK activity (p-JNK/tJNK ratio), bar chart showing p-JNK/tJNK ratio 
showing effects of 10µM apigenin treatment over timecourse in KOA cells. n =2 mean. 
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5.2.4 Human Phospho-Kinase Array 
KOA chondrocytes were cultured and plated as described in section 2.13. KOA cells were 
treated with isoliquiritigenin or apigenin at 10µM for 10 minutes and stimulated with 
5ng/ml IL1. The analysis of phosphorylation profiles of 43 kinases and their protein 
substrates was completed with the Human Phospho-Kinase Array as described by the 
manufacturer's instructions described in section 2.14 (Figure 5.11). Cell lysates were 
analysed using the Human Phospho-kinase array kit and compounds were considered to 
show a weak reduction on a kinase phosphorylation event if the compound treated 
samples signal fold change was below 0.75-fold the IL1-induced change and a strong 
reduction below 0.5-fold change of the IL1 treated control (Figure 5.11). Figure 5.12 shows 
quantified results from Figure 5.11 relative to IL1 control. Compounds were considered to 
induce a weak kinase phosphorylation event if the compound-treated samples signal fold 
change was above 1.25-fold the IL1 induced change and a strong induction above 1.5-fold 
the IL1 induced change (Figure 5.12a). The effects of isoliquiritigenin on the Human 
Phospho Kinase Array from Figure 5.12 were compiled into Table 7. The effects of apigenin 
on the Human Phospho Kinase Array from Figure 5.12 were compiled into Table 8. Apigenin 
showed an induction of the phosphorylation of GSK-3α/β. The phosphorylated levels of 
p53, p70 S6 kinase, eNOS, Fgr, STAT3, p27, PLC-γ1, STAT3 and PYK2 were undetected and 
so were not analysed in Figure 5.12. Figure 5.12b shows quantified results from Figure 5.11 
relative to unstimulated control (C). 
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Figure 5.11. Alteration of kinase signalling in KOA cells after isoliquiritigenin or apigenin 
treatment. KOA cells were either untreated = (C), treated with 5ng/ml IL1 = (IL1) or with 
isoliquiritigenin (ISL + IL1) or apigenin (AP + IL1) at 10µM with 5ng/ml IL1 for 10 minutes. The 
diluted cell lysates were analysed using a human phosphokinase array kit (R&D Systems). Mean 
values (n=2 in each blot). p53, p70 S6 kinase, eNOS, Fgr, STAT3, p27, PLC-γ1, STAT3 and PYK2 
were undetected and so were not analysed in Figure 5.12. (TP) = total protein samples. 
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WEAK REDUCTION WITH 
ISOLIQUIRITIGENIN TREATMENT 
STRONG REDUCTION WITH 
ISOLIQUIRITIGENIN TREATMENT 
HCK HSP27 
JNK 1/2/3 Src 
CREB FAK 
FYN PRAS40 
C-JUN p38a 
ERK 1/2 HSP60 
 β-catenin 
Table 7. The effect of isoliquiritigenin treatment on the Human Phospho Kinase Array. Table 
showing the IL1 induced kinase phosphorylation events reduced in KOA cells with 10µM 
isoliquiritigenin treatment for 10 minutes. HSP60 and β-catenin highlighted in bold were 
total protein values. 
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WEAK INHIBITION WITH           
APIGENIN TREATMENT 
 STRONG INHIBITION WITH        
APIGENIN TREATMENT 
HCK HSP27 
PDGF  RΒ Src 
WNK1 c-JUN 
STAT6 Lck 
P38A CREB 
FAK Akt 1/2/3  
JNK 1/2/3 PRAS40 
 Fyn 
 HSP60 
 β-catenin 
Table 8. The effect of apigenin treatment on the Human Phospho Kinase Array. Table showing 
the IL1 induced kinase phosphorylation events reduced in KOA cells with 10µM apigenin 
treatment for 10 minutes. HSP60 and β-catenin highlighted in bold were total protein values. 
147 
 
 
Figure 5.12a. Analysis of IL1 stimulated kinase signalling in KOA cells after isoliquiritigenin or 
apigenin treatment relative to IL1 fold change. Bar chart analysing data from Figure 5.11. Cell 
lysates were analysed using a human phosphokinase array kit and compounds were considered 
to reduce a kinase phosphorylation event if the compound treated samples signal fold change 
was below 0.75 fold change of the IL1 treated control. Compounds were considered to induce 
a kinase phosphorylation event if the compound treated samples signal fold change was above 
1.25 signal fold change of the IL1 treated control. Mean values (n=2 in each blot) ± mean range 
of phosphoproteins quantified relative to IL1 treated control. 
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Figure 5.12b. Analysis of IL1 stimulated kinase signalling in KOA cells after isoliquiritigenin or 
apigenin treatment relative to unstimulated control fold change. Bar chart analysing data from 
Figure 5.11. Mean values (n=2 in each blot) ± mean range of phosphoproteins quantified 
relative to unstimulated control (C) treated control. 
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5.3 Discussion 
In the previous chapter apigenin and isoliquiritigenin dose-dependently inhibited MMP13, 
MMP1, ADAMTS4 and ADAMTS5 and up-regulated the anti-inflammatory gene HO-1. We 
hypothesised that as apigenin dose-dependently inhibited AXIN2 (a Wnt/β-catenin 
responsive gene) the chondro-protective properties of apigenin may in part be due to 
alterations to the Wnt pathway. In this chapter, I explored the mechanism of action of 
apigenin and isoliquiritigenin.  
Cell-based luciferase assays were used to measure the effect of apigenin or isoliquiritigenin 
pretreatment on the NFκB, TGFβ and Wnt pathways in SW1353 cells. Initially these assays 
were used to measure the effect of cytokines on the NFκB, TGFβ and Wnt pathways over 
1,3,6,12 and 24 hours (Figure 5.2). As all cytokines significantly increased their 
corresponding pathway at 6 hours (Figure 5.2a-c) and apigenin and isoliquiritigenin have 
been shown to significantly inhibit chondro-destructive genes in the previous chapter at 6 
hours, a 6 hour time point was selected for subsequent luciferase experiments. 
Both apigenin and isoliquiritigenin significantly reduced IL1 stimulated NFκB activity in dose 
dependent manners (Figure 5.3a,5.6a) however isoliquiritigenin showed inhibition at 10µM 
whereas apigenin only inhibited NFκB activity at concentrations of 20µM and above. While 
isoliquiritigenin was the more potent IL1 stimulated NFκB inhibitor apigenin was able to 
inhibit unstimulated NFκB activity whereas isoliquiritigenin did not (Figure 5.3b, 5.6b). As 
discussed in the introduction NFκB plays a central role in the development of OA. 
Overexpression of IκB has been shown to decrease MMP1, MMP13 and ADAMTS4 in OA 
synovial cells (Amos et al., 2006), (Bondeson et al., 2007). This data suggests that apigenin 
and isoliquiritigenin may be acting as NFκB inhibitors (Figure 5.3, 5.6) which may contribute 
to the inhibition of MMP1, MMP13 and ADAMTS4 by apigenin and isoliquiritigenin in KOA 
cells seen in the previous chapter. By using siRNA knock down and rescue experiments on 
the p65/p50 subunits of NFκB we could measure whether apigenin or isoliquiritgenin still 
had effects on MMP1, MMP13, ADAMTS4 and ADAMTS5 when the NFκB pathway is 
knocked down. 
While apigenin and isoliquiritigenin appeared to show the same patterns of TGFβ1 
stimulated Smad2/3/4 inhibition (Figure 5.4a, 5.7a) apigenin showed a strong inhibition of 
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unstimulated Smad 2/3/4 (Figure 5.4b) whereas isoliquiritigenin did not (Figure 5.7b). 
These results suggest that apigenin may over inhibit basal levels of TGFβ and could 
potentially prevent the anabolic role TGFβ plays in the joint as TGFβ is known to stimulate 
proteoglycan and collagen synthesis (Redini et al., 1988). As discussed in the introduction 
the role of TGFβ in the joint is complicated as it has been shown to have anabolic and 
catabolic effects in OA models. It has been hypothesised that TGFβ could stimulate 
aggrecan synthesis and degradation (TGFβ has been shown to stimulate ADAMTS4 
expression in human articular chondrocytes (Moulharat et al., 2004) resulting in increased 
aggrecan turnover. The resulting proteoglycan fragments produced by TGFβ stimulated 
aggrecanase could be an inflammatory trigger for cytokine production by chondrocytes 
(Pelletier et al., 2001) leading to an increase in metalloproteinase production and aggrecan 
and collagen degradation seen in OA. This data suggests that the inhibition of ADAMTS4 in 
KOA cells treated with apigenin seen in the previous chapter may be due to apigenin 
inhibiting the TGFβ/Smad2/3/4 pathway (Figure 5.4). By using siRNA targeting Smad2 and 
Smad3 we could measure whether apigenin or isoliquiritigenin still have effects on MMP1, 
MMP13, ADAMTS4 and ADAMTS5 expression when the TGFβ/Smad2/3/4 pathway is 
knocked down. 
Both apigenin significantly reduced Wnt3a stimulated Wnt activity in dose dependent 
manners (Figure 5.5a, 5.8a) and had no significant effect on unstimulated Wnt activity 
(Figure 5.5b, 5.8b). As discussed in the introduction Wnt signalling can induce the 
expression of MMPs in articular chondrocytes, promoting cartilage degradation and 
cartilage catabolism (Yuasa et al., 2008). This data suggests that apigenin and 
isoliquiritigenin may be inhibiting the Wnt/β-catenin potentially contributing to the 
inhibition of MMP1, MMP13 and ADAMTS4 by apigenin in KOA cells seen in the previous 
chapter. These results also support the data seen in the previous chapter where we 
hypothesised that apigenin may be inhibiting the Wnt pathway as apigenin inhibited AXIN2, 
a Wnt/β-catenin responsive gene. Over inhibition of the Wnt/β-catenin signalling pathway 
has been shown to increase cell apoptosis and articular cartilage destruction (Zhu et al., 
2008). As both compounds had no effect on unstimulated Wnt activity (Figure 5.5b 5.8b) 
they would be unlikely to over inhibit the Wnt/β-catenin pathway as seen in the Col2a1-
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ICAT-transgenic mice (Zhu et al., 2008) and instead the compounds may rebalance the 
Wnt/β-catenin pathway to the activity present in a healthy joint. 
Apigenin and isoliquiritigenin may have different mechanisms of actions and could be 
interacting with the pathways in different ways. These data are similar to the effects 
curcumin and resveratrol have on the NFκB pathway. Curcumin had previously been shown 
to suppress the activation of NFκB (Singh & Aggarwal, 1995) as had resveratrol (Meng et 
al., 2005). Inhibition of NFκB by curcumin was shown to be mainly through inhibition of IKK 
activation, in contrast the inhibition of NFκB activation by resveratrol mainly occurred 
through accumulation of phosphorylated IKβα and ubiquitinated IKβα (Csaki et al., 2009). 
If apigenin and isoliquiritigenin inhibited the NFκB and the other pathways in different ways 
they may have stronger inhibitory effects when used together, allowing us to use each 
compound at lower, potentially more easily obtained, concentrations. 
As discussed in chapter 1, OA is a multifactorial disease and pharmacological intervention 
for OA has had a lack of clinical efficacy. This may be due to pharmacological treatments 
typically only having a single mode of action and OA being a multifactoral disease. Bioactive 
compounds were considered an attractive alternative treatment for OA as bioactive 
compounds can simultaneously interact with multiple cellular pathways (Ameye & Chee, 
2006). This chapter has shown that apigenin and isoliquiritigenin are capable of interacting 
with multiple cell pathways including the NFκB, TGFβ and Wnt pathways. The Proteome 
Profiler Array Human Phospho-Kinase Array Kit was used to perform an unbiased dissection 
of the kinase pathways affected by apigenin and isoliquiritigenin. This assay was used to 
detect simultaneously the relative levels of phosphorylation of 43 kinase phosphorylation 
sites and 2 related total proteins measuring the effects of apigenin and isoliquiritigenin 
across multiple cell pathways. To select and validate a timepoint for this assay the 
phosphorylation of the MAPK family of serine/threonine kinases, ERK, p38 and JNK were 
selected for analysis as they were known to be involved in the regulation of 
metalloproteinase gene expression and were included in the 43 kinases of the Human 
Phospho Kinase screen. While IL1 does not induce the phosphorylation of all the kinases in 
the Human Phosphor Kinase screen it was selected to stimulate the assay and the 
phosphorylation of the MAPK family as the effects on IL1 stimulated genes inhibited by 
apigenin and isoliquiritigenin in chapter 4 were under investigation. Over the 60 minute 
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timecourse apigenin and isoliquiritigenin showed the strongest inhibition of the IL1 
stimulated phosphorylation of ERK and p38 at 10 minutes (Figure 5.9b,c 5.10b,c) while 
isoliquiritigenin also showed a slight inhibition of JNK phosphorylation (Figure 5.10d). These 
results were used to select a 10 minute timepoint for the Human Phospho-Kinase array. 
Isoliquiritigenin showed a reduction of the phosphorylation of HSP27, Src, FAK, PRAS40, 
p38a and showed a weak reduction of HSP60, β-catenin, Hck, JNK 1/2/3, CREB, Fyn, c-JUN 
and ERK 1/2 (Table 7). Apigenin showed a strong reduction of the phosphorylation of 
HSP27, HSP60, Src, c-Jun, Lck, CREB, Akt 1/2/3 (at phosphorylation sites S427 and T308), 
PRAS40, Fyn and β-catenin and showed a weak reduction of Hck, PDGF Rβ, WNK1, STAT6, 
p38a, FAK and JNK 1/2/3 (Table 8). Apigenin also showed an induction of the 
phosphorylation of GSK-3α/β (Figure 5.12a).  
Heat shock protein 27 (HSP27) is a protein chaperone and an antioxidant that plays a role 
in cytoskeletal remodelling and the inhibition of apoptosis (Vidyasagar et al., 2012). 
Changes to the expression, phosphorylation and subcellular location of HSP27 are induced 
by environmental stress (Wong et al., 2000). Chondrocytes expression of HSP27 has been 
knocked down with the use of siRNA. This knock down resulted in a reduced secretion of 
IL6 in response to IL1 (Lambrecht et al., 2010). The role of IL6 in OA remains controversial. 
IL6 is elevated in the synovial fluid of OA joints compared to healthy donors, but reports 
regarding its effects on cartilage matrix metabolism are conflicting. IL6 decreases the 
production of type 2 collagen and increases the production of enzymes from the MMPs 
group in cartilage (Porée et al., 2008), (Rowan et al., 2001). However IL6 deficient (IL6(-/-)) 
mice show a tendency to develop much more advanced degenerative changes than healthy 
mice (de Hooge et al., 2005). C6 glioma cells that were transfected with phosphorylated 
HSP27 had suppressed IL1 induced IL6 release and mRNA expression level but cells that 
were transfected with unphosphorylated HSP27 had an enhanced level of IL1 induced IL6 
release and mRNA expression. These results suggest that the phosphorylated status of 
HSP27 plays a role in IL1 induced IL6 synthesis (Tanabe et al., 2010). In our results both 
apigenin and isoliquiritigenin decreased phosphorylated HSP27 levels compared to IL1 
induced control (Figure 5.12a), these lower levels of phosphorylated HSP27 levels may be 
due to the chondrocytes undergoing less oxidative stress after apigenin or isoliquiritigenin 
treatment. Future experiments could look at the protein levels and mRNA expression of IL6 
153 
 
to see if the decrease in HSP27 phosphorylation results in changes to IL6. Interestingly 
apigenin and isoliquiritigenin also reduced the total level of heat shock protein 60 (HSP60) 
which may be due to the chondrocytes undergoing less cell stress. HSP60 was one of the 
two total protein levels detected by the Human Phospho-Kinase assay, the other being β-
catenin. HSP60 is expressed in the synovial membrane of patients with rheumatoid arthritis 
and OA, shear stress has been identified as an inducer of HSP60 in endothelial cells (S. 
Watanabe et al., 2014). HSP60 has been shown to promote the TNF-α-mediated activation 
of the NFκB pathway via direct interaction with Inhibitor of Kappa B Kinase alpha/beta 
(IKKα/β) in the cytoplasm (Chun et al., 2010). The lower levels of HSP60 seen with apigenin 
and isoliquiritigenin treatment in the Human Phospho-Kinase assay (Figure 5.12) may result 
in the lower NFκB activity levels seen in the cell based luciferase assays (Figures 5.3, 5.6). 
We could investigate this by knocking down HSP60 using siRNA  and measure the effects 
on the NFκB pathway after apigenin or isoliquiritigenin treatment using cell based 
luciferase assays (Ghosh et al., 2010).  
Proto-oncogene tyrosine-protein kinase Src (Src) is a proto-oncogene involved in the 
regulation of embryonic development and cell growth (Meyn et al., 2005). Src can trigger 
the activation of downstream signalling pathways including MAPK and NFκB, (Lee et al., 
2007), (Lei & Ingbar, 2011). Inhibition of Src kinase activity using the pharmacological 
compound PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine) in 
primary murine chondrocytes reduced the number of primary chondrocytes but also 
increased the expression of both early markers (such as Sox9, collagen type 2, aggrecan 
and xylosyltransferases) and late markers (collagen type X, Indian hedgehog and p57) of 
chondrocyte differentiation (Bursell et al., 2007). It was hypothesised that PP2 promotes 
chondrogenic gene expression and morphology in monolayer culture and that strategies to 
block Src activity might therefore be useful both in tissue engineering of cartilage and in 
the maintenance of the chondrocyte phenotype in OA. Apigenin and isoliquiritigenin 
strongly reduced the phosphorylation of Src (Figure 5.12) and the phosphorylation of Src 
at Y419 is important for activating the kinase activity towards substrates (Boerner et al., 
1996). IL1 stimulated Hck phosphorylation levels were reduced in KOA cells treated with 
apigenin or isoliquiritigenin. Hck is a tyrosine-protein kinase and a member of the Src family 
of tyrosine kinases.  PP2 the Src kinase inhibitor has been shown to repress the expression 
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of the Src kinases Hck, Lyn and Frk reversing morphological dedifferentiation of 
chondrocytes in monolayer culture (Bursell et al., 2007). Phosphorylation of Hck at T511 
increases kinase activity (Khan et al., 2010). These results suggest that Hck plays a role in 
dedifferentiation in chondrocytes and apigenin and isoliquiritigenin may prevent this 
dedifferentiation by inhibiting Hck activity. The reduction in the level of phosphorylated Src 
caused by apigenin and isoliquiritigenin may contribute to changes seen in the ERK and 
NFκB pathways seen in this chapter. The PP2 inhibitor could be used to inhibit Src kinases 
in KOA cells treated with apigenin or isoliquiritigenin and the effects of apigenin and 
isoliquiritigenin on MMP1, MMP13, ADAMTS4 and ADAMTS5 expression could be 
measured. 
Focal Adhesion Kinase (FAK) is a cytoplasmic protein tyrosine kinase found in the focal 
adhesions that form between cells growing in the presence of ECM constituents. FAK is a 
marker for integrin activation and decreased FAK levels alters cell-matrix interactions and 
response to mechanical load (Svoboda, 1998). Osteochondral explants treated with a FAK 
inhibitor (FAKi) before a cell death-inducing impact load increased cell viability (Jang et al., 
2014). Targeting of FAK by siRNAs has been shown to reduce chondrocyte redifferentiation 
capacity in alginate beads culture with type 2 collagen (Y. Kim & Lee, 2009). Apigenin and 
isoliquiritigenin apparently reduced FAK phosphorylation in KOA chondrocytes (Figure 
5.12), these lower phosphorylated levels of FAK may be closer to those found in normal 
healthy joints as FAK phosphorylation has been reported to be significantly higher in rabbit 
OA chondrocytes (Cheng et al., 2014). Proline-rich AKT1 substrate 40 (PRAS40) is a protein 
that regulates Target of rapamycin (TOR) by acting as a direct inhibitor of substrate binding 
(L. Wang et al., 2007). The phosphorylation of PRAS40 by Akt relives PRAS40 inhibition of 
TOR (Vander Haar et al., 2007). Akt 1/2/3 phosphorylation at S473 was reduced by apigenin 
which is required for its activation (Figure 5.12) less activated Akt 1/2/3 may result in the 
lower levels of phosphorylated PRAS40 seen with apigenin and isoliquiritigenin treatment 
and suggests that the PI3K/Akt pathway is being inhibited by the compounds. PI3K/Akt 
regulates a cascade of changes through its broad target proteins such as NFκB and p53, 
(Dan et al., 2008) (Chen & Huang, 2009). Activated Akt induces NFκB transcription activity 
by stimulating the NFκB trans-activation domain. The reduction of activated Akt 1/2/3 by 
apigenin may result in decrease in the PI3K/Akt and could result in the lower NFκB activity 
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levels seen in the apigenin treated cell based luciferase assays (Figures 5.3). Curcumin (a 
curcuminoid of turmeric) has been suggested to inhibit IL1-stimulated MMP secretion by 
inhibiting pAkt and NFκB  (Schulze-Tanzil et al., 2004) and apigenin may have a similar 
mechanism of action. 
Apigenin also reduced IL1 stimulated phosphorylated Beta-type platelet-derived growth 
factor receptor (PDGF Rβ) levels (Figure 5.12a).  PDGF Rβ coprecipitates with PI3K following 
stimulation of 3T3 fibroblast cells when stimulated with platelet derived growth factor 
(PDGF), mutagenesis of PDGF Rβ Y751 phosphorylation site results in reduced PI3K activity 
(Kazlauskas & Cooper, 1990). Apigenin effects on NFκB in the cell based luciferase assays 
(Figure 5.3) may be due to the reduction in PI3K activity from a reduction in phosphorylated 
PDGF Rβ (at Y751). 
Apigenin and isoliquiritigenin reduced the phosphorylation of p38a in the Human Phospho-
Kinase screen (Figure 5.12) which supports the timecourse western blot data (Figures  5.9c, 
5.10c). While normal and OA chondrocytes express p38 OA chondrocytes show much 
higher phosphorylated p38 compared to normal chondrocytes (Takebe et al., 2011) and 
heat stress or mechanical stress induces apoptosis and increases phosphorylated p38 in 
normal chondrocytes. NO induction of NFκB, p53 and caspase-3 activation has been shown 
to be via phosphorylation of p38 MAPK in rabbit articular chondrocytes inducing 
chondrocyte apoptosis (H. Wang et al., 2007). As discussed in previous chapters elevated 
levels of markers of NO production are found in OA joints suggesting that NO is involved in 
the pathogenesis of osteoarthritis (OA) (Vuolteenaho et al., 2007). These results suggest 
that the decrease in the phosphorylated p38 seen with apigenin and isoliquiritigenin 
treatment could result in the lower NFκB activity levels seen in the cell based luciferase 
assays (Figures 5.3, 5.6).  
Apigenin and isoliquiritigenin reduced IL1 total β-catenin protein levels (Figure 5.12a). β-
catenin was one of the total protein levels detected by the Human Phospho-Kinase assay, 
the other being HSP60. As discussed in the introduction both over and under activation of 
the Wnt/β-catenin can result in OA and a joint must have the correct homeostasis of the 
pathway to remain healthy. The reduced total protein level of β-catenin seen in the Human 
Phospho-Kinase results may contribute to the reduced Wnt pathway activity seen in the 
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cell based luciferase assays (Figure 5.5, 5.8) potentially rebalancing the Wnt/β-catenin 
pathway to the activity present in a healthy joint. The lysine deficient protein kinase 1 
(WNK1) is a submember of the serine/threonine protein kinases. WNK1 has been shown to 
upregulate β-catenin in endothelial cells (Dbouk et al., 2014) and siRNA mediated 
knockdown of WNK1 in human embryonic Kidney 293 cells had a significantly reduced 
expression of a Wnt-signalling reporter (Serysheva et al., 2013). These results suggest that 
WNK kinases are involved in the regulation of the β-catenin/Wnt pathway. While WNK1s 
role in OA is unknown, if the regulation of the β-catenin/Wnt pathway is in part controlled 
by the phosphorylation of WNK1 in chondrocytes apigenin may inhibit the Wnt pathway in 
the cell based luciferase assays (Figure 5.5) by reducing the phosphorylation level of WNK1 
(Figure 5.12) potentially resulting in the dose dependent repression of AXIN2 seen in 
chondrocytes treated with apigenin (Figure 4.15).  
Interestingly apigenin increased GSK-3α/β phosphorylation levels (Figure 5.12). GSK3 
comprises of 2 serine/threonine protein kinases GSK-3α and GSK-3β. GSK-3 is constitutively 
active and is negatively regulated via phosphorylation at S21 (GSK-3α) and S9 (GSK-3β). 
GSK-3 inhibition has been shown to reduce collagen induced arthritis and collagen antibody 
induced arthritis in mice (Cuzzocrea et al., 2006), (Hu et al., 2006) suggesting that the 
inhibition of GSK-3 could have anti inflammatory effects during chronic inflammation. By 
increasing the phosphorylation of GSK-3α/β apigenin may be inactivating the constitutively 
active form of GSK-3, however levels of total GSK-3 need to be measured in future 
experiments to clarify these results. GSK-3 is a part of the β-catenin degradation complex 
and increased levels of GSK-3 could result in higher levels of β-catenin degradation. 
Isoliquiritgenin had no effect on GSK-3α/β phosphorylation levels. 
As discussed in the introduction inflammatory cytokines, osmostic stress and apoptotic 
signals activate JNKs (Davis, 2000). JNKs phosphorylate and activate AP-1 family member 
c-Jun which dimerises with c-Fos during MMP gene transcription (Karin, 1995), (Leppä et 
al., 1998). Apigenin and isoliquiritigenin weakly inhibited the phosphorylation of JNK1/2/3 
in the Human Phospho-Kinase assay (Figure 5.12) which supports the timecourse western 
blot data where isoliquiritigenin showed a slight inhibition of JNK phosphorylation at the 
10 minute timepoint (Figure 5.10d). Phosphorylation of c-JUN is associated with increased 
transcriptional activation capacity of the protein (Pulverer et al., 1991). c-JUN can also 
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transactivate p53-upregulated modulator of apoptosis (PUMA) gene expression to 
promote OA. c-JUN and PUMA have been shown to be upregulated in chondrocytes from 
the articular cartilage of OA patients. PUMA is a pro-apoptotic member of the BH3-only 
subgroup of the Bcl-2 family. IL1 stimulated mouse chondrocytes had an increase in PUMA 
protein and mRNA levels (H. Lu et al., 2014). PUMA was hypothesised to play an important 
role in chondrocyte apoptosis as siRNA knock down of PUMA reduced apoptosis. When the 
JNK/c-Jun pathway was pharmacologically inhibited PUMA expression was supressed and 
apoptosis levels were decreased in IL1 treated chondrocytes (H. Lu et al., 2014). Apigenin 
and isoliquiritigenin reduced the phosphorylation levels of c-JUN in the Human Phospho-
Kinase assay (Figure 5.12) this may be due to chondrocytes lower protein levels of JNK after 
apigenin or isoliquiritigenin treatment (Figure 5.9d, 5.10d). These results suggest that the 
inhibition of IL1 stimulated MMPs by apigenin and isoliquiritigenin seen in previous 
chapters may be due to the inhibition of the JNK/c-JUN pathway.These results suggest that 
the inhibition of IL1 induced MMPs seen in previous chapters may be in part due to 
inhibition of the IL1 induced JNK pathway, future experiments could explore JNK 
phosphorylation levels at different timepoints. 
As discussed in the introduction ERK is a member of the MAPK family of serine/threonine 
kinases. ERKs phosphorylate and activate c-JUN. An ERK specific inhibitor U0126 has been 
shown to significantly inhibit IL1 induced ERK activation resulting in inhibition of IL1 
induced upregulation of iNOS, IL-6, Cox-2, MMP3, and MMP13 in rat annulus fibrosus cells 
(Wei et al., 2013). Apigenin and isoliquiritigenin inhibited ERK protein levels in the western 
blot timecourse assays (Figure 5.9b, 5.10b), isoliquiritigenin also reduced ERK 
phosphorylation levels in the Human Phospho Kinase assay and apigenin showed a trend 
towards ERK phosphorylation reduction (Figure 5.12). These results suggest that the 
inhibition of IL1 stimulated MMPs by apigenin and isoliquiritigenin seen in previous 
chapters may be due to the inhibition of the ERK pathway. 
The cAMP response element-binding protein (CREB) is a transcription factor and 
phosphorylation at S133 increases CREB-mediated gene transcription (De Falco et al., 
2012).  Human articular chondrocytes having undergone CpG demethylation of the MMP13 
promoter showed CREB recruitement leading to the elevated expression of MMP13, this 
CpG is demethylated in OA cartilage, indicating a role for DNA demethylation and thus CREB 
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in the increased expression of MMP13 in OA (Bui et al., 2012). CREB phosphorylation was 
inhibited by apigenin and isoliquiritigenin in the Human Phospho-Kinase assay (Figure 5.12) 
potentially decreasing CREBs transcriptional activity which may contribute to the inhibition 
of MMP13 seen in KOA treated chondrocytes treated with apigenin and isoliquiritigenin in 
the previous chapter. 
Fyn is a proto-oncogene tyrosine kinase that has been implicated in the control of cell 
growth (Berwanger et al., 2002). While the role of Fyn in OA is unknown apigenin and 
isoliquiritigenin lowered IL1 stimulated Fyn phosphorylation levels closer to unstimulated 
levels (Figure 5.12b). 
The lymphocyte-specific protein tyrosine kinase (Lck) is a key signalling molecule in the 
selection and maturation of developing T-cells (Isakov & Biesinger, 2000). During 
rheumatoid arthritis T cells infiltrate the synovium and produce cytokines, chemokines, and 
degradative enzymes promoting inflammation and joint destruction. Inhibition of Lck could 
result in immunosuppression and has been suggested as a potential therapeutic for 
patients with rheumatoid arthritis  (Meyn & Smithgall, 2008). Whether Lck play a role in OA 
is unknown. Lck levels were low in KOA cells and apigenin reduced IL1 Lck phosphorylation 
in the Human Phospho-Kinase array below levels of the unstimulated control (Figure 
5.12b). Isoliquiritigenin had no effect on Lck phosphorylation. 
The signal transducer and activator of transcription 6 (STAT6) is a member of the STAT 
family of transcription factors. CD1a positive dendritic cells express STAT6 in seropositive 
rheumatoid tissue and STAT6 has been suggested to be an alternative marker for 
identifying RA at the level of the synovium. IL4 signalling through STAT6 has been reported 
to have anti-inflammatory effects. A proteoglycan induced murine arthritis model has 
shown that IL4 signalling through STAT6 is required to attenuate the severity of joint 
inflammation (Finnegan et al., 2002). The role of STAT6 in OA is unknown. Apigenin 
decreased IL1 stimulated STAT6 phosphorylation levels to below unstimulated KOA cells 
STAT6 phosphorylation levels (Figure 5.12b). 
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5.3.1 Conclusion 
In conclusion apigenin and isoliquiritigenin inhibited IL1 stimulated and NFκB, TGFβ and 
Wnt pathways and apigenin inhibited the unstimulated NFκB and TGFβ in cell based 
luciferase assays in a dose dependent manner and with distinct differences in the patterns 
of inhibition suggesting that these compounds may have different mechanisms of actions. 
Over 60 minute timecourses 10µM of apigenin and isoliquiritigenin showed inhibition of 
the IL1 stimulated phosphorylation of ERK, p38 and JNK at 10 minutes and this timepoint 
was selected for use with the Human Phospho-Kinase array experiments.  The Human 
Phospho-Kinase Array ascertained the effects apigenin and isoliquiritigenin had on 43 
kinases and 2 related total proteins in IL1 stimulated and unstimulated KOA cells. Apigenin 
and isoliquiritigenin had similar effects on many phosphorylation events, however there 
were kinase phosphorylation events that were specific to either apigenin or isoliquiritigenin 
and these may explain some of the variations seen between the compounds qRT-PCR 
experiments seen in previous chapters and the cell based luciferase assays. 
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Apigenin and isoliquiritigenin reduced β-catenin/Wnt transcriptional activity (Figures 
5.5,5.8) these effects could potentially be due to reduced levels of total β-catenin (Figure 
5.12a), apigenin also reduced levels of WNK1 which has been shown to be important in 
regulation of the β-catenin/Wnt pathway (Serysheva et al., 2013) (Figure 5.13). 
 
 
Figure 5.13. Summary of the effects of apigenin or isoliquiritigenin treatment on the Wnt 
pathway. (1) Total β-catenin levels were reduced in the human phosphor kinase screen by 
apigenin and isoliquiritigenin treatment. (2) Phosphorylated levels of WNK1 were reduced by 
apigenin. (3) Transcriptional activity of the Wnt pathway was reduced by apigenin and 
isoliquiritigenin treatment as shown by luciferase reporter assays. 
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NFκB transcriptional activity was reduced with apigenin and isoliquiritigenin treatment 
(Figures 5.3, 5.6) these effects could potentially be due to reduced total levels of HSP60 
(Figure 5.12a), apigenin also reduced levels of phosphorylated AKT 1/2/3 which could 
potentially result in less NFκB transcriptional activation (Figure 5.14). 
 
 
Figure 5.14. Summary of the effects of apigenin or isoliquiritigenin treatment on the NFκB 
pathway. (1) Total HSP60 levels were reduced in the human phosphor kinase screen by apigenin 
and isoliquiritigenin treatment. (2) Phosphorylated levels of AKT 1/2/3 were reduced by 
apigenin. (3) Transcriptional activity of the NFκB pathway was reduced by apigenin and 
isoliquiritigenin treatment as shown by luciferase reporter assays. 
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Apigenin has previously been shown to suppress MMP13 expression in IL1 treated SW1353 
cells by suppressing the c-fos/AP-1 pathways (Lim et al., 2011). The Human Phospho Kinase 
array (Figure 5.12a) reported that several phosphorylation events involved in the 
regulation of the c-fos-AP-1 pathway were reduced after apigenin and isoliquiritigenin 
treatment (Figure 5.15).  These results could be further validated in future experiments by 
measuring the transcriptional activity of AP-1 by using a luciferase reporter plasmid. 
 
Figure 5.15. Summary of the effects of apigenin or isoliquiritigenin treatment on the AP-1 
pathway. (1) Phosphorylated levels of Src were reduced in the human phosphor kinase screen 
by apigenin and isoliquiritigenin treatment. (2) Phosphorylayed p38 levels were reduced by 
apigenin and isoliquiritigenin. (3) Phosphorylated JNK levels were reduced by apigenin and 
isoliquiritigenin. (4) Phosphorylated ERK levels were reduced by apigenin and isoliquiritigenin. 
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While future experiments are still required to determine the mechanisms of actions of 
apigenin and isoliquiritigenin this data suggests that apigenin and isoliquiritigenin effect 
different pathways and could potentially have synergistic effects when used together.  
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Chapter 6: General discussion 
Pharmacological intervention for OA has had a lack of clinical efficacy. OA is a poorly 
defined disease with a lack of good outcome measures and biomarkers. Current treatments 
for OA have focused on anti-inflammatories and pain relief rather than addressing the 
degradation of cartilage. This lack of clinical efficacy for pharmacological intervention may, 
in part, be due to pharmacological treatments typically only having a single mode of action 
and OA being a multifactoral disease. For this reason nutrition was seen as an attractive 
alternative treatment as foods typically contain multiple bioactives that can interact with 
multiple cellular pathways (Ameye & Chee, 2006). Current treatments for OA such as 
painkillers and anti-inflammatories provide symptomatic relief and are unable to prevent 
the progression of the disease. Joint replacement is offered to patients at end-stage 
disease, at large financial burden to the NHS, and with increasing patient numbers, will 
likely not remain practicable. MMP-13, MMP-1, ADAMTS4 and ADAMTS5 have been shown 
to be a key collagenases and aggrecanases in cartilage degradation. This project aimed to 
identify novel compounds found in the human diet that could offer protection or slow the 
progression of OA via collagenase and/or aggrecanase inhibition.  
6.1 Summary of findings 
6.1.1 Dietary Derived Bioactive Screen 
Compounds were selected from a Bioactive Compound Library which contained 1853 
bioactive chemical compounds from synthetic and natural sources. Only compounds that 
were produced by living organisms were selected from this list creating the Natural Product 
Library containing 143 compounds. Ninety-six dietary derived compounds were selected 
from the Natural Product Library and compiled into a custom-built library in a 96-well plate 
format. This format was selected to ensure accurate comparisons between compounds, all 
compounds were at 10µM and dissolved in DMSO. The advantages of using a custom-built 
library in this format was the standardisation of compounds in terms of purity, 
concentration and form. Purchasing compounds individually often requires a minimum 
quantity and can quickly become expensive narrowing the range of bioactive compounds 
that can be explored. In order to be selected for the 96-well plate custom library the natural 
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products had to be dietary derived. The library was designed to contain bioactive 
compounds with a range of chemical structures including flavonoids, anthocyanins, 
terpenoids, carotenoids and other polyphenols as well as precursors of parent compounds 
such as polydatin (a natural precursor of resveratrol).  
Compounds were screened at an initial concentration of 10µM for IL1 induced and basal 
MMP13 inhibition in SW1353 cells. 10µM was selected as a pragmatic choice based on past 
literature on dietary derived compounds and what concentrations of bioactives are often 
achievable through the diet. Inhibiton of the expression of MMP13 was selected as an initial 
readout for a bioactive compounds potential as a chondro-protective agent, as MMP-13 is 
the collagenase with the highest specific activity for type 2 collagen i.e. the most efficient 
cleavage of the protein (Minond et al., 2006) and it is thought to be the predominant 
collagenase involved in OA (Lopez-Otin, 1996), (Billinghurst et al., 1997), (Flannelly et al., 
2002) compared to other collagenases such as MMP-1. A qRT-PCR approach to analysing 
MMP13 was selected as a strategy to give a medium-high throughput screen using 
relatively low cell numbers compared to other techniques such as northern blots. MMP13 
mRNA levels have also been shown to be comparable to MMP-13 protein levels (Ahmad et 
al., 2009), this allows us to predict compounds effects on the MMP-13 protein levels using 
the medium-high throughput screen, whilst using a western blot method to measure the 
effect of each compound on actual MMP-13 protein levels would be prohibitively expensive 
and time consuming.  
The one-way analysis of variance (ANOVA) with Dunnett’s post test was used to measure 
the statistical significance of a compounds effect on IL1 stimulated MMP13. While multiple 
t-tests could have been used to measure significance the chances of a Type 1 error 
occurring increases with each t-test performed. With 96 compounds being screened 96 t-
tests would need to be completed and the chance of a Type 1 error occurring would be 
unacceptably high. Using an ANOVA controls for these errors so that the chance of a Type 
1 error never exceeds 5%.   
Emodin, ursolic acid, oleanolic acid, luteolin, polydatin, apigenin, neohesperidin 
dihydrochalcone, l-carnitine, isoliquiritigenin, myricetin, theobromine, sesamin, troxerutin, 
aloe-emodin, methyl-hesperidin, fisetin, genistin, hesperetin and biochanin A significantly 
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reduced either IL1 stimulated or unstimulated MMP13 expression in either SW1353 or 
C28/I2 cells. As some of these compounds had either IL1/basal or SW1353/C28/I2 specific 
effects the top twenty compounds showing either a statistically significant effect on 
MMP13 expresssion or a trend for inhibition of MMP13 expression were selected from 
each screen and entered into a four set Venn diagram. Compounds were selected from the 
Venn diagram and compiled into a top twenty compound list for further study in KOA cells 
if the compound effected more than one of the MMP13 expression screens. This was done 
to eliminate compounds that only had an effect in a single experiment and to include 
compounds that showed a trend of inhibiton of MMP13 expression in multiple experiments 
that may not have reached statistical significance in individual screens. The top twenty 
compounds selected included: emodin, ursolic acid, luteolin, polydatin, apigenin, 
neohesperidin dihydrochalcone, l-carnitine, Isoliquiritigenin, myricetin, theobromine, aloe 
emodin, methyl hesperidin, genistin, orotic acid, indole-3-carbinol,  nobiletin, naringin, 
kinetin, quercetin and rheochrysidin. 
6.1.2 Short-listing dietary-derived bioactives in human primary knee osteoarthritis 
chondrocytes 
In chapter 3, twenty compounds were selected for further study (see Chapter 3 Table 5). In 
chapter 4, compounds were screened for inhibition of genes encoding cartilage cartilage-
degrading enzymes MMP13, MMP1, ADAMTS4 and ADAMTS5. Since the two cell lines were 
used to shortlist compounds, the 20 remaining compounds (Table 5) were tested in in 
primary KOA chondrocytes. KOA cells were isolated from the cartilage of patients with knee 
OA. The qRT-PCR MMP13 screen from chapter 3 was repeated in the 20 selected 
compounds in KOA cells. While MMP-13 plays a pivotal role in collagen cleavage in OA 
(Knauper, Lopez-Otin, Smith, Knight, & Murphy, 1996) MMP-1 is also able to cleave native 
fibrillar collagen and contributes to the pathological cleavage of collagen fibrils in OA 
(Burrage, Mix, & Brinckerhoff, 2006). Using the qRT-PCR screen format from chapter 3 the 
effect of the selected 20 compounds on MMP1 expression in KOA cells was measured. As 
discussed in chapter 1 ADAMTSs also play a role in the development of OA. ADAMTS-5 
knock out mice had a significant reduction in the severity of cartilage destruction after 
surgically induced instability when compared with wild type mice (Glasson et al., 2005).  
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ADAMTS4 has been shown to be selectively overexpressed in human osteoarthritic 
cartilage, with a direct correlation with the degree of cartilage destruction suggesting that 
ADAMTS4 may play an important role in the degradation of aggrecan in human 
osteoarthritic cartilage (Naito et al., 2007). ADAMTS5 is constitutively expressed whereas 
ADAMTS4 is induced following IL1 treatment (Tortorella et al., 2001), for this reason only 
the unstimulated expression of ADAMTS5 was measured.  Compounds from the dose 
response were screened for effects on ADAMTS4 and ADAMTS5 in KOA cells. 
Heme oxygenase-1 (HO-1) is the limiting enzyme in heme catabolism (Rousset et al., 2013), 
cleaving heme to form biliverdin, this prevents production of ROS giving HO-1 anti-
inflammatory properties. HO-1 induction in PHCs cultured in hypoxic conditions prevented 
IL1 stimulated loss of type 2 collagen (Guillén et al., 2012). HO-1 was hypothesised to be a 
physiologically important chondro-protective factor. Compounds from the dose response 
assays were screened for effects on HO-1 expression.  
AXIN2 is a Wnt/β-catenin responsive gene which has been shown to be upregulated 
consistently with net activation of canonical Wnt signalling (Lustig et al., 2002). Wnt 
signalling can induce the expression of MMPs in articular chondrocytes which promotes 
cartilage degradation and cartilage catabolism (Yuasa et al., 2008). As the upregulation of 
the Wnt pathway may be deleterious for the joint cartilage the compounds from the dose 
response assays were screened for an effect on the expression of AXIN2. 
Several of the compounds selected in chapter 3 from the SW1353 and C28/I2 screens were 
able to inhibit MMP13, MMP1 ADAMTS4 and ADAMTS5 at 10µM in KOA chondrocytes. Of 
these compounds apigenin and isoliquiritigenin showed the greatest statistically significant 
inhibition of MMP13 while also inhibiting MMP1, ADAMTS4 and ADAMTS5. These two 
selected candidate compounds dose dependently inhibited MMP13, MMP1, ADAMTS4 and 
ADAMTS5 and upregulated the anti-inflammatory gene HO-1 in KOA cells. It was 
hypothesised that apigenin may be having these effects via regulation of the Wnt pathway 
as it dose- dependently inhibited AXIN2, a Wnt/β-catenin responsive gene. Apigenin and 
isoliquiritigenin were hypothesised to have chondro-protective properties and showed no 
cytotoxic effects in chondrocytes. 
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Oral doses of isoliquiritigenin (100mg/kg) in mice have achieved the higher concentrations 
of isoliquiritigenin used in the experiments in this project. In blood plasma, the highest 
concentration of isoliquiritigenin found in plasma was 55.8µM (Wang et al., 2014), (Qiao et 
al., 2014). While absorption of apigenin is much lower, concentrations of apigenin in human 
subjects have been hypothesised to be around 1.7μM after consumption of 10g of dried 
parsley per day (Shibata et al., 2014), and while it would not be impossible to reach plasma 
concentrations of apigenin used in this project through normal dietary intake, 
supplementation could potentially be used to obtain higher doses. 
6.1.3 Ascertaining mechanism of action 
In chapter 4, I identified two potentially chondro-protective dietary-derived bioactive 
compounds, apigenin a plant-derived flavone and isoliquiritigenin a chalcone found in 
liquorice root. In chapter 5, I explored the mechanism of action of these compounds by 
analysing their effect on cell signalling pathways and transcription factors implicated in 
cartilage homeostasis and OA. Cell based luciferase assays were used to measure the effect 
of apigenin or isoliquiritigenin pretreatment on the NFκB, TGFβ and Wnt pathways in 
SW1353 cells. Apigenin and isoliquiritigenin inhibited the NFκB, TGFβ and Wnt pathways in 
SW1353 cells. While both compounds affected the same pathways there was distinct 
differences in the patterns of inhibition. Isoliquiritigenin inhibited NFκB activity at a lower 
dose than apigenin when the pathway was stimulated with IL1, however isoliquiritigenin 
had no effect on the unstimulated NFκB pathway, whereas apigenin significantly inhibited 
the unstimulated NFκB pathway at 40µM. Both compounds inhibited the TGFβ stimulated 
Smad2/3/4 pathway at 10µM, but only apigenin inhibited the unstimulated Smad2/3/4 
pathway and inhibiting the unstimulated Smad2/3/4 pathway in concentrations as low as 
5µM. While what is driving the basal expression of luciferase in these experiments is 
unknown it could potentially be due to epigenetic changes in OA cells, possibly in the form 
of methylation on the promoters of these pathways. Both compounds significantly 
inhibited the Wnt3a stimulated Wnt/ β-catenin with apigenin showing significant inhibition 
at 5µM and isoliquiritigenin at 10µM. Apigenin and isoliquiritigenin had no significant effect 
on the unstimulated Wnt/ β-catenin pathway. It was hypothesised that the distinct 
differences in the patterns of inhibition in the NFκB and TGFβ pathways suggested that 
apigenin and isoliquiritigenin may have different mechanisms of actions and could be 
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interacting with the pathways in different ways. These data are similar to the effects 
curcumin and resveratrol have on the NFκB pathway. Curcumin had previously been shown 
to suppress the activation of NFκB (Singh & Aggarwal, 1995) as had resveratrol (Meng et 
al., 2005). Inhibition of NFκB by curcumin was shown to be mainly through inhibition of IKK 
activation, in contrast the inhibition of NFκB activation by resveratrol mainly occurred 
through accumulation of phosphorylated IKβα and ubiquinated IKβα (Csaki et al., 2009). If 
apigenin and isoliquiritigenin inhibited the NFκB and the other pathways in different ways 
they may have stronger inhibitory effects when used together, allowing us to use each 
compound at lower, potentially more easily obtained, concentrations. 
The Proteome Profiler Array Human Phospho-Kinase Array Kit was used to perform an 
unbiased dissection of the kinase pathways affected by apigenin and isoliquiritigenin. This 
assay was used to detect simultaneously the relative levels of phosphorylation of 43 kinase 
phosphorylation sites and 2 related total proteins measuring the effects of apigenin and 
isoliquiritigenin across multiple cell pathways. To select and validate a timepoint for this 
assay the phosphorylation of the MAPK family of serine/threonine kinases, ERK, p38 and 
JNK were selected for analysis as they were known to be involved in the regulation of 
metalloproteinase gene expression and were included in the 43 kinases of the Human 
Phospho Kinase screen. Over a 60 minute time course apigenin and isoliquiritigenin showed 
the strongest inhibition of the IL1 stimulated phosphorylation of ERK and p38 at 10 minutes 
while also showing a slight inhibition of JNK phosphorylation. These results were used to 
select a 10 minute time point for the Human Phospho-Kinase array. For the Human 
Phospho-Kinase assay KOA cells were treated with isoliquiritigenin or apigenin at 10µM for 
10 minutes and stimulated with 5ng/ml IL1. The Human Phospho-Kinase Array ascertained 
the effects apigenin and isoliquiritigenin had on 43 kinases and 2 related total proteins in 
IL1 stimulated and unstimulated KOA cells (Figure 7.1).  Apigenin and isoliquiritigenin had 
similar effects on many phosphorylation events, however there were kinase 
phosphorylation events that were specific to either apigenin or isoliquiritigenin and these 
could explain some of the variations seen between the compounds qRT-PCR experiments 
seen in chapter 3 and 4. Apigenin increased phosphorylation levels of GSK-3 possibly via 
the inhibition of phosphorylated Akt 1/2/3 this could result in the lower levels of total β-
catenin levels seen after apigenin treatment as GSK-3 is a part of the β-catenin degradation 
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complex. Both apigenin and isoliquiritigenin inhibited total HSP60 levels, together these 
results suggest mechanisms as to how these compounds reduce NFκB activity. The reduced 
Wnt/β-catenin pathway activity seen with apigenin and isoliquiritigenin treatment may be 
due to the reduced levels of total β-catenin levels seen after compound treatment. 
Apigenin also reduced phosphorylated WNK1 levels which could result in reduced Wnt/β-
catenin pathway activity and may result in the dose dependent repression of AXIN2 seen 
in chondrocytes treated with apigenin. While apigenin and isoliquiritigenin reduced 
TGFβ/Smad activity, further experiments need to be done to clarify the compounds 
mechanism of action. It was hypothesised that apigenin and isoliquiritigenin could be used 
at varying concentrations to effect different pathways and could potentially have 
synergistic effects when used together. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figu
re 7
.1
 Su
m
m
ary o
f th
e e
ffects o
f ap
ige
n
in
 an
d
 iso
liq
u
iritige
n
in
 tre
atm
e
n
t in
 ch
o
n
d
ro
cytes 
172 
 
6.2 Future directions 
Future work could involve taking compounds shown to inhibit expression of MMP1 and 
MMP13 from chapter 4 that were not selected for further study and complete dose 
response qRT-PCR experiments for each compound, looking at MMP1, MMP13, ADAMTS4, 
ADAMTS5, HO-1 and AXIN2 expression. While these compounds did not inhibit MMP1 and 
MMP13 to the extent seen with apigenin and isoliquiritigenin treatment, many of them 
could potentially be inhibiting MMP1 and MMP13 via different pathways or be more potent 
at different timepoints/doses. These other compounds would be worth studying as they 
may have synergistic effects when used with apigenin and/or isoliquiritigenin. KOA cell 
experiments from this project could be repeated in normal primary chondrocytes to see if 
apigenin and/or isoliquiritigenin effect gene expression or kinase activity in healthy cell 
models. 
Synergy between compounds could also be assayed. Compounds could be tested for 
synergistic interaction by using the Chou-Talalay method for drug combination. This 
method is based on the median-effect equation, which is derived from the mass-action law 
principle. This is the unified theory that provides the common link between single entity 
and multiple entities, and first order and higher order dynamics. The Chou-Talalay method 
provides a combination index (CI) that gives a quantitative definition for; additive effect 
(CI=1), synergism (CI<1) and antagonism (CI>1) of bioactive combinations (Chou, 2010). 
Future work would also involve using siRNA to knock down individual kinases that were 
hypothesised to be involved in the compounds mechanism of action. For example 
inhibition of total HSP60 was hypothesised to be involved with the reduction of NFκB 
activity seen with apigenin and isoliquiritigenin treatment. By using siRNA to knockdown 
HSP60 we can see if apigenin or isoliquiritigenin treatment reduces NFκB activity further 
than HSP60 knockdown alone. It is also possible to introduce protein using cell-penetrating 
peptides. For kinases of interest western blot time courses could be performed to see if 
apigenin or isoliquiritigenin are more or less potent at different time points and at different 
concentrations.  
Limitations of the Human Phospho Kinase assay included the low number of replicates and 
the use of only one cytokine to stimulate the assay. Repeating the Human Phospho Kinase 
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array will help validate the results seen in this project. Many kinases from the kit that were 
not stimulated with IL1 could potentially be involved in the reduced TGFβ/Smad activity 
seen in the cell luciferase experiments. As the TGFβ/Smad luciferase assays were 
stimulated with TGFβ1 it would be useful to repeat the Human Phospho Kinase array and 
use TGFβ1 to stimulate the chondrocytes. This same method could be repeated using 
Wnt3a to stimulate cells to explore the repression of the Wnt/β-catenin pathway in more 
detail. Western blots could be used to measure the phosphorylation of individual kinases 
that are included in the Human Phospho Kinase assay to provide validation of the results 
seen in the kinase assays. 
Combinations of compounds could be tested in assays of cartilage destruction in vitro. 
These techniques have been developed in our lab and bovine nasal cartilage and murine 
femoral head cartilage can be used to measure the effects compounds have on 
proteoglycan and collagen breakdown. A three week old mouse femoral head cartilage 
assay based on methods developed for larger animal species (Stanton et al., 2011) has been 
developed in our lab to monitor GAG and hydroxyproline release to analyse whether 
dietary compounds can prevent aggrecanolysis. During this project we attempted to 
measure the effects of apigenin and isoliquiritigenin on GAG release in bovine cartilage 
samples, however due to a lack of cartilage tissue samples data was incomplete and could 
not be analysed. With more bovine cartilage tissue samples, future experiments could 
measure GAG release and the effects of apigenin and isoliquiritigenin treatments on 
proteoglycan breakdown could be elucidated.  
Blood, plasma and cartilage samples could be taken from mice fed diets designed to contain 
high concentrations of apigenin or isoliquiritigenin and High-performance liquid 
chromatography tandem mass spectrometry (HPLC-MS/MS) could be used to measure 
levels of apigenin and isoliquiritigenin absorbed by the mice.  High apigenin or high 
isoliquiritigenin diets could also be fed to mice to measure the change in arthritis score in 
the destabilisation of the medial meniscus (DMM) murine model of OA. Gene changes 
induced by this model (Such as MMPs, TIMPs, ADAMTSs, COX2 etc.) could then be 
measured and high apigenin or high isoliquiritigenin diets can be compared to control chow 
diet. These murine models could also be used to predict physiologically achievable 
concentrations of apigenin and isoliquiritigenin in man.   
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6.3 Conclusions 
Dietary derived bioactive compounds have huge potential as new treatments for OA. Diet 
offers a route by which the health of the joint can be protected and OA incidence or 
progression decreased. With escalating rates of obesity and increase in life expectancy, 
incidence of OA will rise over the next decades. Since the unmet need in OA is huge and 
the pharmaceutical industry has not made progress in this area, prevention or slowing of 
OA via dietary intervention or supplementation is an attractive alternative.  
This work has focused on 96 dietary derived bioactive compounds and their effect on IL1 
stimulated and basal MMP1 and MMP13 levels in SW1353 and C28/I2 cell lines. Several 
dietary derived compounds were able to repress MMP1 and MMP13 in these cell lines with 
a sub-group showing significant inhibition of these genes in primary chondrocytes. While 
apigenin and isoliquiritigenin were selected for further study many of the compounds that 
were not taken forward still have potential as OA therapeutics and future studies will 
examine these compounds mechanisms of action and whether they will have synergistic 
effects when used together. Apigenin and isoliquiritigenin likely inhibit metalloproteinase 
gene expression via the NFκB, TGFβ and Wnt pathways and the Human Phospho Kinase 
assay was used to begin to explore the compounds mechanisms of actions. Taken together 
these data suggest that the chondro-protective gene expression changes seen with 
apigenin and isoliquiritigenin treatment involves a complex network of signalling pathways 
that require further characterisation. If these compounds are able to get to the site of OA 
damage and at high enough concentrations they may prevent progression of OA offering a 
safe alternative treatment. 
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Appendix 
Compound 
No. 
Compounds Food types 
1 Capsaicin Chilli peppers 
2 Sclareol Salvia sclarea 
3 (-)-Hupersine A Huperzia serreta 
4 (+)-Usniacin (D-Usnic acid) Lichen 
5 3-Indolebutyric acid (IBA) Maize 
6 4-Methylumbeliferone (4-
MU) 
Rice 
7 Aesculin Conkers (horse chestnut) 
8 Aloe-emodin Aloe vera 
9 Sclareolide Salvia sclarea 
10 shikimic acid American sweetgum 
11 Apigenin Parsley, celery, coffee 
12 Silibinin Milk thistle 
13 Arbutin Bear berries 
14 Artemether Sweet worm wood 
15 Artesunate Sweet wormwood 
16 Asiatic acid Gotu kola 
17 Silymarin Milk thistle 
18 Baicalein Blue and common skullcap 
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19 Sinomenine Sinomenium Actum 
20 Bergenin Bergenia ciliata 
21 Berberine Hydrochloride Berberis 
22 Sitosterol Pecan 
23 Bilobalide Ginkgo biloba 
24 Stigmasterol Soy 
25 Caffeic acid Cucumber 
26 Chlorogenic acid Coffee 
27 Chrysin Honeycomb and passion flower 
28 Tangeretin Tangerine 
29 Theobromine Cocoa bean 
30 Troxerutin Styphnolobium japonicum 
31 Ursolic acid Apples 
32 Cytisine Gymnocladus dioica 
33 Daidzin Soy 
34 Dihydroartemisinin Sweet wormwood (tea) 
35 Diosgenin White yam 
36 Vanillylacetone Ginger 
37 Diosmin Peppermint 
38 DL-Carnitine hydrochloride Beef 
39 Ecdysone Cordyceps, sinensis 
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40 Emodin Rhubarb 
41 Enoxolone Liquorice 
42 Ergosterol Maize 
43 Fisetin Strawberries 
44 Formononetin Red clover 
45 Fumalic acid Asafoetida 
46 Genistin Soy 
47 Glycyrrhizic acid Liquorice 
48 Hydroxytryptophan Turkey 
49 Aloin (Barbaloin) Aloe vera 
50 Gramine Arundo donax 
51 Ammonium Glycyrrhizinate Liquorice 
52 Gynostemma Extract Gynostemma pentaphyllum 
53 Hesperetin Black peppermint 
54 Hesperedin Orange 
55 Honokiol Magnolia grandiflora (tea) 
56 Biochanin A (4-
Methylgenistein 
Soy 
57 Icariin Epimedium grandiflorum (Horny goat 
weed) 
58 Indole-3-carbinol Broccoli 
59 Kaempferol Broccoli 
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60 Gastrodin (Gastrodine) Gastrodia elata 
61 Kinetin Coconut 
62 Hordenine Barley 
63 Limonin Orange/Lemons 
64 Luteolin Celery 
65 Indirubin Woad 
66 L-carnitine Beef 
67 Methyl-Hesperidin Citrus fruits 
68 Naringin Dihydrochalcone Grapefruit 
69 Polydatin (Piceid) Grapes 
70 Myricetin Grapes 
71 Myricitrin Myrica cerifera (Bayberry tree) 
72 Quercetin (Sophoretin) Black elder berry 
73 Sesamin (Fagorol) Sesame seeds 
74 Naringin Grapefruits 
75 Sorbitol (Glucitol) Apples 
76 Neohesperidin 
dihydrochalcone 
Citrus fruits 
77 Rheochrysidin Rumex crispus 
78 Nobiletin Orange 
79 Oleanolic acid Garlic 
80 Salidroside Rhodiola rosea (tea) 
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81 Orotic acid Carrots 
82 Osthole Shishiudo 
83 Palmatine chloride Phellodendron amurense (Amur cork 
tree) 
84 Coenzyme Q10 Red meat 
85 Paeonol Peony 
86 Parthenolide Feverfew 
87 Phloretin Apple 
88 Dihydromyricetin Ampelopsis grossdentata 
89 Rhein Rhubarb 
90 Puerarin Kudzu roots 
91 Quercetin dihydrate Black elder berry 
92 Isoliquiritigenin Liquorice 
93 Rutin Asparagus 
94 Salicin Willow bark 
95 Chrysophanic acid Rhubarb 
96 Curcumol Tumeric 
 
 
 
